WO2011156837A1 - Loc device for pathogen detection with dialysis, thermal lysis, nucleic acid amplification and prehybridization filtering - Google Patents
Loc device for pathogen detection with dialysis, thermal lysis, nucleic acid amplification and prehybridization filtering Download PDFInfo
- Publication number
- WO2011156837A1 WO2011156837A1 PCT/AU2011/000660 AU2011000660W WO2011156837A1 WO 2011156837 A1 WO2011156837 A1 WO 2011156837A1 AU 2011000660 W AU2011000660 W AU 2011000660W WO 2011156837 A1 WO2011156837 A1 WO 2011156837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- section
- nucleic acid
- loc device
- sample
- hybridization
- Prior art date
Links
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 210
- 230000003321 amplification Effects 0.000 title claims abstract description 206
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 155
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 118
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 118
- 238000000502 dialysis Methods 0.000 title claims abstract description 94
- 230000009089 cytolysis Effects 0.000 title claims abstract description 68
- 244000052769 pathogen Species 0.000 title claims abstract description 49
- 238000001914 filtration Methods 0.000 title claims abstract description 9
- 238000001514 detection method Methods 0.000 title description 65
- 230000001717 pathogenic effect Effects 0.000 title description 25
- 239000000523 sample Substances 0.000 claims abstract description 297
- 238000002032 lab-on-a-chip Methods 0.000 claims abstract description 205
- 239000000470 constituent Substances 0.000 claims abstract description 45
- 108091093088 Amplicon Proteins 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 14
- 230000002934 lysing effect Effects 0.000 claims abstract description 11
- 239000012472 biological sample Substances 0.000 claims abstract description 9
- 238000009396 hybridization Methods 0.000 claims description 180
- 239000003153 chemical reaction reagent Substances 0.000 claims description 91
- 238000003752 polymerase chain reaction Methods 0.000 claims description 74
- 230000005499 meniscus Effects 0.000 claims description 36
- 239000012530 fluid Substances 0.000 claims description 35
- 238000009835 boiling Methods 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 25
- 238000004891 communication Methods 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 8
- 238000005382 thermal cycling Methods 0.000 claims description 8
- 230000000717 retained effect Effects 0.000 claims description 5
- 230000001351 cycling effect Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 80
- 102000053602 DNA Human genes 0.000 description 79
- 238000012360 testing method Methods 0.000 description 71
- 230000005284 excitation Effects 0.000 description 68
- 239000013615 primer Substances 0.000 description 68
- 238000000034 method Methods 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 47
- 238000011534 incubation Methods 0.000 description 37
- 238000003556 assay Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 31
- 230000008569 process Effects 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 23
- 230000003287 optical effect Effects 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 230000000295 complement effect Effects 0.000 description 19
- 238000002156 mixing Methods 0.000 description 19
- 230000036961 partial effect Effects 0.000 description 15
- 229920002477 rna polymer Polymers 0.000 description 15
- 102100034343 Integrase Human genes 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 238000013461 design Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 239000003146 anticoagulant agent Substances 0.000 description 13
- 229940127219 anticoagulant drug Drugs 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 12
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 12
- 239000013522 chelant Substances 0.000 description 12
- 239000002699 waste material Substances 0.000 description 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000009792 diffusion process Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 239000007850 fluorescent dye Substances 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 238000012340 reverse transcriptase PCR Methods 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 238000007397 LAMP assay Methods 0.000 description 8
- 238000000137 annealing Methods 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 8
- 238000001917 fluorescence detection Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 7
- 108090000364 Ligases Proteins 0.000 description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000011901 isothermal amplification Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 229910052710 silicon Inorganic materials 0.000 description 7
- 239000010703 silicon Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000003990 capacitor Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 238000005286 illumination Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 5
- 108010091086 Recombinases Proteins 0.000 description 5
- 229910052771 Terbium Inorganic materials 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000005281 excited state Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229910010038 TiAl Inorganic materials 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004656 cell transport Effects 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005459 micromachining Methods 0.000 description 2
- 238000001053 micromoulding Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 238000011330 nucleic acid test Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000009428 plumbing Methods 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000711969 Chandipura virus Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001661732 Isavirus Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001312372 Mycobacterium canettii Species 0.000 description 1
- 241000187919 Mycobacterium microti Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 240000001068 Thogoto virus Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005092 [Ru (Bpy)3]2+ Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000012209 assay specification Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000001444 catalytic combustion detection Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 108700014590 single-stranded DNA binding proteins Proteins 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- -1 tris(2,2'-bipyridine) ruthenium (II) Chemical compound 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502738—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by integrated valves
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K99/00—Subject matter not provided for in other groups of this subclass
- F16K99/0001—Microvalves
- F16K99/0003—Constructional types of microvalves; Details of the cutting-off member
- F16K99/003—Valves for single use only
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K99/00—Subject matter not provided for in other groups of this subclass
- F16K99/0001—Microvalves
- F16K99/0034—Operating means specially adapted for microvalves
- F16K99/0036—Operating means specially adapted for microvalves operated by temperature variations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/023—Sending and receiving of information, e.g. using bluetooth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/024—Storing results with means integrated into the container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0636—Integrated biosensor, microarrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0654—Lenses; Optical fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0883—Serpentine channels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/10—Means to control humidity and/or other gases
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
- B01L2300/1827—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using resistive heater
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0688—Valves, specific forms thereof surface tension valves, capillary stop, capillary break
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/0318—Processes
- Y10T137/0324—With control of flow by a condition or characteristic of a fluid
- Y10T137/0329—Mixing of plural fluids of diverse characteristics or conditions
- Y10T137/0352—Controlled by pressure
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/0318—Processes
- Y10T137/0391—Affecting flow by the addition of material or energy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/0971—Speed responsive valve control
- Y10T137/1044—With other condition responsive valve control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/206—Flow affected by fluid contact, energy field or coanda effect [e.g., pure fluid device or system]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/206—Flow affected by fluid contact, energy field or coanda effect [e.g., pure fluid device or system]
- Y10T137/2076—Utilizing diverse fluids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/206—Flow affected by fluid contact, energy field or coanda effect [e.g., pure fluid device or system]
- Y10T137/218—Means to regulate or vary operation of device
- Y10T137/2202—By movable element
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/11—Automated chemical analysis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/203332—Hydroxyl containing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Definitions
- the present invention relates to diagnostic devices that use microsystems technologies (MST).
- MST microsystems technologies
- the invention relates to microfluidic and biochemical processing and analysis for molecular diagnostics.
- molecular diagnostic tests have the potential to reduce the occurrence of ineffective health care services, enhance patient outcomes, improve disease management and individualize patient care.
- Many of the techniques in molecular diagnostics are based on the detection and identification of specific nucleic acids, both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), extracted and amplified from a biological specimen (such as blood or saliva).
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- the complementary nature of the nucleic acid bases allows short sequences of synthesized DNA (oligonucleotides) to bond (hybridize) to specific nucleic acid sequences for use in nucleic acid tests. If hybridization occurs, then the complementary sequence is present in the sample. This makes it possible, for example, to predict the disease a person will contract in the future, determine the identity and virulence of an infectious pathogen, or determine the response a person will have to a drug.
- a nucleic acid based test has four distinct steps: 1 Sample preparation
- sample types are used for genetic analysis, such as blood, urine, sputum and tissue samples.
- the diagnostic test determines the type of sample required as not all samples are representative of the disease process. These samples have a variety of constituents, but usually only one of these is of interest. For example, in blood, high concentrations of erythrocytes can inhibit the detection of a pathogenic organism.
- Blood is one of the more commonly sought sample types. It has three major constituents: leukocytes (white blood cells), erythrocytes (red blood cells) and
- thrombocytes platelets.
- the thrombocytes facilitate clotting and remain active in vitro.
- the specimen is mixed with an agent such as
- EDTA ethylenediaminetetraacetic acid
- Erythrocytes are usually removed from the sample in order to concentrate the target cells. In humans, erythrocytes account for approximately 99% of the cellular material but do not carry DNA as they have no nucleus. Furthermore, erythrocytes contain components such as haemoglobin that can interfere with the downstream nucleic acid amplification process (described below). Removal of erythrocytes can be achieved by differentially lysing the erythrocytes in a lysis solution, leaving remaining cellular material intact which can then be separated from the sample using centrifugation. This provides a concentration of the target cells from which the nucleic acids are extracted.
- extracting nucleic acids from target cells usually involves a cell lysis step followed by nucleic acid purification.
- the cell lysis step disrupts the cell and nuclear membranes, releasing the genetic material. This is often accomplished using a lysis detergent, such as sodium dodecyl sulfate, which also denatures the large amount of proteins present in the cells.
- the nucleic acids are then purified with an alcohol precipitation step, usually ice- cold ethanol or isopropanol, or via a solid phase purification step, typically on a silica matrix in a column, resin or on paramagnetic beads in the presence of high concentrations of a chaotropic salt, prior to washing and then elution in a low ionic strength buffer.
- An optional step prior to nucleic acid precipitation is the addition of a protease which digests the proteins in order to further purify the sample.
- lysis methods include mechanical lysis via ultrasonic vibration and thermal lysis where the sample is heated to 94°C to disrupt cell membranes.
- the target DNA or RNA may be present in the extracted material in very small amounts, particularly if the target is of pathogenic origin. Nucleic acid amplification provides the ability to selectively amplify (that is, replicate) specific targets present in low concentrations to detectable levels.
- PC polymerase chain reaction
- PCR is a powerful technique that amplifies a target DNA sequence against a background of complex DNA. If RNA is to be amplified (by PCR), it must be first transcribed into cDNA (complementary DNA) using an enzyme called reverse transcriptase. Afterwards, the resulting cDNA is amplified by PCR.
- PCR is an exponential process that proceeds as long as the conditions for sustaining the reaction are acceptable.
- the components of the reaction are:
- pair of primers short single strands of DNA with around 10-30 nucleotides complementary to the regions flanking the target sequence
- DNA polymerase - a thermostable enzyme that synthesizes DNA
- deoxyribonucleoside triphosphates (dNTPs) - provide the nucleotides that are incorporated into the newly synthesized DNA strand
- PCR typically involves placing these reactants in a small tube (-10-50 microlitres) containing the extracted nucleic acids.
- the tube is placed in a thermal cycler; an instrument that subjects the reaction to a series of different temperatures for varying amounts of time.
- the standard protocol for each thermal cycle involves a denaturation phase, an annealing phase, and an extension phase.
- the extension phase is sometimes referred to as the primer extension phase.
- two-step thermal protocols can be employed, in which the annealing and extension phases are combined.
- the denaturation phase typically involves raising the temperature of the reaction to 90 - 95°C to denature the DNA strands; in the annealing phase, the temperature is lowered to ⁇ 50-60°C for the primers to anneal; and then in the extension phase the temperature is raised to the optimal DNA polymerase activity temperature of 60- 72°C for primer extension. This process is repeated cyclically around 20-40 times, the end result being the creation of millions of copies of the target sequence between the primers.
- Multiplex PCR uses multiple primer sets within a single PCR mixture to produce amplicons of varying sizes that are specific to different DNA sequences. By targeting multiple genes at once, additional information may be gained from a single test-run that otherwise would require several experiments. Optimization of multiplex PCR is more difficult though and requires selecting primers with similar annealing temperatures, and amplicons with similar lengths and base composition to ensure the amplification efficiency of each amplicon is equivalent.
- Linker-primed PCR also known as ligation adaptor PCR
- ligation adaptor PCR is a method used to enable nucleic acid amplification of essentially all DNA sequences in a complex DNA mixture without the need for target-specific primers.
- the method firstly involves digesting the target DNA population with a suitable restriction endonuclease (enzyme). Double- stranded oligonucleotide linkers (also called adaptors) with a suitable overhanging end are then ligated to the ends of target DNA fragments using a ligase enzyme. Nucleic acid amplification is subsequently performed using oligonucleotide primers which are specific for the linker sequences. In this way, all fragments of the DNA source which are flanked by linker oligonucleotides can be amplified.
- enzyme double- stranded oligonucleotide linkers
- oligonucleotide primers which are specific for the linker sequences
- Direct PCR describes a system whereby PCR is performed directly on a sample without any, or with minimal, nucleic acid extraction. It has long been accepted that PCR reactions are inhibited by the presence of many components of unpurified biological samples, such as the haem component in blood. Traditionally, PCR has required extensive purification of the target nucleic acid prior to preparation of the reaction mixture. With appropriate changes to the chemistry and sample concentration, however, it is possible to perform PCR with minimal DNA purification, or direct PCR. Adjustments to the PCR chemistry for direct PCR include increased buffer strength, the use of polymerases which have high activity and processivity, and additives which chelate with potential polymerase inhibitors.
- Tandem PCR utilises two distinct rounds of nucleic acid amplification to increase the probability that the correct amplicon is amplified.
- One form of tandem PCR is nested PCR in which two pairs of PCR primers are used to amplify a single locus in separate rounds of nucleic acid amplification. The first pair of primers hybridize to the nucleic acid sequence at regions external to the target nucleic acid sequence. The second pair of primers (nested primers) used in the second round of amplification bind within the first PCR product and produce a second PCR product containing the target nucleic acid, that will be shorter than the first one.
- Real-time PCR or quantitative PCR, is used to measure the quantity of a PCR product in real time.
- a fluorophore-containing probe or fluorescent dyes along with a set of standards in the reaction, it is possible to quantitate the starting amount of nucleic acid in the sample. This is particularly useful in molecular diagnostics where treatment options may differ depending on the pathogen load in the sample.
- Reverse-transcriptase PCR (RT-PCR) is used to amplify DNA from RNA.
- Reverse transcriptase is an enzyme that reverse transcribes RNA into complementary DNA
- RNA virus which is then amplified by PCR.
- RT-PCR is widely used in expression profiling, to determine the expression of a gene or to identify the sequence of an RNA transcript, including transcription start and termination sites. It is also used to amplify RNA viruses such as human immunodeficiency virus or hepatitis C virus.
- Isothermal amplification is another form of nucleic acid amplification which does not rely on the thermal denaturation of the target DNA during the amplification reaction and hence does not require sophisticated machinery. Isothermal nucleic acid amplification methods can therefore be carried out in primitive sites or operated easily outside of a laboratory environment. A number of isothermal nucleic acid amplification methods have been described, including Strand Displacement Amplification, Transcription Mediated Amplification, Nucleic Acid Sequence Based Amplification, Recombinase Polymerase Amplification, Rolling Circle Amplification, Ramification Amplification, Helicase- Dependent Isothermal DNA Amplification and Loop-Mediated Isothermal Amplification.
- Isothermal nucleic acid amplification methods do not rely on the continuing heat denaturation of the template DNA to produce single stranded molecules to serve as templates for further amplification, but instead rely on alternative methods such as enzymatic nicking of DNA molecules by specific restriction endonucleases, or the use of an enzyme to separate the DNA strands, at a constant temperature.
- Strand Displacement Amplification relies on the ability of certain restriction enzymes to nick the unmodified strand of hemi-modified DNA and the ability of a 5 '-3' exonuclease-deficient polymerase to extend and displace the downstream strand.
- Exponential nucleic acid amplification is then achieved by coupling sense and antisense reactions in which strand displacement from the sense reaction serves as a template for the antisense reaction.
- nickase enzymes which do not cut DNA in the traditional manner but produce a nick on one of the DNA strands, such as N. Alwl, N. BstNBl and Mly 1, are useful in this reaction.
- SDA has been improved by the use of a combination of a heat-stable restriction enzyme (Aval) and heat-stable Exo- polymerase (Bst polymerase). This combination has been shown to increase amplification efficiency of the reaction from 10 8 fold amplification to 10 10 fold amplification so that it is possible using this technique to amplify unique single copy molecules.
- TMA Transcription Mediated Amplification
- NASBA Nucleic Acid Sequence Based Amplification
- RNA polymerase uses two primers and two or three enzymes, RNA polymerase, reverse transcriptase and optionally RNase H (if the reverse transcriptase does not have RNase activity).
- One primer contains a promoter sequence for RNA polymerase.
- this primer hybridizes to the target ribosomal RNA (rRNA) at a defined site.
- rRNA target ribosomal RNA
- Reverse transcriptase creates a DNA copy of the target rRNA by extension from the 3' end of the promoter primer.
- RNA in the resulting RNA:DNA duplex is degraded by the RNase activity of the reverse transcriptase if present or the additional RNase H.
- a second primer binds to the DNA copy.
- a new strand of DNA is synthesized from the end of this primer by reverse transcriptase, creating a double-stranded DNA molecule.
- RNA polymerase recognizes the promoter sequence in the DNA template and initiates transcription. Each of the newly synthesized RNA amplicons re-enters the process and serves as a template for a new round of replication.
- RPA Recombinase Polymerase Amplification
- dsDNA double-stranded DNA
- PA employs recombinase-primer complexes to scan dsDNA and facilitate strand exchange at cognate sites.
- the resulting structures are stabilised by single-stranded DNA binding proteins interacting with the displaced template strand, thus preventing the ejection of the primer by branch migration.
- Recombinase disassembly leaves the 3' end of the oligonucleotide accessible to a strand displacing DNA polymerase, such as the large fragment of Bacillus subtilis Pol I (Bsu), and primer extension ensues. Exponential nucleic acid amplification is accomplished by the cyclic repetition of this process.
- HMA Helicase-dependent amplification
- DNA helicase enzyme to generate single-stranded templates for primer hybridization and subsequent primer extension by a DNA polymerase.
- the helicase enzyme traverses along the target DNA, disrupting the hydrogen bonds linking the two strands which are then bound by single-stranded binding proteins. Exposure of the single-stranded target region by the helicase allows primers to anneal.
- the DNA polymerase then extends the 3 ' ends of each primer using free deoxyribonucleoside triphosphates (dNTPs) to produce two DNA replicates. The two replicated dsDNA strands independently enter the next cycle of HDA, resulting in exponential nucleic acid amplification of the target sequence.
- dNTPs free deoxyribonucleoside triphosphates
- DNA-based isothermal techniques include Rolling Circle Amplification
- RCA in which a DNA polymerase extends a primer continuously around a circular DNA template, generating a long DNA product that consists of many repeated copies of the circle. By the end of the reaction, the polymerase generates many thousands of copies of the circular template, with the chain of copies tethered to the original target DNA. This allows for spatial resolution of target and rapid nucleic acid amplification of the signal. Up to 10 12 copies of template can be generated in 1 hour.
- Ramification amplification is a variation of RCA and utilizes a closed circular probe (C-probe) or padlock probe and a DNA polymerase with a high processivity to exponentially amplify the C-probe under isothermal conditions.
- Loop-mediated isothermal amplification offers high selectivity and employs a DNA polymerase and a set of four specially designed primers that recognize a total of six distinct sequences on the target DNA.
- An inner primer containing sequences of the sense and antisense strands of the target DNA initiates LAMP.
- the following strand displacement DNA synthesis primed by an outer primer releases a single-stranded DNA.
- This serves as template for DNA synthesis primed by the second inner and outer primers that hybridize to the other end of the target, which produces a stem-loop DNA structure.
- one inner primer hybridizes to the loop on the product and initiates displacement DNA synthesis, yielding the original stem-loop DNA and a new stem-loop DNA with a stem twice as long.
- the cycling reaction continues with accumulation of 10 9 copies of target in less than an hour.
- the final products are stem-loop DNAs with several inverted repeats of the target and cauliflower-like structures with multiple loops formed by annealing between alternately inverted repeats of the target in the same strand.
- the amplified product After completion of the nucleic acid amplification, the amplified product must be analysed to determine whether the anticipated amplicon (the amplified quantity of target nucleic acids) was generated.
- the methods of analyzing the product range from simply determining the size of the amplicon through gel electrophoresis, to identifying the nucleotide composition of the amplicon using DNA hybridization.
- Gel electrophoresis is one of the simplest ways to check whether the nucleic acid amplification process generated the anticipated amplicon.
- Gel electrophoresis uses an electric field applied to a gel matrix to separate DNA fragments. The negatively charged DNA fragments will move through the matrix at different rates, determined largely by their size. After the electrophoresis is complete, the fragments in the gel can be stained to make them visible. Ethidium bromide is a commonly used stain which fluoresces under UV light.
- the size of the fragments is determined by comparison with a DNA size marker (a DNA ladder), which contains DNA fragments of known sizes, run on the gel alongside the amplicon. Because the oligonucleotide primers bind to specific sites flanking the target DNA, the size of the amplified product can be anticipated and detected as a band of known size on the gel. To be certain of the identity of the amplicon, or if several amplicons have been generated, DNA probe hybridization to the amplicon is commonly employed.
- a DNA size marker a DNA ladder
- DNA hybridization refers to the formation of double-stranded DNA by
- DNA hybridization for positive identification of a specific amplification product requires the use of a DNA probe around 20 nucleotides in length. If the probe has a sequence that is complementary to the amplicon (target) DNA sequence, hybridization will occur under favourable conditions of temperature, pH and ionic concentration. If hybridization occurs, then the gene or DNA sequence of interest was present in the original sample. Optical detection is the most common method to detect hybridization. Either the amplicons or the probes are labelled to emit light through fluorescence or
- electrochemiluminescence processes differ in the means of producing excited states of the light-producing moieties, but both enable covalent labelling of nucleotide strands.
- ECL electrochemiluminescence
- luminophore molecules or complexes upon stimulation with an electric current.
- fluorescence it is illumination with excitation light which leads to emission.
- Fluorescence is detected using an illumination source which provides excitation light at a wavelength absorbed by the fluorescent molecule, and a detection unit.
- the detection unit comprises a photosensor (such as a photomultiplier tube or charge-coupled device (CCD) array) to detect the emitted signal, and a mechanism (such as a wavelength- selective filter) to prevent the excitation light from being included in the photosensor output.
- the fluorescent molecules emit Stokes-shifted light in response to the excitation light, and this emitted light is collected by the detection unit. Stokes shift is the frequency difference or wavelength difference between emitted light and absorbed excitation light.
- ECL emission is detected using a photosensor which is sensitive to the emission wavelength of the ECL species being employed.
- a photosensor which is sensitive to the emission wavelength of the ECL species being employed.
- transition metal-ligand complexes emit light at visible wavelengths, so conventional photodiodes and CCDs are employed as photosensors.
- An advantage of ECL is that, if ambient light is excluded, the ECL emission can be the only light present in the detection system, which improves sensitivity.
- Microarrays allow for hundreds of thousands of DNA hybridization experiments to be performed simultaneously. Microarrays are powerful tools for molecular diagnostics with the potential to screen for thousands of genetic diseases or detect the presence of numerous infectious pathogens in a single test.
- a microarray consists of many different DNA probes immobilized as spots on a substrate. The target DNA (amplicon) is first labelled with a fluorescent or luminescent molecule (either during or after nucleic acid amplification) and then applied to the array of probes. The microarray is incubated in a temperature controlled, humid environment for a number of hours or days while hybridization between the probe and amplicon takes place. Following incubation, the microarray must be washed in a series of buffers to remove unbound strands.
- the microarray surface is dried using a stream of air (often nitrogen).
- the stringency of the hybridization and washes is critical. Insufficient stringency can result in a high degree of nonspecific binding. Excessive stringency can lead to a failure of appropriate binding, which results in diminished sensitivity.
- Hybridization is recognized by detecting light emission from the labelled amplicons which have formed a hybrid with complementary probes.
- Fluorescence from microarrays is detected using a microarray scanner which is generally a computer controlled inverted scanning fluorescence confocal microscope which typically uses a laser for excitation of the fluorescent dye and a photosensor (such as a photomultiplier tube or CCD) to detect the emitted signal.
- the fluorescent molecules emit Stokes-shifted light (described above) which is collected by the detection unit.
- the emitted fluorescence must be collected, separated from the unabsorbed excitation wavelength, and transported to the detector.
- a confocal arrangement is commonly used to eliminate out-of- focus information by means of a confocal pinhole situated at an image plane. This allows only the in- focus portion of the light to be detected. Light from above and below the plane of focus of the object is prevented from entering the detector, thereby increasing the signal to noise ratio.
- the detected fluorescent photons are converted into electrical energy by the detector which is subsequently converted to a digital signal. This digital signal translates to a number representing the intensity of fluorescence from a given pixel. Each feature of the array is made up of one or more such pixels.
- the final result of a scan is an image of the array surface. The exact sequence and position of every probe on the microarray is known, and so the hybridized target sequences can be identified and analysed simultaneously.
- a point-of-care technology serving the physician's office, the hospital bedside or even consumer-based, at home, would offer many advantages including:
- LOC Lab-on-a-chip
- LOC lab-on-a-chip
- a first dialysis section for separating pathogens from larger constituents in the sample
- nucleic acid amplification section downstream of the lysis section for amplifying nucleic acid sequences in the genetic material
- the first dialysis section, the lysis section, the nucleic acid amplification section and the second dialysis section are all supported on the supporting substrate.
- the lysis section has a heater for thermally lysing the pathogens.
- the LOC device also has a hybridization section downstream of the second dialysis section that has an array of probes for hybridization with target nucleic acid sequences in the sample and, a photosensor for detecting hybridization of any probes within the array.
- the first dialysis section has a first channel in fluid communication with the inlet, a second channel in fluid communication with the lysis section and a plurality of first apertures that are larger than the pathogens and smaller than the larger constituents, the second channel being in fluid communication with the first channel via the first apertures such that the pathogens flow into the second channel while the larger constituents are retained in the first channel.
- the first channel and the second channel are configured to fill with the sample by capillary action.
- the second dialysis section has a large component channel, a small component channel and a plurality of second apertures fluidically connecting the large component channel to the small component channel, the second apertures being sized to allow nucleic acid sequences to flow from the large component channel to the small component channel while cell debris larger than the second apertures is retained in the large component channel, the small component channel being in fluid communication with the hybridization section.
- the nucleic acid amplification section is an isothermal nucleic acid amplification section.
- the LOC device also has a reagent reservoir for holding a reagent used for isothermal nucleic acid amplification; and,
- a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus and the reagent flows out of the reagent reservoir.
- the nucleic acid amplification section is polymerase chain reaction (PCR) amplification section.
- PCR polymerase chain reaction
- the LOC device also has CMOS circuitry, a temperature sensor and a microsystems technology (MST) layer which incorporates the PCR section, wherein the CMOS circuitry is positioned between the supporting substrate and the MST layer, the CMOS circuitry being configured to use the temperature sensor output for feedback control of the PCR section.
- MST microsystems technology
- the PCR section has a PCR microchannel for thermally cycling the sample to amplify the nucleic acid sequences, the PCR microchannel defining part of the flow-path for the sample and has a cross sectional area transverse to the flow less than 100,000 square microns.
- the LOC device also has at least one elongate heater element for heating the nucleic acid sequences within the elongate PCR microchannel, the elongate heater element extending parallel to the PCR microchannel.
- the PCR section has a plurality of the elongate PCR chambers each formed by respective sections of the PCR microchannel, the PCR microchannel having a serpentine configuration formed by a series of wide meanders, each of the wide meanders being a channel section that forms one of the elongate PCR chambers.
- the LOC device also has a reagent reservoir for holding a reagent used for PCR; and,
- a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus and the reagent flows out of the reagent reservoir.
- the LOC device also has a hybridization chamber array for containing the probes such that the probes within each hybridization chamber are configured to hybridize with one of the target nucleic acid sequences.
- the photosensor is an array of photodiodes positioned in registration with the hybridization chambers.
- the CMOS circuitry has a digital memory for storing hybridization data from the photosensor output and a data interface for transmission of the hybridization data to an external device.
- the PCR section has an active valve for retaining liquid in the PCR section during thermal cycling and allowing flow to the hybridization chambers in response to an activation signal from the CMOS circuitry.
- the active valve is a boiling-initiated valve with a meniscus anchor configured to pin a meniscus that arrests capillary driven flow of the liquid, and a heater for boiling the liquid to unpin the meniscus from the meniscus anchor such that capillary driven flow resumes.
- the easily usable, mass-producible, and inexpensive pathogen detection LOC device accepts a biological sample through its sample receptacle, uses its dialysis section to separate any pathogens contained in the sample, lyses the pathogens in its thermal lysis chamber to release the pathogens' genetic materials, amplifies any target genetic sequences, and analyzes the sample's nucleic acid sequences via hybridization with oligonucleotide probes with sensing via its integral imaging array, utilizing reagents stored in the LOC device's reagent reservoirs.
- the dialysis section functionality extracts additional information from the sample and increases the sensitivity, signal-to-noise ratio, and dynamic range of the assay system.
- the dialysis section being integral to the device, provides for the low system component- count and simple manufacturing procedures, leading into an inexpensive assay system.
- the lysing process extracts analytical and diagnostic targets from cells in the sample and provides for follow-on processing and analysis of the targets.
- the lysis subunit being integral to the device, provides for simple assay procedures, low system component- count, and simple system manufacturing procedures, leading into an inexpensive assay system.
- the thermal lysing process simplifies assay chemistry requirements and provides for capability for a wide range of sample types.
- the amplification of target genetic sequences increases the sensitivity and signal- to-noise ratio of the assay system.
- the prehybridization filtering removes the debris resulting from the thermal lysis of the sample cells improving the effectiveness of the hybridization process and the consequent improvement in the assay sensitivity, signal-to-noise-ratio, and reliability.
- the prehybridization filtering also permits utilization of the thermal lysis process, with its consequent advantages, for a wider range of sample types.
- the probe hybridization section provides for analysis of the targets via
- the integrated probe hybridization section provides for an easily usable, mass-producible, and inexpensive integrated solution with low system component-count.
- the integrated image sensor obviates the need for an expensive external imaging system and provides for a mass-producible inexpensive integrated solution with low system component-count that is a compact, light, and highly portable system.
- the integrated image sensor increases the readout sensitivity by benefiting from large angle of light collection and obviates the need for optical components in the optical collection train.
- the reagent reservoirs being integral to the LOC device and holding the assay's total reagent requirements, provide for the low system component-count and simple manufacturing procedures, leading into an inexpensive assay system.
- Figure 1 shows a test module and test module reader configured for fluorescence detection
- Figure 2 is a schematic overview of the electronic components in the test module configured for fluorescence detection
- Figure 3 is a schematic overview of the electronic components in the test module reader
- Figure 4 is a schematic representation of the architecture of the LOC device
- Figure 5 is a perspective of the LOC device
- Figure 6 is a plan view of the LOC device with features and structures from all layers superimposed on each other;
- Figure 7 is a plan view of the LOC device with the structures of the cap shown in isolation;
- Figure 8 is a top perspective of the cap with internal channels and reservoirs shown in dotted line;
- Figure 9 is an exploded top perspective of the cap with internal channels and reservoirs shown in dotted line;
- Figure 10 is a bottom perspective of the cap showing the configuration of the top channels
- Figure 11 is a plan view of the LOC device showing the structures of the CMOS + MST device in isolation;
- Figure 12 is a schematic section view of the LOC device at the sample inlet
- Figure 13 is an enlarged view of Inset AA shown in Figure 6;
- Figure 14 is an enlarged view of Inset AB shown in Figure 6;
- Figure 15 is an enlarged view of Inset AE shown in Figure 13;
- Figure 16 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
- Figure 17 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
- Figure 18 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE
- Figure 19 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
- Figure 20 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
- Figure 21 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
- Figure 22 is schematic section view of the lysis reagent reservoir shown in Figure
- Figure 23 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
- Figure 24 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
- Figure 25 is a partial perspective illustrating the laminar structure of the LOC device within Inset AI
- Figure 26 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
- Figure 27 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
- Figure 28 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
- Figure 29 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
- Figure 30 is a schematic section view of the amplification mix reservoir and the polymerase reservoir
- Figure 31 show the features of a boiling- initiated valve in isolation
- Figure 32 is a schematic section view of the boiling-initiated valve taken through line 33-33 shown in Figure 31;
- Figure 33 is an enlarged view of Inset AF shown in Figure 15;
- Figure 34 is a schematic section view of the upstream end of the dialysis section taken through line 35-35 shown in Figure 33;
- Figure 35 is an enlarged view of Inset AC shown in Figure 6;
- Figure 36 is a further enlarged view within Inset AC showing the amplification section
- Figure 37 is a further enlarged view within Inset AC showing the amplification section
- Figure 38 is a further enlarged view within Inset AC showing the amplification section
- Figure 39 is a further enlarged view within Inset AK shown in Figure 38;
- Figure 40 is a further enlarged view within Inset AC showing the amplification chamber
- Figure 41 is a further enlarged view within Inset AC showing the amplification section
- Figure 42 is a further enlarged view within Inset AC showing the amplification chamber
- Figure 43 is a further enlarged view within Inset AL shown in Figure 42;
- Figure 44 is a further enlarged view within Inset AC showing the amplification section;
- Figure 45 is a further enlarged view within Inset AM shown in Figure 44;
- Figure 46 is a further enlarged view within Inset AC showing the amplification chamber
- Figure 47 is a further enlarged view within Inset AN shown in Figure 46;
- Figure 48 is a further enlarged view within Inset AC showing the amplification chamber;
- Figure 49 is a further enlarged view within Inset AC showing the amplification chamber
- Figure 50 is a further enlarged view within Inset AC showing the amplification section
- Figure 51 is a schematic section view of the amplification section
- Figure 52 is an enlarged plan view of the hybridization section
- Figure 53 is a further enlarged plan view of two hybridization chambers in isolation
- Figure 54 is schematic section view of a single hybridization chamber
- Figure 55 is an enlarged view of the humidifier illustrated in Inset AG shown in
- Figure 56 is an enlarged view of Inset AD shown in Figure 52;
- Figure 57 is an exploded perspective view of the LOC device within Inset AD;
- Figure 58 is a diagram of a FRET probe in a closed configuration
- Figure 59 is a diagram of a FRET probe in an open and hybridized configuration
- Figure 60 is a graph of the intensity of an excitation light over time
- Figure 61 is a diagram of the excitation illumination geometry of the hybridization chamber array
- Figure 62 is a diagram of a Sensor Electronic Technology LED illumination geometry
- Figure 63 is an enlarged plan view of the humidity sensor shown in Inset AH of Figure 6;
- Figure 64 is a schematic showing part of the photodiode array of the photosensor;
- Figure 65 is a circuit diagram for a single photodiode;
- Figure 66 is a timing diagram for the photodiode control signals
- Figure 67 is an enlarged view of the evaporator shown in Inset AP of Figure 55;
- Figure 68 is a schematic section view through a hybridization chamber with a detection photodiode and trigger photodiode;
- Figure 69 is a diagram of linker-primed PCR
- Figure 70 is a schematic representation of a test module with a lancet
- Figure 71 is a diagrammatic representation of the architecture of LOC variant VII.
- Figure 72 is a plan view of LOC variant VIII with features and structures from all layers superimposed on each other;
- Figure 73 is an enlarged view of Inset CA shown in Figure 72;
- Figure 74 is a partial perspective illustrating the laminar structure of LOC variant VIII within Inset CA shown in Figure 72;
- Figure 75 is an enlarged view of Inset CE shown in Figure 73;
- Figure 76 is a diagrammatic representation of the architecture of LOC variant VIII.
- Figure 77 is a schematic illustration of the architecture of LOC variant XIV.
- Figure 78 is a schematic illustration of the architecture of LOC variant XIX
- Figure 79 is a schematic illustration of the architecture of LOC variant XLI.
- Figure 80 is a schematic illustration of the architecture of LOC variant XLIII
- Figure 81 is a schematic illustration of the architecture of LOC variant XLIV.
- Figure 82 is a schematic illustration of the architecture of LOC variant XLVII
- Figure 83 is a diagram of a primer-linked, linear fluorescent probe during the initial round of amplification
- Figure 84 is a diagram of a primer-linked, linear fluorescent probe during a subsequent amplification cycle;
- Figures 85A to 85F diagrammatically illustrate thermal cycling of a primer-linked fluorescent stem-and-loop probe;
- Figure 86 is a schematic illustration of the excitation LED relative to the hybridization chamber array and the photodiodes
- Figure 87 is a schematic illustration of the excitation LED and optical lens for directing light onto the hybridization chamber array of the LOC device;
- Figure 88 is a schematic illustration of the excitation LED, optical lens, and optical prisms for directing light onto the hybridization chamber array of the LOC device;
- Figure 89 is a schematic illustration of the excitation LED, optical lens and mirror arrangement for directing light onto the hybridization chamber array of the LOC device;
- Figure 90 is a plan view showing all the features superimposed on each other, and showing the location of Insets DA to DK;
- Figure 91 is an enlarged view of Inset DG shown in Figure 90;
- Figure 92 is an enlarged view of Inset DH shown in Figure 90;
- Figure 93 is a diagrammatic representation of the architecture of LOC variant XII;
- Figure 94 is a perspective view of LOC variant XII
- Figure 95 is a plan view of LOC variant XII showing all features superimposed on each other, and showing the location of Insets FA to FC;
- Figure 96 is a plan view of LOC variant XII showing only the features of the cap in isolation;
- Figure 97 is a plan view of LOC variant XII showing the structures of the CMOS + MST device in isolation;
- Figure 98 is an enlarged view of Inset FA shown in Figure 95;
- Figure 99 is an enlarged view of Inset FB shown in Figure 95;
- Figure 100 is an enlarged view of Inset FC shown in Figure 95;
- Figure 101 shows one embodiment of the shunt transistor for the photodiodes
- Figure 102 shows one embodiment of the shunt transistor for the photodiodes
- Figure 103 shows one embodiment of the shunt transistor for the photodiodes
- Figure 104 is a circuit diagram of the differential imager
- Figure 105 schematically illustrates a negative control fluorescent probe in its stem- and-loop configuration
- Figure 106 schematically illustrates the negative control fluorescent probe of Figure 105 in its open configuration
- Figure 107 schematically illustrates a positive control fluorescent probe in its stem- and-loop configuration
- Figure 108 schematically illustrates the positive control fluorescent probe of Figure 107 in its open configuration
- Figure 109 shows a test module and test module reader configured for use with
- Figure 110 is a schematic overview of the electronic components in the test module configured for use with ECL detection
- Figure 1 11 shows a test module and alternative test module readers
- Figure 112 shows a test module and test module reader along with the hosting system housing various databases
- Test modules 10 and 1 1 are the size of a typical USB memory key and very cheap to produce.
- Test modules 10 and 11 each contain a microfluidic device, typically in the form of a lab-on-a-chip (LOC) device 30 preloaded with reagents and typically more than 1000 probes for the molecular diagnostic assay (see Figures 1 and 109).
- Test module 10 schematically shown in Figure 1 uses a fluorescence-based detection technique to identify target molecules, while test module 11 in Figure 109 uses an electrochemiluminescence- based detection technique.
- the LOC device 30 has an integrated photosensor 44 for fluorescence or electrochemiluminescence detection (described in detail below).
- test modules 10 and 11 use a standard Micro-USB plug 14 for power, data and control, both have a printed circuit board (PCB) 57, and both have external power supply capacitors 32 and an inductor 15.
- PCB printed circuit board
- the test modules 10 and 11 are both single-use only for mass production and distribution in sterile packaging ready for use.
- the outer casing 13 has a macroreceptacle 24 for receiving the biological sample and a removable sterile sealing tape 22, preferably with a low tack adhesive, to cover the macroreceptacle prior to use.
- a membrane seal 408 with a membrane guard 410 forms part of the outer casing 13 to reduce dehumidification within the test module while providing pressure relief from small air pressure fluctuations.
- the membrane guard 410 protects the membrane seal 408 from damage.
- Test module reader 12 powers the test module 10 or 11 via Micro-USB port 16.
- the test module reader 12 can adopt many different forms and a selection of these are described later.
- the version of the reader 12 shown in Figures 1, 3 and 109 is a smart phone embodiment.
- a block diagram of this reader 12 is shown in Figure 3.
- Processor 42 runs application software from program storage 43.
- the processor 42 also interfaces with the display screen 18 and user interface (UI) touch screen 17 and buttons 19, a cellular radio 21, wireless network connection 23, and a satellite navigation system 25.
- the cellular radio 21 and wireless network connection 23 are used for communications.
- Satellite navigation system 25 is used for updating epidemiological databases with location data.
- the location data can, alternatively, be entered manually via the touch screen 17 or buttons 19.
- Data storage 27 holds genetic and diagnostic information, test results, patient information, assay and probe data for identifying each probe and its array position.
- Data storage 27 and program storage 43 may be shared in a common memory facility.
- Application software installed on the test module reader 12 provides analysis of results, along with additional test and diagnostic information.
- test module 10 (or test module 1 1) is inserted into the Micro-USB port 16 on the test module reader 12.
- the sterile sealing tape 22 is peeled back and the biological sample (in a liquid form) is loaded into the sample macroreceptacle 24.
- Pressing start button 20 initiates testing via the application software.
- the sample flows into the LOC device 30 and the on-board assay extracts, incubates, amplifies and hybridizes the sample nucleic acids (the target) with presynthesized hybridization- responsive oligonucleotide probes.
- test module 10 which uses fluorescence-based detection
- the probes are fluorescently labelled and the LED 26 housed in the casing 13 provides the necessary excitation light to induce fluorescence emission from the hybridized probes (see Figures 1 and 2).
- test module 11 which uses fluorescence-based detection
- ECL electrochemiluminescence
- the LOC device 30 is loaded with ECL probes (discussed above) and the LED 26 is not necessary for generating the luminescent emission. Instead, electrodes 860 and 870 provide the excitation electrical current (see Figure 110).
- the emission fluorescent or luminescent is detected using a photosensor 44 integrated into CMOS circuitry of each LOC device. The detected signal is amplified and converted to a digital output which is analyzed by the test module reader 12. The reader then displays the results.
- the data may be saved locally and'or uploaded to a network server containing patient records.
- the test module 10 or 11 is removed from the test module reader 12 and disposed of appropriately.
- Figures 1, 3 and 109 show the test module reader 12 configured as a mobile phone/smart phone 28.
- the test module reader is a laptop/notebook 101, a dedicated reader 103, an ebook reader 107, a tablet computer 109 or desktop computer 105 for use in hospitals, private practices or laboratories (see Figure 111).
- the reader can interface with a range of additional applications such as patient records, billing, online databases and multi-user environments. It can also be interfaced with a range of local or remote peripherals such as printers and patient smart cards.
- the data generated by the test module 10 can be used to update, via the reader 12 and network 125, the epidemiological databases hosted on the hosting system for epidemiological data 11 1, the genetic databases hosted on the hosting system for genetic data 113, the electronic health records hosted on the hosting system for electronic health records (EHR) 1 15, the electronic medical records hosted on the hosting system for electronic medical records (EMR) 121, and the personal health records hosted on the hosting system for personal health records (PHR) 123.
- EHR electronic health records hosted on the hosting system for electronic health records
- PHR personal health records hosted on the hosting system for personal health records
- the epidemiological data hosted on the hosting system for epidemiological data 111 can be used to update, via network 125 and the reader 12, the digital memory in the LOC 30 of the test module 10.
- the reader 12 uses battery power in the mobile phone configuration.
- the mobile phone reader contains all test and diagnostic information preloaded. Data can also be loaded or updated via a number of wireless or contact interfaces to enable communications with peripheral devices, computers or online servers.
- a Micro-USB port 16 is provided for connection to a computer or mains power supply for battery recharge.
- Figure 70 shows an embodiment of the test module 10 used for tests that only require a positive or negative result for a particular target, such as testing whether a person is infected with, for example, H1N1 Influenza A virus.
- a positive or negative result for a particular target such as testing whether a person is infected with, for example, H1N1 Influenza A virus.
- Only a purpose built USB power/indicator-only module 47 is adequate. No other reader or application software is necessary.
- An indicator 45 on the USB power/indicator-only module 47 signals positive or negative results. This configuration is well suited to mass screening.
- test tube containing reagents for pre-treatment of certain samples may include a test tube containing reagents for pre-treatment of certain samples, along with spatula and lancet for sample collection.
- Figure 70 shows an embodiment of the test module incorporating a spring- loaded, retractable lancet 390 and lancet release button 392 for convenience.
- a satellite phone can be used in remote areas.
- FIGS 2 and 110 are block diagrams of the electronic components in the test modules 10 and 11, respectively.
- the CMOS circuitry integrated in the LOC device 30 has a USB device driver 36, a controller 34, a USB-compatible LED driver 29, clock 33, power conditioner 31, RAM 38 and program and data flash memory 40. These provide the control and memory for the entire test module 10 or 11 including the photosensor 44, the temperature sensors 170, the liquid sensors 174, and the various heaters 152, 154, 182, 234, together with associated drivers 37 and 39 and registers 35 and 41.
- Only the LED 26 in the case of test module 10
- external power supply capacitors 32 and the Micro-USB plug 14 are external to the LOC device 30.
- the LOC devices 30 include bond-pads for making connections to these external components.
- the RAM 38 and the program and data flash memory 40 have the application software and the diagnostic and test information (Flash/Secure storage, e.g. via encryption) for over 1000 probes.
- the diagnostic and test information Flash/Secure storage, e.g. via encryption
- test module 1 1 configured for ECL detection
- LED 26 there is no LED 26 (see Figures 109 and 110).
- Data is encrypted by the LOC device 30 for secure storage and secure communication with an external device.
- the LOC devices 30 are loaded with electrochemiluminescent probes and the hybridization chambers each have a pair of ECL excitation electrodes 860 and 870.
- test modules 10 are manufactured in a number of test forms, ready for off-the-shelf use. The differences between the test forms lie in the on board assay of reagents and probes.
- infectious diseases rapidly identified with this system include:
- Streptococcus pneumoniae Staphylococcus aureus • Tuberculosis - Mycobacterium tuberculosis, bovis, africanum, canetti, and microti
- HIV Human immunodeficiency virus
- HSV Herpes simplex virus
- CMV Cytomegalovirus
- a small selection of cancers identified by the diagnostic system include:
- the LOC device 30 is central to the diagnostic system. It rapidly performs the four major steps of a nucleic acid based molecular diagnostic assay, i.e. sample preparation, nucleic acid extraction, nucleic acid amplification, and detection, using a microfluidic platform.
- the LOC device also has alternative uses, and these are detailed later.
- test modules 10 and 11 can adopt many different configurations to detect different targets.
- the LOC device 30 has numerous different embodiments tailored to the target(s) of interest.
- One form of the LOC device 30 is LOC device 301 for fluorescent detection of target nucleic acid sequences in the pathogens of a whole blood sample.
- LOC device 301 for fluorescent detection of target nucleic acid sequences in the pathogens of a whole blood sample.
- Figure 4 is a schematic representation of the architecture of the LOC device 301.
- process stages shown in Figure 4 are indicated with the reference numeral corresponding to the functional sections of the LOC device 301 that perform that process stage.
- the process stages associated with each of the major steps of a nucleic acid based molecular diagnostic assay are also indicated: sample input and preparation 288, extraction 290, incubation 291, amplification 292 and detection 294.
- sample input and preparation 288 extraction 290
- incubation 291 amplification 292
- detection 294 The various reservoirs, chambers, valves and other components of the LOC device 301 will be described in more detail later.
- FIG. 5 is a perspective view of the LOC device 301. It is fabricated using high volume CMOS and MST (microsystems technology) manufacturing techniques. The laminar structure of the LOC device 301 is illustrated in the schematic (not to scale) partial section view of Figure 12.
- the LOC device 301 has a silicon substrate 84 which supports the CMOS + MST chip 48, comprising CMOS circuitry 86 and an MST layer 87, with a cap 46 overlaying the MST layer 87.
- the term 'MST layer' is a reference to a collection of structures and layers that process the sample with various reagents.
- these structures and components are configured to define flow-paths with characteristic dimensions that will support capillary driven flow of liquids with physical characteristics similar to those of the sample during processing.
- the MST layer and components are typically fabricated using surface micromachining techniques and/or bulk micromachining techniques. However, other fabrication methods can also produce structures and components dimensioned for capillary driven flows and processing very small volumes.
- the specific embodiments described in this specification show the MST layer as the structures and active components supported on the CMOS circuitry 86, but excluding the features of the cap 46. However, the skilled addressee will appreciate that the MST layer need not have underlying CMOS or indeed an overlying cap in order for it to process the sample.
- LOC devices fabricated for different applications may have different dimensions.
- Figure 6 shows the features of the MST layer 87 superimposed with the features of the cap.
- Insets AA to AD, AG and AH shown in Figure 6 are enlarged in Figures 13, 14, 35, 56, 55 and 63, respectively, and described in detail below for a comprehensive understanding of each structure within the LOC device 301.
- Figures 7 to 10 show the features of the cap 46 in isolation while Figure 1 1 shows the CMOS + MST device 48 structures in isolation.
- FIGS. 12 and 22 are sketches that diagrammatically show the laminar structure of the CMOS + MST device 48, the cap 46 and the fluidic interaction between the two. The figures are not to scale for the purposes of illustration.
- Figure 12 is a schematic section view through the sample inlet 68 and Figure 22 is a schematic section through the reservoir 54.
- the CMOS + MST device 48 has a silicon substrate 84 which supports the CMOS circuitry 86 that operates the active elements within the MST layer 87 above.
- a passivation layer 88 seals and protects the CMOS layer 86 from the fluid flows through the MST layer 87.
- Cell transport occurs in the larger channels 94 fabricated in the cap 46, while biochemical processes are carried out in the smaller MST channels 90.
- Cell transport channels are sized so as to be able to transport cells in the sample to predetermined sites in the MST channels 90.
- Transportation of cells with sizes greater than 20 microns for example, certain leukocytes
- MST channels particularly at locations in the LOC where transport of cells is not required, can be significantly smaller.
- cap channel 94 and MST channel 90 are generic references and particular MST channels 90 may also be referred to as (for example) heated microchannels or dialysis MST channels in light of their particular function.
- MST channels 90 are formed by etching through a MST channel layer 100 deposited on the passivation layer 88 and patterned with photoresist.
- the MST channels 90 are enclosed by a roof layer 66 which forms the top (with respect to the orientation shown in the figures) of the CMOS + MST device 48.
- the cap channel layer 80 and the reservoir layer 78 are formed from a unitary piece of material.
- the piece of material may also be non-unitary. This piece of material is etched from both sides in order to form a cap channel layer 80 in which the cap channels 94 are etched and the reservoir layer 78 in which the reservoirs 54, 56, 58, 60 and 62 are etched.
- the reservoirs and the cap channels are formed by a micromolding process. Both etching and micromolding techniques are used to produce channels with cross sectional areas transverse to the flow as large as 20,000 square microns, and as small as 8 square microns.
- the cross sectional area of the channel transverse to the flow there can be a range of appropriate choices for the cross sectional area of the channel transverse to the flow.
- a cross-sectional area of up to 20,000 square microns for example, a 200 micron wide channel in a 100 micron thick layer
- small quantities of liquid, or mixtures without large cells present are contained in the channel, a very small cross sectional area transverse to the flow is preferable.
- a lower seal 64 encloses the cap channels 94 and the upper seal layer 82 encloses the reservoirs 54, 56, 58, 60 and 62.
- the five reservoirs 54, 56, 58, 60 and 62 are preloaded with assay-specific reagents. In the embodiment described here, the reservoirs are preloaded with the following reagents, but other reagents can easily be substituted: ⁇ reservoir 54: anticoagulant with option to include erythrocyte lysis buffer
- reservoir 58 restriction enzymes, ligase and linkers (for linker-primed PCR (see Figure 69, extracted from T. Stachan et al, Human Molecular Genetics 2, Garland Science, NY and London, 1999))
- ⁇ reservoir 60 amplification mix (dNTPs, primers, buffer) and
- the cap 46 and the CMOS+MST layers 48 are in fluid communication via corresponding openings in the lower seal 64 and the roof layer 66. These openings are referred to as uptakes 96 and downtakes 92 depending on whether fluid is flowing from the MST channels 90 to the cap channels 94 or vice versa.
- LOC device 301 The operation of the LOC device 301 is described below in a step-wise fashion with reference to analysing pathogenic DNA in a blood sample.
- other types of biological or non-biological fluid are also analysed using an appropriate set, or combination, of reagents, test protocols, LOC variants and detection systems.
- the sample input and preparation step 288 involves mixing the blood with an anticoagulant 116 and then separating pathogens from the leukocytes and erythrocytes with the pathogen dialysis section 70.
- the blood sample enters the device via the sample inlet 68. Capillary action draws the blood sample along the cap channel 94 to the reservoir 54.
- Anticoagulant is released from the reservoir 54 as the sample blood flow opens its surface tension valve 118 (see Figures 15 and 22). The anticoagulant prevents the formation of clots which would block the flow.
- the anticoagulant 1 16 is drawn out of the reservoir 54 by capillary action and into the MST channel 90 via the downtake 92.
- the downtake 92 has a capillary initiation feature (CIF) 102 to shape the geometry of the meniscus such that it does not anchor to the rim of the downtake 92.
- Vent holes 122 in the upper seal 82 allows air to replace the anticoagulant 1 16 as it is drawn out of the reservoir 54.
- the MST channel 90 shown in Figure 22 is part of a surface tension valve 1 18.
- the anticoagulant 1 16 fills the surface tension valve 118 and pins a meniscus 120 to the uptake 96 to a meniscus anchor 98.
- the meniscus 120 remains pinned at the uptake 96 so the anticoagulant does not flow into the cap channel 94.
- the meniscus 120 is removed and the anticoagulant is drawn into the flow.
- Figures 15 to 21 show Inset AE which is a portion of Inset AA shown in Figure 13.
- the surface tension valve 118 has three separate MST channels 90 extending between respective downtakes 92 and uptakes 96.
- the number of MST channels 90 in a surface tension valve can be varied to change the flow rate of the reagent into the sample mixture.
- the flow rate out of the reservoir determines the concentration of the reagent in the sample flow.
- the surface tension valve for each of the reservoirs is configured to match the desired reagent concentration.
- the blood passes into a pathogen dialysis section 70 (see Figures 4 and 15) where target cells are concentrated from the sample using an array of apertures 164 sized according to a predetermined threshold. Cells smaller than the threshold pass through the apertures while larger cells do not pass through the apertures. Unwanted cells, which may be either the larger cells withheld by the array of apertures 164 or the smaller cells that pass through the apertures, are redirected to a waste unit 76 while the target cells continue as part of the assay.
- the pathogens from the whole blood sample are concentrated for microbial DNA analysis.
- the array of apertures is formed by a multitude of 3 micron diameter holes 164 fluidically connecting the input flow in the cap channel 94 to a target channel 74.
- the 3 micron diameter apertures 164 and the dialysis uptake holes 168 for the target channel 74 are connected by a series of dialysis MST channels 204 (best shown in Figures 15 and 21).
- Pathogens are small enough to pass through the 3 micron diameter apertures 164 and fill the target channel 74 via the dialysis MST channels 204.
- Cells larger than 3 microns such as erythrocytes and leukocytes, stay in the waste channel 72 in the cap 46 which leads to a waste reservoir 76 (see Figure 7).
- Other aperture shapes, sizes and aspect ratios can be used to isolate specific pathogens or other target cells such as leukocytes for human DNA analysis. Greater detail on the dialysis section and dialysis variants is provided later.
- the flow is drawn through the target channel 74 to the surface tension valve 128 of the lysis reagent reservoir 56.
- the surface tension valve 128 has seven MST channels 90 extending between the lysis reagent reservoir 56 and the target channel 74.
- the flow rate from all seven of the MST channels 90 will be greater than the flow rate from the anticoagulant reservoir 54 where the surface tension valve 118 has three MST channels 90 (assuming the physical characteristics of the fluids are roughly equivalent).
- the proportion of lysis reagent in the sample mixture is greater than that of the anticoagulant.
- the lysis reagent and target cells mix by diffusion in the target channel 74 within the chemical lysis section 130.
- a boiling-initiated valve 126 stops the flow until sufficient time has passed for diffusion and lysis to take place, releasing the genetic material from the target cells (see Figures 6 and 7).
- the structure and operation of the boiling-initiated valves are described in greater detail below with reference to Figures 31 and 32.
- Other active valve types as opposed to passive valves such as the surface tension valve 118 have also been developed by the Applicant which may be used here instead of the boiling- initiated valve. These alternative valve designs are also described later.
- the boiling-initiated valve 126 opens, the lysed cells flow into a mixing section 131 for pre-amplification restriction digestion and linker ligation.
- restriction enzymes, linkers and ligase are released from the reservoir 58 when the flow unpins the menisci at the surface tension valve 132 at the start of the mixing section 131.
- the mixture flows the length of the mixing section 131 for diffusion mixing.
- At the end of the mixing section 131 is downtake 134 leading into the incubator inlet channel 133 of the incubation section 114 (see Figure 13).
- the incubator inlet channel 133 feeds the mixture into a serpentine configuration of heated microchannels 210 which provides an incubation chamber for holding the sample during restriction digestion and ligation of the linkers (see Figures 13 and 14).
- FIGS 23, 24, 25, 26, 27, 28 and 29 show the layers of the LOC device 301 within
- this incubation step 291 (see Figure 4) is optional and only required for some nucleic acid amplification assay types. Furthermore, in some instances, it may be necessary to have a heating step at the end of the incubation period to spike the temperature above the incubation temperature. The temperature spike inactivates the restriction enzymes and ligase prior to entering the amplification section 1 12. Inactivation of the restriction enzymes and ligase has particular relevance when isothermal nucleic acid amplification is being employed.
- the boiling-initiated valve 106 is activated (opened) and the flow resumes into the amplification section 112.
- the mixture fills the serpentine configuration of heated microchannels 158, which form one or more amplification chambers, until it reaches the boiling-initiated valve 108.
- amplification mix dNTPs, primers, buffer
- polymerase is subsequently released from reservoir 62 into the intermediate MST channel 212 connecting the incubation and amplification sections (114 and 112 respectively).
- FIGS 35 to 51 show the layers of the LOC device 301 within Inset AC of Figure 6. Each figure shows the sequential addition of layers forming the structures of the CMOS + MST device 48 and the cap 46.
- Inset AC is at the end of the amplification section 1 12 and the start of the hybridization and detection section 52.
- the incubated sample, amplification mix and polymerase flow through the microchannels 158 to the boiling- initiated valve 108.
- the heaters 154 in the microchannels 158 are activated for thermal cycling or isothermal amplification.
- the amplification mix goes through a predetermined number of thermal cycles or a preset amplification time to amplify sufficient target DNA.
- the boiling-initiated valve 108 opens and flow resumes into the hybridization and detection section 52. The operation of boiling- initiated valves is described in more detail later.
- the hybridization and detection section 52 has an array of hybridization chambers 1 10.
- Figures 52, 53, 54 and 56 show the hybridization chamber array 110 and individual hybridization chambers 180 in detail.
- a diffusion barrier 175 which prevents diffusion of the target nucleic acid, probe strands and hybridized probes between the hybridization chambers 180 during hybridization so as to prevent erroneous hybridization detection results.
- the diffusion barriers 175 present a flow-path-length that is long enough to prevent the target sequences and probes diffusing out of one chamber and contaminating another chamber within the time taken for the probes and nucleic acids to hybridize and the signal to be detected, thus avoiding an erroneous result.
- the CMOS circuitry 86 derives a single result from the photodiodes 184 corresponding to the hybridization chambers 180 that contain identical probes. Anomalous results can be disregarded or weighted differently in the derivation of the single result.
- CMOS-controlled heaters 182 (described in more detail below). After the heater is activated, hybridization occurs between complementary target-probe sequences.
- the LED driver 29 in the CMOS circuitry 86 signals the LED 26 located in the test module 10 to illuminate. These probes only fluoresce when hybridization has occurred thereby avoiding washing and drying steps that are typically required to remove unbound strands. Hybridization forces the stem-and- loop structure of the FRET probes 186 to open, which allows the fluorophore to emit fluorescent energy in response to the LED excitation light, as discussed in greater detail later.
- Fluorescence is detected by a photodiode 184 in the CMOS circuitry 86 underlying each hybridization chamber 180 (see hybridization chamber description below).
- the photodiodes 184 for all hybridization chambers and associated electronics collectively form the photosensor 44 (see Figure 64).
- the photosensor may be an array of charge coupled devices (CCD array).
- the detected signal from the photodiodes 184 is amplified and converted to a digital output which is analyzed by the test module reader 12. Further details of the detection method are described later.
- the LOC device 301 has many functional sections, including the reagent reservoirs 54, 56, 58, 60 and 62, the dialysis section 70, lysis section 130, incubation section 1 14, and amplification section 112, valve types, the humidifier and humidity sensor. In other embodiments of the LOC device, these functional sections can be omitted, additional functional sections can be added or the functional sections can be used for alternative purposes to those described above.
- the incubation section 1 14 can be used as the first amplification section 112 of a tandem amplification assay system, with the chemical lysis reagent reservoir 56 being used to add the first amplification mix of primers, dNTPs and buffer and reagent reservoir 58 being used for adding the reverse transcriptase and/or polymerase.
- a chemical lysis reagent can also be added to the reservoir 56 along with the amplification mix if chemical lysis of the sample is desired or, alternatively, thermal lysis can occur in the incubation section by heating the sample for a predetermined time.
- an additional reservoir can be incorporated immediately upstream of reservoir 58 for the mix of primers, dNTPs and buffer if there is a requirement for chemical lysis and a separation of this mix from the chemical lysis reagent is desired.
- a LOC device can be specifically fabricated to omit the reagent reservoir 58 and incubation section 1 14, or the reservoir can simply not be loaded with reagents or the active valves, if present, not activated to dispense the reagents into the sample flow, and the incubation section then simply becomes a channel to transport the sample from the lysis section 130 to the amplification section 112.
- the heaters are independently operable and therefore, where reactions are dependent on heat, such as thermal lysis, programming the heaters not to activate during this step ensures thermal lysis does not occur in LOC devices that do not require it.
- the dialysis section 70 can be located at the beginning of the fluidic system within the micro fluidic device as shown in Figure 4 or can be located anywhere else within the microfluidic device. For example, dialysis after the amplification phase 292 to remove cellular debris prior to the
- hybridization and detection step 294 may be beneficial in some circumstances.
- two or more dialysis sections can be incorporated at any location throughout the LOC device.
- additional amplification sections 1 12 to enable multiple targets to be amplified in parallel or in series prior to being detected in the hybridization chamber arrays 110 with specific nucleic acid probes.
- the dialysis section 70 is simply omitted from the sample input and preparation section 288 of the LOC design. In some cases, it is not necessary to omit the dialysis section 70 from the LOC device even if the analysis does not require dialysis. If there is no geometric hindrance to the assay by the existence of a dialysis section, a LOC with the dialysis section 70 in the sample input and preparation section can still be used without a loss of the required functionality.
- the detection section 294 may encompass proteomic chamber arrays which are identical to the hybridization chamber arrays but are loaded with probes designed to conjugate or hybridize with sample target proteins present in non-amplified sample instead of nucleic acid probes designed to hybridize to target nucleic acid sequences.
- the LOC devices fabricated for use in this diagnostic system are different combinations of functional sections selected in accordance with the particular LOC application.
- the vast majority of functional sections are common to many of the LOC devices and the design of additional LOC devices for new application is a matter of compiling an appropriate combination of functional sections from the extensive selection of functional sections used in the existing LOC devices.
- LOC variants can accept and analyze the nucleic acid or protein content of a variety of sample types in liquid form including, but not limited to, blood and blood products, saliva, cerebrospinal fluid, urine, semen, amniotic fluid, umbilical cord blood, breast milk, sweat, pleural effusion, tear, pericardial fluid, peritoneal fluid, environmental water samples and drink samples.
- Amplicon obtained from macroscopic nucleic acid amplification can also be analysed using the LOC device; in this case, all the reagent reservoirs will be empty or configured not to release their contents, and the dialysis, lysis, incubation and amplification sections will be used solely to transport the sample from the sample inlet 68 to the hybridization chambers 180 for nucleic acid detection, as described above.
- a pre-processing step is required, for example semen may need to be liquefied and mucus may need to be pre-treated with an enzyme to reduce the viscosity prior to input into the LOC device.
- the sample is added to the macroreceptacle 24 of the test module 10.
- the macroreceptacle 24 is a truncated cone which feeds into the inlet 68 of the LOC device 301 by capillary action. Here it flows into the 64 ⁇ wide x 60 ⁇ deep cap channel 94 where it is drawn towards the anticoagulant reservoir 54, also by capillary action.
- This volume is easily less than 1,000,000,000 cubic microns, in the vast majority of cases less than 300,000,000 cubic microns, typically less than 70,000,000 cubic microns and in the case of the LOC device 301 shown in the drawings, less than 20,000,000 cubic microns.
- the pathogen dialysis section 70 is designed to concentrate pathogenic target cells from the sample.
- a plurality of apertures in the form of 3 micron diameter holes 164 in the roof layer 66 filter the target cells from the bulk of the sample.
- microbial pathogens pass through the holes into a series of dialysis MST channels 204 and flow back up into the target channel 74 via 16 ⁇ dialysis uptake holes 168 (see Figures 33 and 34).
- the remainder of the sample (erythrocytes and so on) stay in the cap channel 94.
- the cap channel 94 becomes the waste channel 72 leading to the waste reservoir 76.
- a foam insert or other porous element 49 within the outer casing 13 of the test module 10 is configured to be in fluid communication with the waste reservoir 76 (see Figure 1).
- the pathogen dialysis section 70 functions entirely on capillary action of the fluid sample.
- the 3 micron diameter apertures 164 at the upstream end of the pathogen dialysis section 70 have capillary initiation features (CIFs) 166 (see Figure 33) so that the fluid is drawn down into the dialysis MST channel 204 beneath.
- the first uptake hole 198 for the target channel 74 also has a CIF 202 (see Figure 15) to avoid the flow simply pinning a meniscus across the dialysis uptake holes 168.
- the small constituents dialysis section 682 schematically shown in Figure 79 can have a similar structure to the pathogen dialysis section 70.
- the small constituents dialysis section separates any small target cells or molecules from a sample by sizing (and, if necessary, shaping) apertures suitable for allowing the small target cells or molecules to pass into the target channel and continue for further analysis. Larger sized cells or molecules are removed to a waste reservoir 766.
- the LOC device 30 (see Figures 1 and 109) is not limited to separating pathogens that are less than 3 ⁇ in size, but can be used to separate cells or molecules of any size desired.
- the genetic material in the sample is released from the cells by a chemical lysis process.
- a lysis reagent from the lysis reservoir 56 mixes with the sample flow in the target channel 74 downstream of the surface tension valve 128 for the lysis reservoir 56.
- some diagnostic assays are better suited to a thermal lysis process, or even a combination of chemical and thermal lysis of the target cells.
- the LOC device 301 accommodates this with the heated microchannels 210 of the incubation section 1 14.
- the sample flow fills the incubation section 114 and stops at the boiling-initiated valve 106.
- the incubation microchannels 210 heat the sample to a temperature at which the cellular membranes are disrupted.
- the LOC device 301 has three boiling-initiated valves 126, 106 and 108. The location of these valves is shown in Figure 6.
- Figure 31 is an enlarged plan view of the boiling-initiated valve 108 in isolation at the end of the heated microchannels 158 of the amplification section 1 12.
- the sample flow 1 19 is drawn along the heated microchannels 158 by capillary action until it reaches the boiling-initiated valve 108.
- the leading meniscus 120 of the sample flow pins at a meniscus anchor 98 at the valve inlet 146.
- the geometry of the meniscus anchor 98 stops the advancing meniscus to arrest the capillary flow.
- the meniscus anchor 98 is an aperture provided by an uptake opening from the MST channel 90 to the cap channel 94. Surface tension in the meniscus 120 keeps the valve closed.
- An annular heater 152 is at the periphery of the valve inlet 146.
- the annular heater 152 is CMOS-controlled via the boiling- initiated valve heater contacts 153.
- the CMOS circuitry 86 sends an electrical pulse to the valve heater contacts 153.
- the annular heater 152 resistively heats until the liquid sample 1 19 boils. The boiling unpins the meniscus 120 from the valve inlet 146 and initiates wetting of the cap channel 94. Once wetting the cap channel 94 begins, capillary flow resumes.
- the fluid sample 119 fills the cap channel 94 and flows through the valve downtake 150 to the valve outlet 148 where capillary driven flow continues along the amplification section exit channel 160 into the hybridization and detection section 52.
- Liquid sensors 174 are placed before and after the valve for diagnostics.
- INCUBATION SECTION AND NUCLEIC ACID AMPLIFICATION SECTION Figures 6, 7, 13, 14, 23, 24, 25, 35 to 45, 50 and 51 show the incubation section 114 and the amplification section 112.
- the incubation section 114 has a single, heated incubation microchannel 210 etched in a serpentine pattern in the MST channel layer 100 from the downtake opening 134 to the boiling-initiated valve 106 (see Figures 13 and 14). Control over the temperature of the incubation section 114 enables enzymatic reactions to take place with greater efficiency.
- the amplification section 112 has a heated amplification microchannel 158 in a serpentine configuration leading from the boiling- initiated valve 106 to the boiling-initiated valve 108 (see Figures 6 and 14). These valves arrest the flow to retain the target cells in the heated incubation or amplification microchannels 210 or 158 while mixing, incubation and nucleic acid amplification takes place.
- the serpentine pattern of the microchannels also facilitates (to some extent) mixing of the target cells with reagents.
- each meander of the serpentine configuration of the heated incubation microchannel 210 and amplification microchannel 158 has three separately operable heaters 154 extending between their respective heater contacts 156 (see Figure 14) which provides for the two-dimensional control of input heat flux density.
- the heaters 154 are supported on the roof layer 66 and embedded in the lower seal 64.
- the heater material is TiAl but many other conductive metals would be suitable.
- the elongate heaters 154 are parallel with the longitudinal extent of each channel section that forms the wide meanders of the serpentine shape.
- each of the wide meanders can operate as separate PC chambers via individual heater control.
- each channel section increases the heating rate of the amplification fluid mix. All the fluid is kept a relatively short distance from the heater 154. Reducing the channel cross section (that is the amplification microchannel 158 cross section) to less than 100,000 square microns achieves appreciably higher heating rates than that provided by more 'macro-scale' equipment. Lithographic fabrication techniques allow the amplification microchannel 158 to have a cross sectional area transverse to the flow- path less than 16,000 square microns which gives substantially higher heating rates.
- the cross sectional area can be reduced to less than 2,500 square microns.
- a cross sectional area transverse to the flow of between 400 square microns and 1 square micron is adequate.
- the heater element in the amplification microchannel 158 heats the nucleic acid sequences at a rate more than 80 Kelvin (K) per second, in the vast majority of cases at a rate greater than 100 K per second.
- K Kelvin
- the heater element heats the nucleic acid sequences at a rate more than 1,000 K per second and in many cases, the heater element heats the nucleic acid sequences at a rate more than 10,000 per second.
- the heater element heats the nucleic acid sequences at a rate more than 100,000 K per second, more than 1,000,000 K per second more than 10,000,000 K per second, more than 20,000,000 per second, more than 40,000,000 K per second, more than 80,000,000 K per second and more than 160,000,000 K per second.
- a small cross-sectional area channel is also beneficial for diffusive mixing of any reagents with the sample fluid.
- diffusion of one liquid into the other is greatest near the interface between the two. Concentration decreases with distance from the interface.
- Using microchannels with relatively small cross sections transverse to the flow direction keeps both fluid flows close to the interface for more rapid diffusive mixing. Reducing the channel cross section to less than 100,000 square microns achieves appreciably higher mixing rates than that provided by more 'macro-scale' equipment. Lithographic fabrication techniques allows microchannels with a cross sectional area transverse to the flow-path less than 16000 square microns which gives significantly higher mixing rates.
- the cross sectional area can be reduced to less than 2500 square microns.
- a cross sectional area transverse to the flow of between 400 square microns and 1 square micron is adequate.
- each thermal cycle i.e. denaturing, annealing and primer extension
- target sequences up to 150 base pairs (bp) long base pairs
- the individual thermal cycle times are less than 11 seconds, and a large proportion are less than 4 seconds.
- LOC devices 30 with some of the most common diagnostic assays have thermal cycles time between 0.45 seconds to 1.5 seconds for target sequences up to 150 bp long. Thermal cycling at this rate allows the test module to complete the nucleic acid amplification process in much less than 10 minutes; often less than 220 seconds.
- the amplification section For most assays, the amplification section generates sufficient amplicon in less than 80 seconds from the sample fluid entering the sample inlet. For a great many assays, sufficient amplicon is generated in 30 seconds.
- the amplicon Upon completion of a preset number of amplification cycles, the amplicon is fed into the hybridization and detection section 52 via the boiling-initiated valve 108.
- FIGS 52, 53, 54, 56 and 57 show the hybridization chambers 180 in the hybridization chamber array 1 10.
- the hybridization and detection section 52 has a 24 x 45 array 110 of hybridization chambers 180, each with hybridization-responsive FRET probes 186, heater element 182 and an integrated photodiode 184.
- the photodiode 184 is incorporated for detection of fluorescence resulting from the hybridization of a target nucleic acid sequence or protein with the FRET probes 186.
- Each photodiode 184 is independently controlled by the CMOS circuitry 86. Any material between the FRET probes 186 and the photodiode 184 must be transparent to the emitted light.
- the wall section 97 between the probes 186 and the photodiode 184 is also optically transparent to the emitted light.
- the wall section 97 is a thin (approximately 0.5 micron) layer of silicon dioxide.
- the hybridization section has more than 1,000 chambers in an area of 1,500 microns by 1,500 microns (i.e. less than 2,250 square microns per chamber). Smaller volumes also reduce the reaction times so that hybridization and detection is faster.
- An additional advantage of the small amount of probe required in each chamber is that only very small quantities of probe solution need to be spotted into each chamber during production of the LOC device.
- Embodiments of the LOC device according to the invention can be spotted using a probe solution volume of 1 picoliter or less.
- boiling-initiated valve 108 is activated and the amplicon flows along the flow-path 176 and into each of the hybridization chambers 180 (see Figures 52 and 56).
- An end-point liquid sensor 178 indicates when the hybridization chambers 180 are filled with amplicon and the heaters 182 can be activated.
- the LED 26 (see Figure 2) is activated.
- the opening in each of the hybridization chambers 180 provides an optical window 136 for exposing the FRET probes 186 to the excitation radiation (see Figures 52, 54 and 56).
- the LED 26 is illuminated for a sufficiently long time in order to induce a fluorescence signal from the probes with high intensity.
- the photodiode 184 is shorted.
- the photodiode 184 is enabled and fluorescence emission is detected in the absence of the excitation light.
- the incident light on the active area 185 of the photodiode 184 (see Figure 54) is converted into a photocurrent which can then be measured using CMOS circuitry 86.
- the hybridization chambers 180 are each loaded with probes for detecting a single target nucleic acid sequence. Each hybridization chambers 180 can be loaded with probes to detect over 1,000 different targets if desired. Alternatively, many or all the
- hybridization chambers can be loaded with the same probes to detect the same target nucleic acid repeatedly. Replicating the probes in this way throughout the hybridization chamber array 1 10 leads to increased confidence in the results obtained and the results can be combined by the photodiodes adjacent those hybridization chambers to provide a single result if desired.
- the person skilled in the art will recognise that it is possible to have from one to over 1,000 different probes on the hybridization chamber array 1 10, depending on the assay specification.
- HUMIDIFIER AND HUMIDITY SENSOR Inset AG of Figure 6 indicates the position of the humidifier 196.
- the humidifier prevents evaporation of the reagents and probes during operation of the LOC device 301.
- a water reservoir 188 is fluidically connected to three evaporators 190.
- the water reservoir 188 is filled with molecular biology-grade water and sealed during manufacturing.
- water is drawn into three downtakes 194 and along respective water supply channels 192 by capillary action to a set of three uptakes 193 at the evaporators 190. A meniscus pins at each uptake 193 to retain the water.
- the evaporators have annular shaped heaters 191 which encircle the uptakes 193.
- the annular heaters 191 are connected to the CMOS circuitry 86 by the conductive columns 376 to the top metal layer 195 (see Figure 37). Upon activation, the annular heaters 191 heat the water causing evaporation and humidifying the device surrounds.
- the position of the humidity sensor 232 is also shown in Figure 6. However, as best shown in the enlarged view of Inset AH in Figure 63, the humidity sensor has a capacitive comb structure.
- lithographically etched second electrode 298 face each other such that their teeth are interleaved.
- the opposed electrodes form a capacitor with a capacitance that can be monitored by the CMOS circuitry 86. As the humidity increases, the permittivity of the air gap between the electrodes increases, so that the capacitance also increases.
- the humidity sensor 232 is adjacent the hybridization chamber array 110 where humidity measurement is most important to slow evaporation from the solution containing the exposed probes.
- Temperature and liquid sensors are incorporated throughout the LOC device 301 to provide feedback and diagnostics during device operation. Referring to Figure 35, nine temperature sensors 170 are distributed throughout the amplification section 1 12.
- the incubation section 114 also has nine temperature sensors 170. These sensors each use a 2x2 array of bipolar junction transistors (BJTs) to monitor the fluid temperature and provide feedback to the CMOS circuitry 86.
- BJTs bipolar junction transistors
- the CMOS circuitry 86 uses this to precisely control the thermal cycling during the nucleic acid amplification process and any heating during thermal lysis and incubation.
- the CMOS circuitry 86 uses the hybridization heaters 182 as temperature sensors (see Figure 56).
- the electrical resistance of the hybridization heaters 182 is temperature dependent and the CMOS circuitry 86 uses this to derive a temperature reading for each of the hybridization chambers 180.
- the LOC device 301 also has a number of MST channel liquid sensors 174 and cap channel liquid sensors 208.
- Figure 35 shows a line of MST channel liquid sensors 174 at one end of every other meander in the heated microchannel 158.
- the MST channel liquid sensors 174 are a pair of electrodes formed by exposed areas of the top metal layer 195 in the CMOS structure 86. Liquid closes the circuit between the electrodes to indicate its presence at the sensor's location.
- Figure 25 shows an enlarged perspective of cap channel liquid sensors 208.
- Opposing pairs of TiAl electrodes 218 and 220 are deposited on the roof layer 66. Between the electrodes 218 and 220 is a gap 222 to hold the circuit open in the absence of liquid. The presence of liquid closes the circuit and the CMOS circuitry 86 uses this feedback to monitor the flow.
- test modules 10 are orientation independent. They do not need to be secured to a flat stable surface in order to operate. Capillary driven fluid flows and a lack of external plumbing into ancillary equipment allow the modules to be truly portable and simply plugged into a similarly portable hand held reader such as a mobile telephone. Having a gravitationally independent operation means the test modules are also accelerationally independent to all practical extents. They are resistant to shock and vibration and will operate on moving vehicles or while the mobile telephone is being carried around.
- LOC variant VIII 518 and shown in Figures 72, 73, 74 and 75.
- This LOC device has a dialysis section that fills with the fluid sample without leaving air bubbles trapped in the channels.
- LOC variant VIII 518 also has an additional layer of material referred to as an interface layer 594.
- the interface layer 594 is positioned between the cap channel layer 80 and the MST channel layer 100 of the CMOS + MST device 48.
- the interface layer 594 allows a more complex fluidic interconnection between the reagent reservoirs and the MST layer 87 without increasing the size of the silicon substrate 84.
- the bypass channel 600 is designed to introduce a time delay in the fluid sample flow from the interface waste channel 604 to the interface target channel 602. This time delay allows the fluid sample to flow through the dialysis MST channel 204 to the dialysis uptake 168 where it pins a meniscus.
- a capillary initiation feature (CIF) 202 at the uptake from the bypass channel 600 to the interface target channel 602, the sample fluid fills the interface target channel 602 from a point upstream of all the dialysis uptakes 168 from the dialysis MST channels 204.
- the interface target channel 602 still starts filling from the upstream end, but eventually the advancing meniscus reaches and passes over an uptake belonging to an MST channel that has not yet filled, leading into air entrapment at that point. Trapped air reduces the sample flow rate through the leukocyte dialysis section 328.
- LOC variant XII 758 uses a small constituents dialysis section 682 placed at the outlet of the amplification section 112 (see Figures 93 to 100).
- the small constituents dialysis section 682 provides a pre-hybridization filter purification phase 293 (see Figure 93).
- Pre-hybridization filtering removes cell debris remaining in the sample flow following cell lysis. Hybridization efficiency can be affected by cell debris, so it is advantageous to reduce the concentration of cell debris prior to hybridization.
- the small constituents dialysis section 682 has three adjacent channels fabricated in the bottom channel layer 100; a large constituents channel 760 flanked by two small constituents channels 762.
- a series of stoma in the form of inverse tapered openings 764 along both sides of the large constituents channel 760 provide a fluidic connection to the small constituents channels 762.
- the stoma will be between 1 to 8 microns wide and 1 to 8 microns high.
- the small constituents amplicons fill all the individual hybridization chambers 180 prior to detection.
- PCR requires extensive purification of the target DNA prior to preparation of the reaction mixture.
- this approach is called direct PCR.
- LOC devices where nucleic acid amplification is performed at a controlled, constant temperature, the approach is direct isothermal amplification.
- Direct nucleic acid amplification techniques have considerable advantages for use in LOC devices, particularly relating to simplification of the required fluidic design.
- Adjustments to the amplification chemistry for direct PCR or direct isothermal amplification include increased buffer strength, the use of polymerases which have high activity and processivity, and additives which chelate with potential polymerase inhibitors. Dilution of inhibitors present in the sample is also important.
- the LOC device designs incorporate two additional features.
- the first feature is reagent reservoirs (for example reservoir 58 in Figure 8) which are appropriately dimensioned to supply a sufficient quantity of amplification reaction mix, or diluent, so that the final concentrations of sample components which might interfere with amplification chemistry are low enough to permit successful nucleic acid amplification.
- the desired dilution of non-cellular sample components is in the range of 5X to 20X.
- Different LOC structures for example the pathogen dialysis section 70 in Figure 4, are used when appropriate to ensure that the concentration of target nucleic acid sequences is maintained at a high enough level for amplification and detection.
- a dialysis section which effectively concentrates pathogens small enough to be passed into the amplification section 292 is employed upstream of the sample extraction section 290, and rejects larger cells to a waste receptacle 76.
- a dialysis section is used to selectively deplete proteins and salts in blood plasma while retaining cells of interest.
- the second LOC structural feature which supports direct nucleic acid amplification is design of channel aspect ratios to adjust the mixing ratio between the sample and the amplification mix components.
- the length and cross-section of the sample and reagent channels are designed such that the sample channel, upstream of the location where mixing is initiated, constitutes a flow impedance 4X - 19X higher than the flow impedance of the channels through which the reagent mixture flows. Control over flow impedances in microchannels is readily achieved through control over the design geometry. The flow impedance of a microchannel increases linearly with the channel length, for a constant cross-section.
- flow impedance in microchannels depends more strongly on the smallest cross-sectional dimension.
- the flow impedance of a microchannel with rectangular cross-section is inversely proportional to the cube of the smallest perpendicular dimension, when the aspect ratio is far from unity.
- RNA such as from RNA viruses or messenger RNA
- cDNA complementary DNA
- the reverse transcription reaction can be performed in the same chamber as the PCR (one-step RT-PCR) or it can be performed as a separate, initial reaction (two-step RT-PCR).
- a one-step RT-PCR can be performed simply by adding the reverse transcriptase to reagent reservoir 62 along with the polymerase and programming the heaters 154 to cycle firstly for the reverse transcription step and then progress onto the nucleic acid amplification step.
- a two-step RT-PCR could also be easily achieved by utilizing the reagent reservoir 58 to store and dispense the buffers, primers, dNTPs and reverse transcriptase and the incubation section 1 14 for the reverse transcription step followed by amplification in the normal way in the amplification section 1 12.
- isothermal nucleic acid amplification is the preferred method of nucleic acid amplification, thus avoiding the need to repetitively cycle the reaction components through various temperature cycles but instead maintaining the amplification section at a constant temperature, typically around 37°C to 41°C.
- a number of isothermal nucleic acid amplification methods have been described, including Strand Displacement Amplification (SDA), Transcription Mediated Amplification (TMA), Nucleic Acid Sequence Based Amplification (NASBA), Recombinase Polymerase Amplification (RPA), Helicase-Dependent isothermal DNA Amplification (HDA), Rolling Circle Amplification (RCA), Ramification Amplification (RAM) and Loop-mediated Isothermal Amplification (LAMP), and any of these, or other isothermal amplification methods, can be employed in particular embodiments of the LOC device described herein.
- SDA Strand Displacement Amplification
- TMA Transcription Mediated Amplification
- NASBA Nucleic Acid Sequence Based Amplification
- RPA Recombinase Polymerase Amplification
- HDA Helicase-Dependent isothermal DNA Amplification
- RCA Rolling Circle Amplification
- RAM Ramification Amplification
- LAMP Loop-mediated Isothermal Amplification
- the reagent reservoirs 60 and 62 adjoining the amplification section will be loaded with the appropriate reagents for the specified isothermal method instead of PCR amplification mix and polymerase.
- reagent reservoir 60 contains amplification buffer, primers and dNTPs and reagent reservoir 62 contains an appropriate nickase enzyme and Exo- DNA polymerase.
- reagent reservoir 60 contains the amplification buffer, primers, dNTPs and recombinase proteins, with reagent reservoir 62 containing a strand displacing DNA polymerase such as Bsu.
- reagent reservoir 60 contains amplification buffer, primers and dNTPs and reagent reservoir 62 contains an appropriate DNA polymerase and a helicase enzyme to unwind the double stranded DNA strand instead of using heat.
- reagent reservoir 62 contains an appropriate DNA polymerase and a helicase enzyme to unwind the double stranded DNA strand instead of using heat.
- the necessary reagents can be split between the two reagent reservoirs in any manner appropriate for the nucleic acid amplification process.
- RNA viruses such as HIV or hepatitis
- reagent reservoir 60 is filled with amplification buffer
- primers and dNTPs are filled with RNA polymerase, reverse transcriptase and, optionally, RNase H.
- isothermal nucleic acid amplification it may be necessary to have an initial denaturation cycle to separate the double stranded DNA template, prior to maintaining the temperature for the isothermal nucleic acid amplification to proceed. This is readily achievable in all embodiments of the LOC device described herein, as the temperature of the mix in the amplification section 112 can be carefully controlled by the heaters 154 in the amplification microchannels 158 (see Figure 14).
- Isothermal nucleic acid amplification is more tolerant of potential inhibitors in the sample and, as such, is generally suitable for use where direct nucleic acid amplification from the sample is desired. Therefore, isothermal nucleic acid amplification is sometimes useful in LOC variant XLIII 673, LOC variant XLIV 674 and LOC variant XLVII 677, amongst others, shown in Figures 80, 81 and 82, respectively.
- Direct isothermal amplification may also be combined with one or more pre-amplification dialysis steps 70, 686 or 682 as shown in Figures 80 and 82 and/or a pre-hybridization dialysis step 682 as indicated in Figure 81 to help partially concentrate the target cells in the sample before nucleic acid amplification or remove unwanted cellular debris prior to the sample entering the hybridization chamber array 110, respectively.
- pre-amplification dialysis and pre-hybridization dialysis can be used.
- Isothermal nucleic acid amplification can also be performed in parallel amplification sections such as those schematically represented in Figures 71, 76 and 77, multiplexed and some methods of isothermal nucleic acid amplification, such as LAMP, are compatible with an initial reverse transcription step to amplify RNA.
- Figures 58 and 59 show the hybridization-responsive FRET probes 236. These are often referred to as molecular beacons and are stem-and-loop probes, generated from a single strand of nucleic acid, that fluoresce upon hybridization to complementary nucleic acids.
- Figure 58 shows a single FRET probe 236 prior to hybridization with a target nucleic acid sequence 238.
- the probe has a loop 240, stem 242, a fluorophore 246 at the 5' end, and a quencher 248 at the 3' end.
- the loop 240 consists of a sequence complementary to the target nucleic acid sequence 238. Complementary sequences on either side of the probe sequence anneal together to form the stem 242.
- the probe In the absence of a complementary target sequence, the probe remains closed as shown in Figure 58.
- the stem 242 keeps the fluorophore-quencher pair in close proximity to each other, such that significant resonant energy transfer can occur between them, substantially eliminating the ability of the fluorophore to fluoresce when illuminated with the excitation light 244.
- Figure 59 shows the FRET probe 236 in an open or hybridized configuration.
- the stem-and- loop structure is disrupted, the fluorophore and quencher are spatially separated, thus restoring the ability of the fluorophore 246 to fluoresce.
- the fluorescence emission 250 is optically detected as an indication that the probe has hybridized.
- the probes hybridize with very high specificity with complementary targets, since the stem helix of the probe is designed to be more stable than a probe-target helix with a single nucleotide that is not complementary. Since double-stranded DNA is relatively rigid, it is sterically impossible for the probe-target helix and the stem helix to coexist.
- Primer-linked, stem-and-loop probes and primer-linked, linear probes are an alternative to molecular beacons and can be used for real-time and quantitative nucleic acid amplification in the LOC device. Real-time amplification could be performed directly in the hybridization chambers of the LOC device.
- the benefit of using primer-linked probes is that the probe element is physically linked to the primer, thus only requiring a single hybridization event to occur during the nucleic acid amplification rather than separate hybridizations of the primers and probes being required. This ensures that the reaction is effectively instantaneous and results in stronger signals, shorter reaction times and better discrimination than when using separate primers and probes.
- the probes (along with polymerase and the amplification mix) would be deposited into the hybridization chambers 180 during fabrication and there would be no need for a separate amplification section on the LOC device. Alternatively, the amplification section is left unused or used for other reactions.
- Figures 83 and 84 show a primer-linked linear probe 692 during the initial round of nucleic acid amplification and in its hybridized configuration during subsequent rounds of nucleic acid amplification, respectively.
- the primer-linked linear probe 692 has a double-stranded stem segment 242.
- One of the strands incorporates the primer linked probe sequence 696 which is homologous to a region on the target nucleic acid 696 and is labelled on its 5' end with fluorophore 246, and linked on its 3' end to an oligonucleotide primer 700 via an amplification blocker 694.
- the other strand of the stem 242 is labelled at its 3 ⁇ end with a quencher moiety 248.
- the probe can loop around and hybridize to the extended strand with the, now complementary, sequence 698.
- the oligonucleotide primer 700 anneals to the target DNA 238 ( Figure 83) and is then extended, forming a DNA strand containing both the probe sequence and the amplification product.
- the amplification blocker 694 prevents the polymerase from reading through and copying the probe region 696.
- the extended oligonucleotide primer 700/template hybrid is dissociated and so is the double stranded stem 242 of the primer-linked linear probe, thus releasing the quencher 248.
- the primer linked probe sequence 696 of the primer-linked linear probe curls around and hybridizes to the amplified complementary sequence 698 on the extended strand and fluorescence is detected indicating the presence of the target DNA.
- Non-extended primer- linked linear probes retain their double-stranded stem and fluorescence remains quenched. This detection method is particularly well suited for fast detection systems as it relies on a single-molecule process.
- Figures 85A to 85F show the operation of a primer-linked stem-and-loop probe 704.
- the primer-linked stem-and-loop probe 704 has a stem 242 of complementary double-stranded DNA and a loop 240 which incorporates the probe sequence.
- One of the stem strands 708 is labelled at its 5' end with fluorophore 246.
- the other strand 710 is labelled with a 3 '-end quencher 248 and carries both the amplification blocker 694 and oligonucleotide primer 700.
- the strands of the target nucleic acid 238 separate, as does the stem 242 of the primer-linked, stem-and-loop probe 704.
- the oligonucleotide primer 700 on the primer-linked stem-and-loop probe 704 hybridizes to the target nucleic acid sequence 238.
- the complement 706 to the target nucleic acid sequence 238 is synthesized forming a DNA strand containing both the probe sequence 704 and the amplified product.
- the amplification blocker 694 prevents the polymerase from reading through and copying the probe region 704.
- the probe sequence of the loop segment 240 of the primer-linked stem-and-loop probe (see Figure 85F) anneals to the complementary sequence 706 on the extended strand.
- This configuration leaves the fluorophore 246 relatively remote from the quencher 248, resulting in a significant increase in fluorescence emission.
- the hybridization chamber array 110 includes some hybridization chambers 180 with positive and negative control probes used for assay quality control.
- Figures 105 and 105 are examples of hybridization chambers 180 with positive and negative control probes used for assay quality control.
- 107 and 108 are sketches of positive control probes without a quencher 798.
- the positive and negative control probes have a stem-and-loop structure like the FRET probes described above. However, a fluorescence signal 250 will always be emitted from positive control probes 798 and no fluorescence signal 250 is ever emitted from negative control probes 796, regardless of whether the probes hybridize into an open configuration or remain closed.
- the negative control probe 796 has no fluorophore (and may or may not have a quencher 248). Hence, whether the target nucleic acid sequence 238 hybridizes with the probe (see Figure 106), or the probe remains in its stem-and-loop configuration (see Figure 105), the response to the excitation light 244 is negligible. Alternatively, the negative control probe 796 could be designed so that it always remains quenched.
- the stem 242 of the probe molecule will re-hybridize to itself and the fluorophore and quencher will remain in close proximity and no appreciable fluorescence signal will be emitted.
- This negative control signal would correspond to low level emissions from hybridization chambers 180 in which the probes has not hybridized but the quencher does not quench all emissions from the reporter.
- the positive control probe 798 is constructed without a quencher as illustrated in Figures 107 and 108. None quenches the fluorescence emission 250 from the fluorophore 246 in response to the excitation light 244 regardless of whether the positive control probe 798 hybridizes with the target nucleic acid sequence 238.
- Figure 52 shows a possible distribution of the positive and negative control probes (378 and 380 respectively) throughout the hybridization chamber array 1 10.
- the control probes 378 and 380 are placed in hybridization chambers 180 positioned in a line across the hybridization chamber array 1 10.
- the arrangement of the control probes within the array is arbitrary (as is the configuration of the hybridization chamber array 1 10).
- Fluorophores with long fluorescence lifetimes are required in order to allow enough time for the excitation light to decay to an intensity below that of the fluorescence emission at which time the photosensor 44 is enabled, thereby providing a sufficient signal to noise ratio. Also, longer fluorescence lifetime translates into larger integrated fluorescence photon count.
- the fluorophores 246 (see Figure 59) have a fluorescence lifetime greater than 100 nanoseconds, often greater than 200 nanoseconds, more commonly greater than 300 nanoseconds and in most cases greater than 400 nanoseconds.
- the metal-ligand complexes based on the transition metals or lanthanides have long lifetimes (from hundreds of nanoseconds to milliseconds), adequate quantum yields, and high thermal, chemical and photochemical stability, which are all favourable properties with respect to the fluorescence detection system requirements.
- a particularly well-studied metal-ligand complex based on the transition metal ion Ruthenium (Ru (II)) is tris(2,2'-bipyridine) ruthenium (II) ([Ru(bpy) 3 ] 2+ ) which has a lifetime of approximately 1 ⁇ 8.
- This complex is available commercially from Biosearch Technologies under the brand name Pulsar 650.
- the fluorescence detection system used by the LOC device 301 does not utilize filters to remove unwanted background fluorescence. It is therefore advantageous if the quencher 248 has no native emission in order to increase the signal-to-noise ratio. With no native emission, there is no contribution to background fluorescence from the quencher 248. High quenching efficiency is also important so that fluorescence is prevented until a hybridization event occurs.
- the Black Hole Quenchers (BHQ), available from Biosearch Technologies, Inc. of Novato California, have no native emission and high quenching efficiency, and are suitable quenchers for the system.
- BHQ- 1 has an absorption maximum at 534 nm, and a quenching range of 480-580 nm, making it a suitable quencher for the Tb- chelate fluorophore.
- BHQ-2 has an absorption maximum at 579 nm, and a quenching range of 560-670 nm, making it a suitable quencher for Pulsar 650.
- Iowa Black Quenchers (Iowa Black FQ and RQ), available from Integrated DNA Technologies of Coralville, Iowa, are suitable alternative quenchers with little or no background emission.
- Iowa Black FQ has a quenching range from 420-620 nm, with an absorption maximum at 531 nm and would therefore be a suitable quencher for the Tb- chelate fluorophore.
- Iowa Black RQ has an absorption maximum at 656 nm, and a quenching range of 500-700 nm, making it an ideal quencher for Pulsar 650.
- the quencher 248 is a functional moiety which is initially attached to the probe, but other embodiments are possible in which the quencher is a separate molecule free in solution.
- a LED is chosen as the excitation source instead of a laser diode, high power lamp or laser due to the low power consumption, low cost and small size.
- the LED 26 is positioned directly above the hybridization chamber array 110 on an external surface of the LOC device 301.
- the photosensor 44 On the opposing side of the hybridization chamber array 110, is the photosensor 44, made up of an array of photodiodes 184 (see Figures 53, 54 and 64) for detection of fluorescence signals from each of the chambers.
- Figures 87, 88 and 89 schematically illustrate other embodiments for exposing the probes to excitation light.
- the excitation light 244 generated by the excitation LED 26 is directed onto the hybridization chamber array 1 10 by the lens 254.
- the excitation LED 26 is pulsed and the fluorescence emissions are detected by the photosensor 44.
- the excitation light 244 generated by the excitation LED 26 is directed onto the hybridization chamber array 1 10 by the lens 254, a first optical prism 712 and second optical prism 714.
- the excitation LED 26 is pulsed and the fluorescence emissions are detected by the photosensor 44.
- the excitation light 244 generated by the excitation LED 26 is directed onto the hybridization chamber array 1 10 by the lens 254, a first mirror 716 and second mirror 718. Again, the excitation LED 26 is pulsed and the fluorescence emissions are detected by the photosensor 44.
- the excitation wavelength of the LED 26 is dependent on the choice of fluorescent dye.
- the Philips LXK2-PR14-R00 is a suitable excitation source for the Pulsar 650 dye.
- the SET UVTOP335T039BL LED is a suitable excitation source for the Tb-chelate label.
- UV LED excitation source can be used but the broad spectrum of the LED 26 reduces the effectiveness of this method.
- a filtered UV LED can be used.
- a UV laser can be the excitation source unless the relatively high cost of the laser is impractical for the particular test module market.
- the LED driver 29 drives the LED 26 at a constant current for the required duration.
- a lower power USB 2.0-certifiable device can draw at most 1 unit load (100 mA), with a minimum operating voltage of 4.4 V.
- a standard power conditioning circuit is used for this purpose.
- Figure 54 shows the photodiode 184 integrated into the CMOS circuitry 86 of the LOC device 301.
- the photodiode 184 is fabricated as part of the CMOS circuitry 86 without additional masks or steps. This is one significant advantage of a CMOS photodiode over a CCD, an alternate sensing technology which could be integrated on the same chip using non-standard processing steps, or fabricated on an adjacent chip.
- On-chip detection is low cost and reduces the size of the assay system.
- the shorter optical path length reduces noise from the surrounding environment for efficient collection of the fluorescence signal and eliminates the need for a conventional optical assembly of lenses and filters.
- Quantum efficiency of the photodiode 184 is the fraction of photons impinging on its active area 185 that are effectively converted to photo-electrons.
- the quantum efficiency is in the range of 0.3 to 0.5 for visible light, depending on process parameters such as the amount and absorption properties of the cover layers.
- the detection threshold of the photodiode 184 determines the smallest intensity of the fluorescence signal that can be detected.
- the detection threshold also determines the size of the photodiode 184 and hence the number of hybridization chambers 180 in the hybridization and detection section 52 (see Figure 52).
- the size and number of chambers are technical parameters that are limited by the dimensions of the LOC device (in the case of the LOC device 301, the dimensions are 1760 ⁇ x 5824 ⁇ ) and the real estate available after other functional modules such as the pathogen dialysis section 70 and amplification section(s) 1 12 are incorporated.
- the photodiode 184 detects a minimum of 5 photons. However, to ensure reliable detection, the minimum can be set to 10 photons. Therefore with the quantum efficiency range being 0.3 to 0.5 (as discussed above), the fluorescence emission from the probes should be a minimum of 17 photons but 30 photons would incorporate a suitable margin of error for reliable detection.
- calibration signals are generated by exposing one or more calibration photodiodes 184 in the array to respective calibration sources.
- a low calibration source is used for determining a negative result in which a target has not reacted with a probe.
- a high calibration source is indicative of a positive result from a probe-target complex.
- the low calibration light source is provided by calibration chambers 382 in the hybridization chamber array 1 10 which:
- probes with a reporter and quencher configured such that quenching is always expected to occur.
- the output signal from such calibration chambers 382 closely approximates the noise and offset in the output signal from all the hybridization chambers in the LOC device. Subtracting the calibration signal from the output signals generated by the other hybridization chambers substantially removes the background and leaves the signal generated by the fluorescence emission (if any). Signals arising from ambient light in the region of the chamber array are also subtracted.
- the calibration chambers 382 can provide a high calibration source to generate a high signal in the corresponding photodiodes.
- the high signal corresponds to all probes in a chamber having hybridized. Spotting probes with reporters and no quenchers, or just reporters will consistently provide a signal approximating that of a hybridization chamber in which a predominant number of the probes have hybridized. It will also be appreciated that calibration chambers 382 can be used instead of control probes, or in addition to control probes.
- the hybridization chamber array 110 has one calibration chamber 382 for every eight hybridization chambers 180. That is, a calibration chamber 382 is positioned in the middle of every three by three square of hybridization chambers 180. In this configuration, the hybridization chambers 180 are calibrated by a calibration chamber 382 that is immediately adjacent.
- Figure 104 shows a differential imager circuit 788 used to substract the signal from the photodiode 184 corresponding to the calibration chamber 382 as a result of excitation light, from the fluorescence signal from the surrounding hybridization chambers 180.
- the differential imager circuit 788 samples the signal from the pixel 790 and a "dummy" pixel 792.
- the "dummy" pixel 792 is shielded from light, so its output signal provides a dark reference.
- the "dummy" pixel 792 can be exposed to the excitation light along with the rest of the array. In the embodiment where the
- pixel 792 is open to light, signals arising from ambient light in the region of the chamber array are also subtracted.
- the signals from the pixel 790 are small (i.e. close to dark signal), and without a reference to a dark level it is hard to differentiate between the background and a very small signal.
- the "read_row” 794 and “read row d" 795 are activated and M4 797 and MD4 801 transistors are turned on.
- Switches 807 and 809 are closed such that the outputs from the pixel 790 and "dummy" pixel 792 are stored on pixel capacitor 803 and dummy pixel capacitor 805 respectively.
- switches 807 and 809 are deactivated.
- the "read_col” switch 81 1 and dummy "read col” switch 813 are closed, and the switched capacitor amplifier 815 at the output amplifies the differential signal 817.
- FIG 65 is a circuit diagram for a single photodiode 184 and Figure 66 is a timing diagram for the photodiode control signals.
- the circuit has photodiode 184 and six MOS transistors, M shunt 394, M ⁇ 396, M rese t 398, M sf 400, M rea d 402 and Mbias 404.
- M shunt 394 M ⁇ 396
- M rese t 398 M sf 400
- M rea d 402 Mbias 404.
- the excitation photons generate carriers in the photodiode 184. These carriers have to be removed, as the amount of generated carriers can be sufficient to saturate the photodiode 184.
- M s h un t 394 directly removes the carriers generated in photodiode 184, while M rese t 398 resets any carriers that have accumulated on node 'NS' 406 due to leakage in transistors or due to diffusion of excitation-produced carriers in the substrate.
- a capture cycle commences at t4. During this cycle, the emitted response from the fluorophore is captured and integrated in the circuit on node 'NS' 406.
- Figures 101, 102 and 103 show three possible configurations 778, 780, 782 for the shunt transistor 394.
- the M s h un t transistor 394 has a very high off ratio at maximum
- the M s h un t gate 384 is configured to be on the edge of the photodiode 184.
- the M s hunt gate 384 may be configured to surround the photodiode 184.
- a third option is to configure the M sn unt gate 384 inside the photodiode 184, as shown in Figure 103. Under this third option there would be less photodiode active area 185.
- the configuration 782 in Figure 103 positions the M s h un t gate 384 within the active area 185. This provides the shortest average path length to the M s h un t gate 384 and hence the shortest transition time. However, the impingement on the active area 185 is greatest. It also poses a wider leakage path.
- a trigger photodiode drives the shunt transistor with a fixed delay.
- a trigger photodiode drives the shunt transistor with programmable delay.
- the shunt transistor is driven from the LED drive pulse with a fixed delay.
- FIG 68 is a schematic section view through a hybridization chamber 180 showing a photodiode 184 and trigger photodiode 187 embedded in the CMOS circuitry 86. A small area in the corner of the photodiode 184 is replaced with the trigger photodiode 187. A trigger photodiode 187 with a small area is sufficient as the intensity of the excitation light will be high in comparison with the fluorescence emission. The trigger photodiode 187 is sensitive to the excitation light 244.
- the trigger photodiode 187 registers that the excitation light 244 has extinguished and activates the photodiode 184 after a short time delay At 300 (see Figure 2). This delay allows the fluorescence photodiode 184 to detect the fluorescence emission from the FRET probes 186 in the absence of the excitation light 244. This enables detection and improves the signal to noise ratio.
- Both photodiodes 184 and trigger photodiodes 187 are located in the CMOS circuitry 86 under each hybridization chamber 180.
- the array of photodiodes combines, along with appropriate electronics, to form the photosensor 44 (see Figure 64).
- the photodiodes 184 are pn-junction fabricated during CMOS structure manufacturing without additional masks or steps.
- the dielectric layer (not shown) above the photodiodes 184 is optionally thinned using the standard MST photolithography techniques to allow more fluorescent light to illuminate the active area 185 of the photodiode 184.
- the photodiode 184 has a field of view such that the fluorescence signal from the probe-target hybrids within the hybridization chamber 180 is incident on the sensor face.
- the fluorescent light is converted into a photocurrent which can then be measured using CMOS circuitry 86.
- one or more hybridization chambers 180 can be dedicated to a trigger photodiode 187 only. These options can be used in these in combination with 2a and 2b above.
- the following derivations elucidate the delayed detection of fluorescence using a long-lifetime fluorophore for the LED/fluorophore combinations described above.
- the fluorescence intensity is derived as a function of time after excitation by an ideal pulse of constant intensity I e between time t ⁇ and 3 ⁇ 4 as shown in Figure 60.
- the fluorescence intensity is given by the following equation:
- I f (t) I e sclri—W - e (h - h)lT ⁇ ( ⁇ - )1 ⁇ > ...(10)
- I f (t) I e scl ⁇ e ' ⁇ ' 2> ' Tf ior t ⁇ t 2 ...(11)
- n f (t) —— is the number of fluorescent photons per unit time per unit area
- h v f is the number of excitation photons per unit time per unit area.
- n f (t) n f (t)dt ...(13)
- n f the number of fluorescent photons per unit area
- ? 3 the instant of time at which the photodiode is turned on.
- n s (t) the number of fluorescent photons that reach the photodiode per unit time per unit area
- ⁇ 0 is the light gathering efficiency of the optical system.
- n s ⁇ ⁇ ⁇ ⁇ ⁇ f e ⁇ kt ' Tf - - -(lV)
- the optimal value of h is when the rate of electrons generated in the photodiode 184 due to fluorescence photons becomes equal to the rate of electrons generated in the photodiode 184 by the excitation photons, as the flux of the excitation photons decays much faster than that of the fluorescence photons.
- the rate of sensor output electrons per unit fluorescent area due to fluorescence is the rate of sensor output electrons per unit fluorescent area due to fluorescence.
- ⁇ ⁇ is the quantum efficiency of the sensor at the excitation wavelength
- x e is the time-constant corresponding to the "off characteristics of the excitation LED.
- the optimal time for fluorescence detection and the number of fluorescence photons detected using the Philips LXK2-P 14-R00 LED and Pulsar 650 dye are determined as follows.
- the number of photons detected is determined using equation (21). First, the number of excitation photons emitted per unit time « e is determined by examining the illumination geometry.
- n l ' ri cos(6>) . . .(23)
- n) is the number of photons emitted per unit time per unit solid angle at an angle of ⁇ off the LED's forward axial direction
- n m is the valve of n) in the forward axial direction.
- the total number of photons emitted by the LED per unit time is:
- the optical centre 252 and the lens 254 of the LED 26 are schematically shown.
- the photodiodes are 16 ⁇ x 16 ⁇ , and for the photodiode in the middle of the array, the solid angle ( ⁇ ) of the cone of light emitted from the LED 26 to the photodiode 184 is approximately:
- central photodiode 184 of the photodiode array 44 is used for the purpose of these calculations.
- a sensor located at the edge of the array would only receive 2% less photons upon a hybridization event for a Lambertian excitation source intensity distribution.
- the SET LED illumination geometry is shown in Figure 62.
- the LED's optical centre 252, 17.5 mm away from the hybridization chamber array 110 we would approximately concentrate this output flux in a circular spot size which has a maximum diameter of 2 mm.
- n s (0.5)[3.34(10) n ][6.94(10)- 5 ][l(10)- 3 ]e- 3 - 98(10r9 /1(10r3
- This angle is calculated by considering light emitted from a probe at the centroid of the face of the hybridization chamber closest to the photodiode, which has a planar active surface area parallel to that chamber face.
- the cone of emission angles within which light is able to be absorbed by the photodiode is defined as having the emitting probe at its vertex and the corner of the sensor on the perimeter of its planar face.
- the vertex angle of this cone is 170°; in the limiting case where the photodiode is expanded so that its area matches that of the 29 micron x 19.75 micron hybridization chamber, the vertex angle is 173°.
- a separation between the chamber face and the photodiode active surface of 1 micron or less is readily achievable.
- Employing a non-imaging optics scheme does require the photodiode 184 to be very close to the hybridization chamber in order to collect sufficient photons of fluorescence emission.
- the maximum spacing between the photodiode and probes is determined as follows with reference to Figure 54. Utilizing a terbium chelate fluorophore and a SET UVTOP335T039BL LED, we calculated 11600 photons reaching our 16 micron x 16 micron photodiode 184 from the respective hybridization chamber 180.
- Each hybridization chamber releases 23200 photons.
- the base area of the light-collecting region of the hybridization chamber 180 is 29 micron x 19.75 micron.
- the LOC device 301 described and illustrated above in full is just one of many possible LOC device designs. Variations of the LOC device that use different
- LOC VARIANT XII LOC variant XII 758 is shown in Figures 93 to 100.
- This LOC device extracts 290, incubates 291, amplifies 292 and detects 294 pathogenic DNA, and uses a pre- hybridization purification step 293 to increase hybridization efficiency.
- the sample (such as whole blood) is added to the sample inlet 68 (see Figure 95) and capillary action draws the sample to the surface tension valve 118 where anticoagulant is added from reservoir 54.
- the sample continues in the cap channel 94 to the pathogen dialysis section 70.
- the dialysis section 70 has a bypass channel 600 to prevent trapped air bubbles (see Figure 95).
- the erythrocyte and leukocyte stream is directed to a waste reservoir 76 while the pathogens continue in the sample flow to surface tension valve 128 where a lysis reagent is added from reservoir 56.
- the sample fills the chemical lysis chamber 130 where it is retained by boiling-initiated valve 206 until the lysis reagent has diffused through the sample to release most, if not all, of the pathogenic DNA.
- the boiling-initiated valve 206 opens, the sample flows to surface tension valve 132 where restriction enzymes, ligase and linker primers are added from reservoir 58.
- the sample fills the incubation section 114 and is heated while restriction digestion and linker ligation of the pathogenic DNA occurs (see Figure 95).
- the boiling-initiated valve 207 opens for the sample to flow into the amplification sectionl 12.
- Amplification mix from reservoir 60 is added via surface tension valve 138 and polymerase from reservoir 62 through surface tension valve 140 as the sample flows into the amplification section 112.
- the pathogenic DNA is amplified by thermal cycling before the boiling-initiated valve 108 opens for the amplicon to flow to the small constituents dialysis section 682 where large components are removed (see Figure 95).
- the small constituents dialysis section 682 has a large constituents channel 760 between two small constituents channels 762 formed in the bottom channel layer 100 (see Figure 94).
- the large constituents channel 760 is connected to the small constituents channels 762 by stoma in the form of a series of inverse tapered openings 764 (smaller at the large constituents channel end). In most practical applications, the stoma will be between 1 to 8 microns wide and 1 to 8 microns high.
- small constituents small constituents (smaller than the inverse tapered openings 764) start to diffuse into the small constituents channels 762.
- the concentration of small constituents in the large constituents channel 760 reduces as the flow progresses to the downstream end of the small constituents dialysis section 682.
- An additional advantage of microfabricated stoma is that the number of stoma per unit length along the channel is very high, so that the separation is more efficient.
- the spacing between adjacent stoma is between 1 micron and 10 microns; in the embodiment shown in Figure 99, the spacing between adjacent stoma is 8 microns.
- Figure 100 shows the downstream end of the small constituents dialysis section
- the large constituents channel 760 diverts into a wide meander ending at a blind end 766 which provides a waste reservoir.
- the two small constituents channels 762 lead to opposite sides of the hybridization chamber array 110 where they both follow serpentine paths through the array to respective blind ends 768.
- the small constituents amplicon fills all the individual hybridization chambers 180 prior to timed initiation of the hybridization heaters and subsequent probe-target hybrid detection (as described previously).
- the small constituents dialysis section 682 removes cell debris which may still remain in the sample flow following cell lysis. Cell debris may interfere with
- the LOC variant XIX 646 shown in Figure 78 has pathogen dialysis section 70 and thermal lysis section 638 of the sample prior to nucleic acid amplification (amplification section 112), but also adds a pre-hybridization purification step 293 between the amplification 292 and detection phases 294.
- the pre-hybridization, small constituents dialysis section 682 removes cell debris in the sample flow resulting from cell lysis.
- Most nucleic acid amplification protocols are sufficiently tolerant of cell debris in the sample.
- hybridization can be affected by cell debris and so pre-hybridization dialysis via the small constituents dialysis section 682 is used to substantially reduce the concentration of debris in the amplicon immediately prior to filling the hybridization chamber array 110.
Abstract
A lab-on-a-chip (LOC) device for detecting pathogens in a biological sample, the LOC device having an inlet for receiving the sample, a supporting substrate, a first dialysis section for separating pathogens from larger constituents in the sample, a lysis section downstream of the dialysis section for lysing the pathogens to release genetic material therein, the lysis section having a lysis chamber and a heater for lysing the pathogens while the sample is in the lysis chamber, a nucleic acid amplification section downstream of the lysis section for amplifying nucleic acid sequences in the genetic material, and, a second dialysis section downstream of the nucleic acid amplification section for prehybridization filtration of amplicon produced by the nucleic acid amplification section, the second dialysis section being configured to remove cell debris from the amplicon, wherein, the first dialysis section, the lysis section, the nucleic acid amplification section and the second dialysis section are all supported on the supporting substrate.
Description
LOC DEVICE FOR PATHOGEN DETECTION WITH DIALYSIS, THERMAL LYSIS, NUCLEIC ACID AMPLIFICATION AND PREHYBRIDIZATION
FILTERING
FIELD OF THE INVENTION The present invention relates to diagnostic devices that use microsystems technologies (MST). In particular, the invention relates to microfluidic and biochemical processing and analysis for molecular diagnostics.
BACKGROUND OF THE INVENTION
Molecular diagnostics has emerged as a field that offers the promise of early disease detection, potentially before symptoms have manifested. Molecular diagnostic testing is used to detect:
• Inherited disorders
• Acquired disorders
• Infectious diseases
· Genetic predisposition to health-related conditions.
With high accuracy and fast turnaround times, molecular diagnostic tests have the potential to reduce the occurrence of ineffective health care services, enhance patient outcomes, improve disease management and individualize patient care. Many of the techniques in molecular diagnostics are based on the detection and identification of specific nucleic acids, both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), extracted and amplified from a biological specimen (such as blood or saliva). The complementary nature of the nucleic acid bases allows short sequences of synthesized DNA (oligonucleotides) to bond (hybridize) to specific nucleic acid sequences for use in nucleic acid tests. If hybridization occurs, then the complementary sequence is present in the sample. This makes it possible, for example, to predict the disease a person will contract in the future, determine the identity and virulence of an infectious pathogen, or determine the response a person will have to a drug.
NUCLEIC ACID BASED MOLECULAR DIAGNOSTIC TEST
A nucleic acid based test has four distinct steps:
1 Sample preparation
2. Nucleic acid extraction
3 Nucleic acid amplification (optional)
4, Detection
Many sample types are used for genetic analysis, such as blood, urine, sputum and tissue samples. The diagnostic test determines the type of sample required as not all samples are representative of the disease process. These samples have a variety of constituents, but usually only one of these is of interest. For example, in blood, high concentrations of erythrocytes can inhibit the detection of a pathogenic organism.
Therefore a purification and/or concentration step at the beginning of the nucleic acid test is often required.
Blood is one of the more commonly sought sample types. It has three major constituents: leukocytes (white blood cells), erythrocytes (red blood cells) and
thrombocytes (platelets). The thrombocytes facilitate clotting and remain active in vitro. To inhibit coagulation, the specimen is mixed with an agent such as
ethylenediaminetetraacetic acid (EDTA) prior to purification and concentration.
Erythrocytes are usually removed from the sample in order to concentrate the target cells. In humans, erythrocytes account for approximately 99% of the cellular material but do not carry DNA as they have no nucleus. Furthermore, erythrocytes contain components such as haemoglobin that can interfere with the downstream nucleic acid amplification process (described below). Removal of erythrocytes can be achieved by differentially lysing the erythrocytes in a lysis solution, leaving remaining cellular material intact which can then be separated from the sample using centrifugation. This provides a concentration of the target cells from which the nucleic acids are extracted.
The exact protocol used to extract nucleic acids depends on the sample and the diagnostic assay to be performed. For example, the protocol for extracting viral RNA will vary considerably from the protocol to extract genomic DNA. However, extracting nucleic acids from target cells usually involves a cell lysis step followed by nucleic acid purification. The cell lysis step disrupts the cell and nuclear membranes, releasing the genetic material. This is often accomplished using a lysis detergent, such as sodium dodecyl sulfate, which also denatures the large amount of proteins present in the cells.
The nucleic acids are then purified with an alcohol precipitation step, usually ice- cold ethanol or isopropanol, or via a solid phase purification step, typically on a silica
matrix in a column, resin or on paramagnetic beads in the presence of high concentrations of a chaotropic salt, prior to washing and then elution in a low ionic strength buffer. An optional step prior to nucleic acid precipitation is the addition of a protease which digests the proteins in order to further purify the sample.
Other lysis methods include mechanical lysis via ultrasonic vibration and thermal lysis where the sample is heated to 94°C to disrupt cell membranes.
The target DNA or RNA may be present in the extracted material in very small amounts, particularly if the target is of pathogenic origin. Nucleic acid amplification provides the ability to selectively amplify (that is, replicate) specific targets present in low concentrations to detectable levels.
The most commonly used nucleic acid amplification technique is the polymerase chain reaction (PC ). PCR is well known in this field and comprehensive description of this type of reaction is provided in E. van Pelt-Verkuil et al, Principles and Technical Aspects of PCR Amplification, Springer, 2008.
PCR is a powerful technique that amplifies a target DNA sequence against a background of complex DNA. If RNA is to be amplified (by PCR), it must be first transcribed into cDNA (complementary DNA) using an enzyme called reverse transcriptase. Afterwards, the resulting cDNA is amplified by PCR.
PCR is an exponential process that proceeds as long as the conditions for sustaining the reaction are acceptable. The components of the reaction are:
1. pair of primers - short single strands of DNA with around 10-30 nucleotides complementary to the regions flanking the target sequence
2. DNA polymerase - a thermostable enzyme that synthesizes DNA
3. deoxyribonucleoside triphosphates (dNTPs) - provide the nucleotides that are incorporated into the newly synthesized DNA strand
4. buffer - to provide the optimal chemical environment for DNA synthesis
PCR typically involves placing these reactants in a small tube (-10-50 microlitres) containing the extracted nucleic acids. The tube is placed in a thermal cycler; an instrument that subjects the reaction to a series of different temperatures for varying amounts of time. The standard protocol for each thermal cycle involves a denaturation phase, an annealing phase, and an extension phase. The extension phase is sometimes referred to as the primer extension phase. In addition to such three-step protocols, two-step thermal protocols can be employed, in which the annealing and extension phases are
combined. The denaturation phase typically involves raising the temperature of the reaction to 90 - 95°C to denature the DNA strands; in the annealing phase, the temperature is lowered to ~50-60°C for the primers to anneal; and then in the extension phase the temperature is raised to the optimal DNA polymerase activity temperature of 60- 72°C for primer extension. This process is repeated cyclically around 20-40 times, the end result being the creation of millions of copies of the target sequence between the primers.
There are a number of variants to the standard PC protocol such as multiplex PCR, linker-primed PCR, direct PCR, tandem PCR, real-time PCR and reverse- transcriptase PCR, amongst others, which have been developed for molecular diagnostics.
Multiplex PCR uses multiple primer sets within a single PCR mixture to produce amplicons of varying sizes that are specific to different DNA sequences. By targeting multiple genes at once, additional information may be gained from a single test-run that otherwise would require several experiments. Optimization of multiplex PCR is more difficult though and requires selecting primers with similar annealing temperatures, and amplicons with similar lengths and base composition to ensure the amplification efficiency of each amplicon is equivalent.
Linker-primed PCR, also known as ligation adaptor PCR, is a method used to enable nucleic acid amplification of essentially all DNA sequences in a complex DNA mixture without the need for target-specific primers. The method firstly involves digesting the target DNA population with a suitable restriction endonuclease (enzyme). Double- stranded oligonucleotide linkers (also called adaptors) with a suitable overhanging end are then ligated to the ends of target DNA fragments using a ligase enzyme. Nucleic acid amplification is subsequently performed using oligonucleotide primers which are specific for the linker sequences. In this way, all fragments of the DNA source which are flanked by linker oligonucleotides can be amplified.
Direct PCR describes a system whereby PCR is performed directly on a sample without any, or with minimal, nucleic acid extraction. It has long been accepted that PCR reactions are inhibited by the presence of many components of unpurified biological samples, such as the haem component in blood. Traditionally, PCR has required extensive purification of the target nucleic acid prior to preparation of the reaction mixture. With appropriate changes to the chemistry and sample concentration, however, it is possible to perform PCR with minimal DNA purification, or direct PCR. Adjustments to the PCR chemistry for direct PCR include increased buffer strength, the use of polymerases which
have high activity and processivity, and additives which chelate with potential polymerase inhibitors.
Tandem PCR utilises two distinct rounds of nucleic acid amplification to increase the probability that the correct amplicon is amplified. One form of tandem PCR is nested PCR in which two pairs of PCR primers are used to amplify a single locus in separate rounds of nucleic acid amplification. The first pair of primers hybridize to the nucleic acid sequence at regions external to the target nucleic acid sequence. The second pair of primers (nested primers) used in the second round of amplification bind within the first PCR product and produce a second PCR product containing the target nucleic acid, that will be shorter than the first one. The logic behind this strategy is that if the wrong locus were amplified by mistake during the first round of nucleic acid amplification, the probability is very low that it would also be amplified a second time by a second pair of primers and thus ensures specificity.
Real-time PCR, or quantitative PCR, is used to measure the quantity of a PCR product in real time. By using a fluorophore-containing probe or fluorescent dyes along with a set of standards in the reaction, it is possible to quantitate the starting amount of nucleic acid in the sample. This is particularly useful in molecular diagnostics where treatment options may differ depending on the pathogen load in the sample.
Reverse-transcriptase PCR (RT-PCR) is used to amplify DNA from RNA. Reverse transcriptase is an enzyme that reverse transcribes RNA into complementary DNA
(cDNA), which is then amplified by PCR. RT-PCR is widely used in expression profiling, to determine the expression of a gene or to identify the sequence of an RNA transcript, including transcription start and termination sites. It is also used to amplify RNA viruses such as human immunodeficiency virus or hepatitis C virus.
Isothermal amplification is another form of nucleic acid amplification which does not rely on the thermal denaturation of the target DNA during the amplification reaction and hence does not require sophisticated machinery. Isothermal nucleic acid amplification methods can therefore be carried out in primitive sites or operated easily outside of a laboratory environment. A number of isothermal nucleic acid amplification methods have been described, including Strand Displacement Amplification, Transcription Mediated Amplification, Nucleic Acid Sequence Based Amplification, Recombinase Polymerase Amplification, Rolling Circle Amplification, Ramification Amplification, Helicase- Dependent Isothermal DNA Amplification and Loop-Mediated Isothermal Amplification.
Isothermal nucleic acid amplification methods do not rely on the continuing heat denaturation of the template DNA to produce single stranded molecules to serve as templates for further amplification, but instead rely on alternative methods such as enzymatic nicking of DNA molecules by specific restriction endonucleases, or the use of an enzyme to separate the DNA strands, at a constant temperature.
Strand Displacement Amplification (SDA) relies on the ability of certain restriction enzymes to nick the unmodified strand of hemi-modified DNA and the ability of a 5 '-3' exonuclease-deficient polymerase to extend and displace the downstream strand.
Exponential nucleic acid amplification is then achieved by coupling sense and antisense reactions in which strand displacement from the sense reaction serves as a template for the antisense reaction. The use of nickase enzymes which do not cut DNA in the traditional manner but produce a nick on one of the DNA strands, such as N. Alwl, N. BstNBl and Mly 1, are useful in this reaction. SDA has been improved by the use of a combination of a heat-stable restriction enzyme (Aval) and heat-stable Exo- polymerase (Bst polymerase). This combination has been shown to increase amplification efficiency of the reaction from 108 fold amplification to 1010 fold amplification so that it is possible using this technique to amplify unique single copy molecules.
Transcription Mediated Amplification (TMA) and Nucleic Acid Sequence Based Amplification (NASBA) use an RNA polymerase to copy RNA sequences but not corresponding genomic DNA. The technology uses two primers and two or three enzymes, RNA polymerase, reverse transcriptase and optionally RNase H (if the reverse transcriptase does not have RNase activity). One primer contains a promoter sequence for RNA polymerase. In the first step of nucleic acid amplification, this primer hybridizes to the target ribosomal RNA (rRNA) at a defined site. Reverse transcriptase creates a DNA copy of the target rRNA by extension from the 3' end of the promoter primer. The RNA in the resulting RNA:DNA duplex is degraded by the RNase activity of the reverse transcriptase if present or the additional RNase H. Next, a second primer binds to the DNA copy. A new strand of DNA is synthesized from the end of this primer by reverse transcriptase, creating a double-stranded DNA molecule. RNA polymerase recognizes the promoter sequence in the DNA template and initiates transcription. Each of the newly synthesized RNA amplicons re-enters the process and serves as a template for a new round of replication.
In Recombinase Polymerase Amplification (RPA), the isothermal amplification of specific DNA fragments is achieved by the binding of opposing oligonucleotide primers to
template DNA and their extension by a DNA polymerase. Heat is not required to denature the double-stranded DNA (dsDNA) template. Instead, PA employs recombinase-primer complexes to scan dsDNA and facilitate strand exchange at cognate sites. The resulting structures are stabilised by single-stranded DNA binding proteins interacting with the displaced template strand, thus preventing the ejection of the primer by branch migration. Recombinase disassembly leaves the 3' end of the oligonucleotide accessible to a strand displacing DNA polymerase, such as the large fragment of Bacillus subtilis Pol I (Bsu), and primer extension ensues. Exponential nucleic acid amplification is accomplished by the cyclic repetition of this process.
Helicase-dependent amplification (HDA) mimics the in vivo system in that it uses a
DNA helicase enzyme to generate single-stranded templates for primer hybridization and subsequent primer extension by a DNA polymerase. In the first step of the HDA reaction, the helicase enzyme traverses along the target DNA, disrupting the hydrogen bonds linking the two strands which are then bound by single-stranded binding proteins. Exposure of the single-stranded target region by the helicase allows primers to anneal. The DNA polymerase then extends the 3 ' ends of each primer using free deoxyribonucleoside triphosphates (dNTPs) to produce two DNA replicates. The two replicated dsDNA strands independently enter the next cycle of HDA, resulting in exponential nucleic acid amplification of the target sequence.
Other DNA-based isothermal techniques include Rolling Circle Amplification
(RCA) in which a DNA polymerase extends a primer continuously around a circular DNA template, generating a long DNA product that consists of many repeated copies of the circle. By the end of the reaction, the polymerase generates many thousands of copies of the circular template, with the chain of copies tethered to the original target DNA. This allows for spatial resolution of target and rapid nucleic acid amplification of the signal. Up to 1012 copies of template can be generated in 1 hour. Ramification amplification is a variation of RCA and utilizes a closed circular probe (C-probe) or padlock probe and a DNA polymerase with a high processivity to exponentially amplify the C-probe under isothermal conditions.
Loop-mediated isothermal amplification (LAMP), offers high selectivity and employs a DNA polymerase and a set of four specially designed primers that recognize a total of six distinct sequences on the target DNA. An inner primer containing sequences of the sense and antisense strands of the target DNA initiates LAMP. The following strand displacement DNA synthesis primed by an outer primer releases a single-stranded DNA.
This serves as template for DNA synthesis primed by the second inner and outer primers that hybridize to the other end of the target, which produces a stem-loop DNA structure. In subsequent LAMP cycling one inner primer hybridizes to the loop on the product and initiates displacement DNA synthesis, yielding the original stem-loop DNA and a new stem-loop DNA with a stem twice as long. The cycling reaction continues with accumulation of 109 copies of target in less than an hour. The final products are stem-loop DNAs with several inverted repeats of the target and cauliflower-like structures with multiple loops formed by annealing between alternately inverted repeats of the target in the same strand.
After completion of the nucleic acid amplification, the amplified product must be analysed to determine whether the anticipated amplicon (the amplified quantity of target nucleic acids) was generated. The methods of analyzing the product range from simply determining the size of the amplicon through gel electrophoresis, to identifying the nucleotide composition of the amplicon using DNA hybridization.
Gel electrophoresis is one of the simplest ways to check whether the nucleic acid amplification process generated the anticipated amplicon. Gel electrophoresis uses an electric field applied to a gel matrix to separate DNA fragments. The negatively charged DNA fragments will move through the matrix at different rates, determined largely by their size. After the electrophoresis is complete, the fragments in the gel can be stained to make them visible. Ethidium bromide is a commonly used stain which fluoresces under UV light.
The size of the fragments is determined by comparison with a DNA size marker (a DNA ladder), which contains DNA fragments of known sizes, run on the gel alongside the amplicon. Because the oligonucleotide primers bind to specific sites flanking the target DNA, the size of the amplified product can be anticipated and detected as a band of known size on the gel. To be certain of the identity of the amplicon, or if several amplicons have been generated, DNA probe hybridization to the amplicon is commonly employed.
DNA hybridization refers to the formation of double-stranded DNA by
complementary base pairing. DNA hybridization for positive identification of a specific amplification product requires the use of a DNA probe around 20 nucleotides in length. If the probe has a sequence that is complementary to the amplicon (target) DNA sequence, hybridization will occur under favourable conditions of temperature, pH and ionic concentration. If hybridization occurs, then the gene or DNA sequence of interest was present in the original sample.
Optical detection is the most common method to detect hybridization. Either the amplicons or the probes are labelled to emit light through fluorescence or
electrochemiluminescence. These processes differ in the means of producing excited states of the light-producing moieties, but both enable covalent labelling of nucleotide strands. In electrochemiluminescence (ECL), light is produced by luminophore molecules or complexes upon stimulation with an electric current. In fluorescence, it is illumination with excitation light which leads to emission.
Fluorescence is detected using an illumination source which provides excitation light at a wavelength absorbed by the fluorescent molecule, and a detection unit. The detection unit comprises a photosensor (such as a photomultiplier tube or charge-coupled device (CCD) array) to detect the emitted signal, and a mechanism (such as a wavelength- selective filter) to prevent the excitation light from being included in the photosensor output. The fluorescent molecules emit Stokes-shifted light in response to the excitation light, and this emitted light is collected by the detection unit. Stokes shift is the frequency difference or wavelength difference between emitted light and absorbed excitation light.
ECL emission is detected using a photosensor which is sensitive to the emission wavelength of the ECL species being employed. For example, transition metal-ligand complexes emit light at visible wavelengths, so conventional photodiodes and CCDs are employed as photosensors. An advantage of ECL is that, if ambient light is excluded, the ECL emission can be the only light present in the detection system, which improves sensitivity.
Microarrays allow for hundreds of thousands of DNA hybridization experiments to be performed simultaneously. Microarrays are powerful tools for molecular diagnostics with the potential to screen for thousands of genetic diseases or detect the presence of numerous infectious pathogens in a single test. A microarray consists of many different DNA probes immobilized as spots on a substrate. The target DNA (amplicon) is first labelled with a fluorescent or luminescent molecule (either during or after nucleic acid amplification) and then applied to the array of probes. The microarray is incubated in a temperature controlled, humid environment for a number of hours or days while hybridization between the probe and amplicon takes place. Following incubation, the microarray must be washed in a series of buffers to remove unbound strands. Once washed, the microarray surface is dried using a stream of air (often nitrogen). The stringency of the hybridization and washes is critical. Insufficient stringency can result in a high degree of nonspecific binding. Excessive stringency can lead to a failure of
appropriate binding, which results in diminished sensitivity. Hybridization is recognized by detecting light emission from the labelled amplicons which have formed a hybrid with complementary probes.
Fluorescence from microarrays is detected using a microarray scanner which is generally a computer controlled inverted scanning fluorescence confocal microscope which typically uses a laser for excitation of the fluorescent dye and a photosensor (such as a photomultiplier tube or CCD) to detect the emitted signal. The fluorescent molecules emit Stokes-shifted light (described above) which is collected by the detection unit.
The emitted fluorescence must be collected, separated from the unabsorbed excitation wavelength, and transported to the detector. In microarray scanners, a confocal arrangement is commonly used to eliminate out-of- focus information by means of a confocal pinhole situated at an image plane. This allows only the in- focus portion of the light to be detected. Light from above and below the plane of focus of the object is prevented from entering the detector, thereby increasing the signal to noise ratio. The detected fluorescent photons are converted into electrical energy by the detector which is subsequently converted to a digital signal. This digital signal translates to a number representing the intensity of fluorescence from a given pixel. Each feature of the array is made up of one or more such pixels. The final result of a scan is an image of the array surface. The exact sequence and position of every probe on the microarray is known, and so the hybridized target sequences can be identified and analysed simultaneously.
More information regarding fluorescent probes can be found at:
http://www. premierbiosoft. com/tech_notes/FRET_probe. html and
http ://www. invitrogen. com/site/us/ en/nome/References/Molecular-Probes-The- Handbook/Technical-Notes-and-Product-Highlights/Fluorescence-Resonance- Energy-Transfer-FRET. html
POINT-OF-CARE MOLECULAR DIAGNOSTICS
Despite the advantages that molecular diagnostic tests offer, the growth of this type of testing in the clinical laboratory has been slower than expected and remains a minor part of the practice of laboratory medicine. This is primarily due to the complexity and costs associated with nucleic acid testing compared with tests based on methods not involving nucleic acids. The widespread adaptation of molecular diagnostics testing to the clinical setting is intimately tied to the development of instrumentation that significantly reduces
the cost, provides a rapid and automated assay from start (specimen processing) to finish (generating a result) and operates without major intervention by personnel.
A point-of-care technology serving the physician's office, the hospital bedside or even consumer-based, at home, would offer many advantages including:
• rapid availability of results enabling immediate facilitation of treatment and
improved quality of care.
• ability to obtain laboratory values from testing very small samples.
• reduced clinical workload.
• reduced laboratory workload and improved office efficiency by reducing
administrative work.
• improved cost per patient through reduced length of stay of hospitalization,
conclusion of outpatient consultation at the first visit, and reduced handling, storing and shipping of specimens.
• facilitation of clinical management decisions such as infection control and
antibiotic use.
LAB-ON-A-CHIP (LOC) BASED MOLECULAR DIAGNOSTICS
Molecular diagnostic systems based on microfluidic technologies provide the means to automate and speed up molecular diagnostic assays. The quicker detection times are primarily due to the extremely low volumes involved, automation, and the low- overhead inbuilt cascading of the diagnostic process steps within a microfluidic device. Volumes in the nanoliter and microliter scale also reduce reagent consumption and cost. Lab-on-a-chip (LOC) devices are a common form of microfluidic device. LOC devices have MST structures within a MST layer for fluid processing integrated onto a single supporting substrate (usually silicon). Fabrication using the VLSI (very large scale integrated) lithographic techniques of the semiconductor industry keeps the unit cost of each LOC device very low. However, controlling fluid flow through the LOC device, adding reagents, controlling reaction conditions and so on necessitate bulky external plumbing and electronics. Connecting a LOC device to these external devices effectively restricts the use of LOC devices for molecular diagnostics to the laboratory setting. The cost of the external equipment and complexity of its operation precludes LOC-based molecular diagnostics as a practical option for point-of-care settings.
In view of the above, there is a need for a molecular diagnostic system based on a LOC device for use at point-of-care.
SUMMARY OF THE INVENTION
Various aspects of the present invention are now described in the following numbered paragraphs.
GCF007.1 This aspect of the invention provides a lab-on-a-chip (LOC) device for detecting pathogens in a biological sample, the LOC device comprising:
an inlet for receiving the sample;
a supporting substrate;
a first dialysis section for separating pathogens from larger constituents in the sample;
a lysis section downstream of the dialysis section for lysing the pathogens to release genetic material therein, the lysis section having a lysis chamber and a heater for lysing the pathogens while the sample is in the lysis chamber;
a nucleic acid amplification section downstream of the lysis section for amplifying nucleic acid sequences in the genetic material; and,
a second dialysis section downstream of the nucleic acid amplification section for prehybridization filtration of amplicon produced by the nucleic acid amplification section, the second dialysis section being configured to remove cell debris from the amplicon; wherein,
the first dialysis section, the lysis section, the nucleic acid amplification section and the second dialysis section are all supported on the supporting substrate.
GCF007.2 Preferably, the lysis section has a heater for thermally lysing the pathogens.
GCF007.3 Preferably, the LOC device also has a hybridization section downstream of the second dialysis section that has an array of probes for hybridization with target nucleic acid sequences in the sample and, a photosensor for detecting hybridization of any probes within the array.
GCF007.4 Preferably, the first dialysis section has a first channel in fluid communication with the inlet, a second channel in fluid communication with the lysis section and a plurality of first apertures that are larger than the pathogens and smaller than the larger constituents, the second channel being in fluid communication with the first
channel via the first apertures such that the pathogens flow into the second channel while the larger constituents are retained in the first channel.
GCF007.5 Preferably, the first channel and the second channel are configured to fill with the sample by capillary action.
GCF007.6 Preferably, the second dialysis section has a large component channel, a small component channel and a plurality of second apertures fluidically connecting the large component channel to the small component channel, the second apertures being sized to allow nucleic acid sequences to flow from the large component channel to the small component channel while cell debris larger than the second apertures is retained in the large component channel, the small component channel being in fluid communication with the hybridization section.
GCF007.7 Preferably, the nucleic acid amplification section is an isothermal nucleic acid amplification section.
GCF007.8 Preferably, the LOC device also has a reagent reservoir for holding a reagent used for isothermal nucleic acid amplification; and,
a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus and the reagent flows out of the reagent reservoir.
GCF007.9 Preferably, the nucleic acid amplification section is polymerase chain reaction (PCR) amplification section.
GCF007.10 Preferably, the LOC device also has CMOS circuitry, a temperature sensor and a microsystems technology (MST) layer which incorporates the PCR section, wherein the CMOS circuitry is positioned between the supporting substrate and the MST layer, the CMOS circuitry being configured to use the temperature sensor output for feedback control of the PCR section.
GCF007.11 Preferably, the PCR section has a PCR microchannel for thermally cycling the sample to amplify the nucleic acid sequences, the PCR microchannel defining part of the flow-path for the sample and has a cross sectional area transverse to the flow less than 100,000 square microns.
GCF007.12 Preferably, the LOC device also has at least one elongate heater element for heating the nucleic acid sequences within the elongate PCR microchannel, the elongate heater element extending parallel to the PCR microchannel.
GCF007.13 Preferably, at least one section of the PCR microchannel forms an elongate PCR chamber.
GCF007.14 Preferably, the PCR section has a plurality of the elongate PCR chambers each formed by respective sections of the PCR microchannel, the PCR microchannel having a serpentine configuration formed by a series of wide meanders, each of the wide meanders being a channel section that forms one of the elongate PCR chambers.
GCF007.15 Preferably, the LOC device also has a reagent reservoir for holding a reagent used for PCR; and,
a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus and the reagent flows out of the reagent reservoir.
GCF007.16 Preferably, the LOC device also has a hybridization chamber array for containing the probes such that the probes within each hybridization chamber are configured to hybridize with one of the target nucleic acid sequences.
GCF007.17 Preferably, the photosensor is an array of photodiodes positioned in registration with the hybridization chambers.
GCF007.18 Preferably, the CMOS circuitry has a digital memory for storing hybridization data from the photosensor output and a data interface for transmission of the hybridization data to an external device.
GCF007.19 Preferably, the PCR section has an active valve for retaining liquid in the PCR section during thermal cycling and allowing flow to the hybridization chambers in response to an activation signal from the CMOS circuitry.
GCF007.20 Preferably, the active valve is a boiling-initiated valve with a meniscus anchor configured to pin a meniscus that arrests capillary driven flow of the liquid, and a heater for boiling the liquid to unpin the meniscus from the meniscus anchor such that capillary driven flow resumes.
The easily usable, mass-producible, and inexpensive pathogen detection LOC device accepts a biological sample through its sample receptacle, uses its dialysis section to separate any pathogens contained in the sample, lyses the pathogens in its thermal lysis chamber to release the pathogens' genetic materials, amplifies any target genetic sequences, and analyzes the sample's nucleic acid sequences via hybridization with oligonucleotide probes with sensing via its integral imaging array, utilizing reagents stored in the LOC device's reagent reservoirs.
The dialysis section functionality extracts additional information from the sample and increases the sensitivity, signal-to-noise ratio, and dynamic range of the assay system. The dialysis section being integral to the device, provides for the low system component- count and simple manufacturing procedures, leading into an inexpensive assay system.
The lysing process extracts analytical and diagnostic targets from cells in the sample and provides for follow-on processing and analysis of the targets. The lysis subunit being integral to the device, provides for simple assay procedures, low system component- count, and simple system manufacturing procedures, leading into an inexpensive assay system. The thermal lysing process simplifies assay chemistry requirements and provides for capability for a wide range of sample types.
The amplification of target genetic sequences increases the sensitivity and signal- to-noise ratio of the assay system.
The prehybridization filtering removes the debris resulting from the thermal lysis of the sample cells improving the effectiveness of the hybridization process and the consequent improvement in the assay sensitivity, signal-to-noise-ratio, and reliability. The prehybridization filtering also permits utilization of the thermal lysis process, with its consequent advantages, for a wider range of sample types.
The probe hybridization section provides for analysis of the targets via
hybridization. The integrated probe hybridization section provides for an easily usable, mass-producible, and inexpensive integrated solution with low system component-count.
The integrated image sensor obviates the need for an expensive external imaging system and provides for a mass-producible inexpensive integrated solution with low system component-count that is a compact, light, and highly portable system. The integrated image sensor increases the readout sensitivity by benefiting from large angle of light collection and obviates the need for optical components in the optical collection train.
The reagent reservoirs, being integral to the LOC device and holding the assay's total reagent requirements, provide for the low system component-count and simple manufacturing procedures, leading into an inexpensive assay system.
BRIEF DESCRIPTION OF THE DRAWINGS
Preferred embodiments of the present invention will now be described by way of example only with reference to the accompanying drawings, in which:
Figure 1 shows a test module and test module reader configured for fluorescence detection;
Figure 2 is a schematic overview of the electronic components in the test module configured for fluorescence detection;
Figure 3 is a schematic overview of the electronic components in the test module reader;
Figure 4 is a schematic representation of the architecture of the LOC device; Figure 5 is a perspective of the LOC device;
Figure 6 is a plan view of the LOC device with features and structures from all layers superimposed on each other;
Figure 7 is a plan view of the LOC device with the structures of the cap shown in isolation;
Figure 8 is a top perspective of the cap with internal channels and reservoirs shown in dotted line;
Figure 9 is an exploded top perspective of the cap with internal channels and reservoirs shown in dotted line;
Figure 10 is a bottom perspective of the cap showing the configuration of the top channels;
Figure 11 is a plan view of the LOC device showing the structures of the CMOS + MST device in isolation;
Figure 12 is a schematic section view of the LOC device at the sample inlet;
Figure 13 is an enlarged view of Inset AA shown in Figure 6;
Figure 14 is an enlarged view of Inset AB shown in Figure 6;
Figure 15 is an enlarged view of Inset AE shown in Figure 13;
Figure 16 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
Figure 17 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
Figure 18 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
Figure 19 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
Figure 20 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
Figure 21 is a partial perspective illustrating the laminar structure of the LOC device within Inset AE;
Figure 22 is schematic section view of the lysis reagent reservoir shown in Figure
21;
Figure 23 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
Figure 24 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
Figure 25 is a partial perspective illustrating the laminar structure of the LOC device within Inset AI;
Figure 26 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
Figure 27 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
Figure 28 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
Figure 29 is a partial perspective illustrating the laminar structure of the LOC device within Inset AB;
Figure 30 is a schematic section view of the amplification mix reservoir and the polymerase reservoir;
Figure 31 show the features of a boiling- initiated valve in isolation;
Figure 32 is a schematic section view of the boiling-initiated valve taken through line 33-33 shown in Figure 31;
Figure 33 is an enlarged view of Inset AF shown in Figure 15;
Figure 34 is a schematic section view of the upstream end of the dialysis section taken through line 35-35 shown in Figure 33;
Figure 35 is an enlarged view of Inset AC shown in Figure 6;
Figure 36 is a further enlarged view within Inset AC showing the amplification section;
Figure 37 is a further enlarged view within Inset AC showing the amplification section;
Figure 38 is a further enlarged view within Inset AC showing the amplification section;
Figure 39 is a further enlarged view within Inset AK shown in Figure 38;
Figure 40 is a further enlarged view within Inset AC showing the amplification chamber;
Figure 41 is a further enlarged view within Inset AC showing the amplification section;
Figure 42 is a further enlarged view within Inset AC showing the amplification chamber;
Figure 43 is a further enlarged view within Inset AL shown in Figure 42; Figure 44 is a further enlarged view within Inset AC showing the amplification section;
Figure 45 is a further enlarged view within Inset AM shown in Figure 44;
Figure 46 is a further enlarged view within Inset AC showing the amplification chamber;
Figure 47 is a further enlarged view within Inset AN shown in Figure 46; Figure 48 is a further enlarged view within Inset AC showing the amplification chamber;
Figure 49 is a further enlarged view within Inset AC showing the amplification chamber;
Figure 50 is a further enlarged view within Inset AC showing the amplification section;
Figure 51 is a schematic section view of the amplification section;
Figure 52 is an enlarged plan view of the hybridization section;
Figure 53 is a further enlarged plan view of two hybridization chambers in isolation;
Figure 54 is schematic section view of a single hybridization chamber;
Figure 55 is an enlarged view of the humidifier illustrated in Inset AG shown in
Figure 6;
Figure 56 is an enlarged view of Inset AD shown in Figure 52;
Figure 57 is an exploded perspective view of the LOC device within Inset AD;
Figure 58 is a diagram of a FRET probe in a closed configuration;
Figure 59 is a diagram of a FRET probe in an open and hybridized configuration; Figure 60 is a graph of the intensity of an excitation light over time;
Figure 61 is a diagram of the excitation illumination geometry of the hybridization chamber array;
Figure 62 is a diagram of a Sensor Electronic Technology LED illumination geometry;
Figure 63 is an enlarged plan view of the humidity sensor shown in Inset AH of Figure 6;
Figure 64 is a schematic showing part of the photodiode array of the photosensor; Figure 65 is a circuit diagram for a single photodiode;
Figure 66 is a timing diagram for the photodiode control signals;
Figure 67 is an enlarged view of the evaporator shown in Inset AP of Figure 55; Figure 68 is a schematic section view through a hybridization chamber with a detection photodiode and trigger photodiode;
Figure 69 is a diagram of linker-primed PCR;
Figure 70 is a schematic representation of a test module with a lancet;
Figure 71 is a diagrammatic representation of the architecture of LOC variant VII;
Figure 72 is a plan view of LOC variant VIII with features and structures from all layers superimposed on each other;
Figure 73 is an enlarged view of Inset CA shown in Figure 72;
Figure 74 is a partial perspective illustrating the laminar structure of LOC variant VIII within Inset CA shown in Figure 72;
Figure 75 is an enlarged view of Inset CE shown in Figure 73;
Figure 76 is a diagrammatic representation of the architecture of LOC variant VIII;
Figure 77 is a schematic illustration of the architecture of LOC variant XIV;
Figure 78 is a schematic illustration of the architecture of LOC variant XIX;
Figure 79 is a schematic illustration of the architecture of LOC variant XLI;
Figure 80 is a schematic illustration of the architecture of LOC variant XLIII;
Figure 81 is a schematic illustration of the architecture of LOC variant XLIV;
Figure 82 is a schematic illustration of the architecture of LOC variant XLVII;
Figure 83 is a diagram of a primer-linked, linear fluorescent probe during the initial round of amplification;
Figure 84 is a diagram of a primer-linked, linear fluorescent probe during a subsequent amplification cycle;
Figures 85A to 85F diagrammatically illustrate thermal cycling of a primer-linked fluorescent stem-and-loop probe;
Figure 86 is a schematic illustration of the excitation LED relative to the hybridization chamber array and the photodiodes;
Figure 87 is a schematic illustration of the excitation LED and optical lens for directing light onto the hybridization chamber array of the LOC device;
Figure 88 is a schematic illustration of the excitation LED, optical lens, and optical prisms for directing light onto the hybridization chamber array of the LOC device;
Figure 89 is a schematic illustration of the excitation LED, optical lens and mirror arrangement for directing light onto the hybridization chamber array of the LOC device;
Figure 90 is a plan view showing all the features superimposed on each other, and showing the location of Insets DA to DK;
Figure 91 is an enlarged view of Inset DG shown in Figure 90;
Figure 92 is an enlarged view of Inset DH shown in Figure 90;
Figure 93 is a diagrammatic representation of the architecture of LOC variant XII;
Figure 94 is a perspective view of LOC variant XII;
Figure 95 is a plan view of LOC variant XII showing all features superimposed on each other, and showing the location of Insets FA to FC;
Figure 96 is a plan view of LOC variant XII showing only the features of the cap in isolation;
Figure 97 is a plan view of LOC variant XII showing the structures of the CMOS + MST device in isolation;
Figure 98 is an enlarged view of Inset FA shown in Figure 95;
Figure 99 is an enlarged view of Inset FB shown in Figure 95;
Figure 100 is an enlarged view of Inset FC shown in Figure 95;
Figure 101 shows one embodiment of the shunt transistor for the photodiodes;
Figure 102 shows one embodiment of the shunt transistor for the photodiodes;
Figure 103 shows one embodiment of the shunt transistor for the photodiodes;
Figure 104 is a circuit diagram of the differential imager;
Figure 105 schematically illustrates a negative control fluorescent probe in its stem- and-loop configuration;
Figure 106 schematically illustrates the negative control fluorescent probe of Figure 105 in its open configuration;
Figure 107 schematically illustrates a positive control fluorescent probe in its stem- and-loop configuration;
Figure 108 schematically illustrates the positive control fluorescent probe of Figure 107 in its open configuration;
Figure 109 shows a test module and test module reader configured for use with
ECL detection;
Figure 110 is a schematic overview of the electronic components in the test module configured for use with ECL detection;
Figure 1 11 shows a test module and alternative test module readers;
Figure 112 shows a test module and test module reader along with the hosting system housing various databases;
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
OVERVIEW
This overview identifies the main components of a molecular diagnostic system that incorporates embodiments of the present invention. Comprehensive details of the system architecture and operation are set out later in the specification.
Referring to Figures 1, 2, 3, 109 and 1 10, the system has the following top level components:
Test modules 10 and 1 1 are the size of a typical USB memory key and very cheap to produce. Test modules 10 and 11 each contain a microfluidic device, typically in the form of a lab-on-a-chip (LOC) device 30 preloaded with reagents and typically more than 1000 probes for the molecular diagnostic assay (see Figures 1 and 109). Test module 10 schematically shown in Figure 1 uses a fluorescence-based detection technique to identify target molecules, while test module 11 in Figure 109 uses an electrochemiluminescence- based detection technique. The LOC device 30 has an integrated photosensor 44 for fluorescence or electrochemiluminescence detection (described in detail below). Both test modules 10 and 11 use a standard Micro-USB plug 14 for power, data and control, both have a printed circuit board (PCB) 57, and both have external power supply capacitors 32 and an inductor 15. The test modules 10 and 11 are both single-use only for mass production and distribution in sterile packaging ready for use.
The outer casing 13 has a macroreceptacle 24 for receiving the biological sample and a removable sterile sealing tape 22, preferably with a low tack adhesive, to cover the
macroreceptacle prior to use. A membrane seal 408 with a membrane guard 410 forms part of the outer casing 13 to reduce dehumidification within the test module while providing pressure relief from small air pressure fluctuations. The membrane guard 410 protects the membrane seal 408 from damage.
Test module reader 12 powers the test module 10 or 11 via Micro-USB port 16.
The test module reader 12 can adopt many different forms and a selection of these are described later. The version of the reader 12 shown in Figures 1, 3 and 109 is a smart phone embodiment. A block diagram of this reader 12 is shown in Figure 3. Processor 42 runs application software from program storage 43. The processor 42 also interfaces with the display screen 18 and user interface (UI) touch screen 17 and buttons 19, a cellular radio 21, wireless network connection 23, and a satellite navigation system 25. The cellular radio 21 and wireless network connection 23 are used for communications.
Satellite navigation system 25 is used for updating epidemiological databases with location data. The location data can, alternatively, be entered manually via the touch screen 17 or buttons 19. Data storage 27 holds genetic and diagnostic information, test results, patient information, assay and probe data for identifying each probe and its array position. Data storage 27 and program storage 43 may be shared in a common memory facility.
Application software installed on the test module reader 12 provides analysis of results, along with additional test and diagnostic information.
To conduct a diagnostic test, the test module 10 (or test module 1 1) is inserted into the Micro-USB port 16 on the test module reader 12. The sterile sealing tape 22 is peeled back and the biological sample (in a liquid form) is loaded into the sample macroreceptacle 24. Pressing start button 20 initiates testing via the application software. The sample flows into the LOC device 30 and the on-board assay extracts, incubates, amplifies and hybridizes the sample nucleic acids (the target) with presynthesized hybridization- responsive oligonucleotide probes. In the case of test module 10 (which uses fluorescence- based detection), the probes are fluorescently labelled and the LED 26 housed in the casing 13 provides the necessary excitation light to induce fluorescence emission from the hybridized probes (see Figures 1 and 2). In test module 11 (which uses
electrochemiluminescence (ECL) detection), the LOC device 30 is loaded with ECL probes (discussed above) and the LED 26 is not necessary for generating the luminescent emission. Instead, electrodes 860 and 870 provide the excitation electrical current (see Figure 110). The emission (fluorescent or luminescent) is detected using a photosensor 44 integrated into CMOS circuitry of each LOC device. The detected signal is amplified and
converted to a digital output which is analyzed by the test module reader 12. The reader then displays the results.
The data may be saved locally and'or uploaded to a network server containing patient records. The test module 10 or 11 is removed from the test module reader 12 and disposed of appropriately.
Figures 1, 3 and 109 show the test module reader 12 configured as a mobile phone/smart phone 28. In other forms, the test module reader is a laptop/notebook 101, a dedicated reader 103, an ebook reader 107, a tablet computer 109 or desktop computer 105 for use in hospitals, private practices or laboratories (see Figure 111). The reader can interface with a range of additional applications such as patient records, billing, online databases and multi-user environments. It can also be interfaced with a range of local or remote peripherals such as printers and patient smart cards.
Referring to Figure 112, the data generated by the test module 10 can be used to update, via the reader 12 and network 125, the epidemiological databases hosted on the hosting system for epidemiological data 11 1, the genetic databases hosted on the hosting system for genetic data 113, the electronic health records hosted on the hosting system for electronic health records (EHR) 1 15, the electronic medical records hosted on the hosting system for electronic medical records (EMR) 121, and the personal health records hosted on the hosting system for personal health records (PHR) 123. Conversely, the epidemiological data hosted on the hosting system for epidemiological data 111 , the genetic data hosted on the hosting system for genetic data 113, the electronic health records hosted on the hosting system for electronic health records (EHR) 1 15, the electronic medical records hosted on the hosting system for electronic medical records (EMR) 121, and the personal health records hosted on the hosting system for personal health records (PHR) 123, can be used to update, via network 125 and the reader 12, the digital memory in the LOC 30 of the test module 10.
Referring back to Figures 1, 2, 109 and 1 10 the reader 12 uses battery power in the mobile phone configuration. The mobile phone reader contains all test and diagnostic information preloaded. Data can also be loaded or updated via a number of wireless or contact interfaces to enable communications with peripheral devices, computers or online servers. A Micro-USB port 16 is provided for connection to a computer or mains power supply for battery recharge.
Figure 70 shows an embodiment of the test module 10 used for tests that only require a positive or negative result for a particular target, such as testing whether a person
is infected with, for example, H1N1 Influenza A virus. Only a purpose built USB power/indicator-only module 47 is adequate. No other reader or application software is necessary. An indicator 45 on the USB power/indicator-only module 47 signals positive or negative results. This configuration is well suited to mass screening.
Additional items supplied with the system may include a test tube containing reagents for pre-treatment of certain samples, along with spatula and lancet for sample collection. Figure 70 shows an embodiment of the test module incorporating a spring- loaded, retractable lancet 390 and lancet release button 392 for convenience. A satellite phone can be used in remote areas. TEST MODULE ELECTRONICS
Figures 2 and 110 are block diagrams of the electronic components in the test modules 10 and 11, respectively. The CMOS circuitry integrated in the LOC device 30 has a USB device driver 36, a controller 34, a USB-compatible LED driver 29, clock 33, power conditioner 31, RAM 38 and program and data flash memory 40. These provide the control and memory for the entire test module 10 or 11 including the photosensor 44, the temperature sensors 170, the liquid sensors 174, and the various heaters 152, 154, 182, 234, together with associated drivers 37 and 39 and registers 35 and 41. Only the LED 26 (in the case of test module 10), external power supply capacitors 32 and the Micro-USB plug 14 are external to the LOC device 30. The LOC devices 30 include bond-pads for making connections to these external components. The RAM 38 and the program and data flash memory 40 have the application software and the diagnostic and test information (Flash/Secure storage, e.g. via encryption) for over 1000 probes. In the case of test module 1 1 configured for ECL detection, there is no LED 26 (see Figures 109 and 110). Data is encrypted by the LOC device 30 for secure storage and secure communication with an external device. The LOC devices 30 are loaded with electrochemiluminescent probes and the hybridization chambers each have a pair of ECL excitation electrodes 860 and 870.
Many types of test modules 10 are manufactured in a number of test forms, ready for off-the-shelf use. The differences between the test forms lie in the on board assay of reagents and probes.
Some examples of infectious diseases rapidly identified with this system include:
• Influenza - Influenza virus A, B, C, Isavirus, Thogotovirus
• Pneumonia - respiratory syncytial virus (RSV), adenovirus, metapneumovirus,
Streptococcus pneumoniae, Staphylococcus aureus
• Tuberculosis - Mycobacterium tuberculosis, bovis, africanum, canetti, and microti
• Plasmodium falciparum, Toxoplasma gondii and other protozoan parasites
• Typhoid - Salmonella enterica serovar typhi
• Ebola virus
• Human immunodeficiency virus (HIV)
• Dengue Fever - Flavivirus
• Hepatitis (A through E)
• Hospital acquired infections - for example Clostridium difficile, Vancomycin resistant Enterococcus, and Methicillin resistant Staphylococcus aureus
• Herpes simplex virus (HSV)
• Cytomegalovirus (CMV)
• Epstein-Barr virus (EBV)
• Encephalitis - Japanese Encephalitis virus, Chandipura virus
• Whooping cough - Bordetella pertussis
• Measles - paramyxovirus
• Meningitis - Streptococcus pneumoniae and Neisseria meningitidis
• Anthrax - Bacillus anthracis Some examples of genetic disorders identified with this system include:
• Cystic fibrosis
• Haemophilia
• Sickle cell disease
• Tay-Sachs disease
· Haemochromatosis
• Cerebral arteriopathy
• Crohn's disease
• Polycistic kidney disease
• Congential heart disease
· Rett syndrome
A small selection of cancers identified by the diagnostic system include:
• Ovarian
• Colon carcinoma
• Multiple endocrine neoplasia
• Retinoblastoma
• Turcot syndrome
The above lists are not exhaustive and the diagnostic system can be configured to detect a much greater variety of diseases and conditions using nucleic acid and proteomic analysis.
DETAILED ARCHITECTURE OF SYSTEM COMPONENTS LOC DEVICE
The LOC device 30 is central to the diagnostic system. It rapidly performs the four major steps of a nucleic acid based molecular diagnostic assay, i.e. sample preparation, nucleic acid extraction, nucleic acid amplification, and detection, using a microfluidic platform. The LOC device also has alternative uses, and these are detailed later. As discussed above, test modules 10 and 11 can adopt many different configurations to detect different targets. Likewise, the LOC device 30 has numerous different embodiments tailored to the target(s) of interest. One form of the LOC device 30 is LOC device 301 for fluorescent detection of target nucleic acid sequences in the pathogens of a whole blood sample. For the purposes of illustration, the structure and operation of LOC device 301 is now described in detail with reference to Figures 4 to 26 and 27 to 57.
Figure 4 is a schematic representation of the architecture of the LOC device 301. For convenience, process stages shown in Figure 4 are indicated with the reference numeral corresponding to the functional sections of the LOC device 301 that perform that process stage. The process stages associated with each of the major steps of a nucleic acid based molecular diagnostic assay are also indicated: sample input and preparation 288, extraction 290, incubation 291, amplification 292 and detection 294. The various reservoirs, chambers, valves and other components of the LOC device 301 will be described in more detail later.
Figure 5 is a perspective view of the LOC device 301. It is fabricated using high volume CMOS and MST (microsystems technology) manufacturing techniques. The laminar structure of the LOC device 301 is illustrated in the schematic (not to scale) partial section view of Figure 12. The LOC device 301 has a silicon substrate 84 which supports
the CMOS + MST chip 48, comprising CMOS circuitry 86 and an MST layer 87, with a cap 46 overlaying the MST layer 87. For the purposes of this patent specification, the term 'MST layer' is a reference to a collection of structures and layers that process the sample with various reagents. Accordingly, these structures and components are configured to define flow-paths with characteristic dimensions that will support capillary driven flow of liquids with physical characteristics similar to those of the sample during processing. In light of this, the MST layer and components are typically fabricated using surface micromachining techniques and/or bulk micromachining techniques. However, other fabrication methods can also produce structures and components dimensioned for capillary driven flows and processing very small volumes. The specific embodiments described in this specification show the MST layer as the structures and active components supported on the CMOS circuitry 86, but excluding the features of the cap 46. However, the skilled addressee will appreciate that the MST layer need not have underlying CMOS or indeed an overlying cap in order for it to process the sample.
The overall dimensions of the LOC device shown in the following figures are
1760μιη x 824μιη. Of course, LOC devices fabricated for different applications may have different dimensions.
Figure 6 shows the features of the MST layer 87 superimposed with the features of the cap. Insets AA to AD, AG and AH shown in Figure 6 are enlarged in Figures 13, 14, 35, 56, 55 and 63, respectively, and described in detail below for a comprehensive understanding of each structure within the LOC device 301. Figures 7 to 10 show the features of the cap 46 in isolation while Figure 1 1 shows the CMOS + MST device 48 structures in isolation.
LAMINAR STRUCTURE Figures 12 and 22 are sketches that diagrammatically show the laminar structure of the CMOS + MST device 48, the cap 46 and the fluidic interaction between the two. The figures are not to scale for the purposes of illustration. Figure 12 is a schematic section view through the sample inlet 68 and Figure 22 is a schematic section through the reservoir 54. As best shown in Figure 12, the CMOS + MST device 48 has a silicon substrate 84 which supports the CMOS circuitry 86 that operates the active elements within the MST layer 87 above. A passivation layer 88 seals and protects the CMOS layer 86 from the fluid flows through the MST layer 87.
Fluid flows through both the cap channels 94 and the MST channels 90 (see for example Figures 7 and 16) in the cap layer 46 and MST channel layer 100, respectively. Cell transport occurs in the larger channels 94 fabricated in the cap 46, while biochemical processes are carried out in the smaller MST channels 90. Cell transport channels are sized so as to be able to transport cells in the sample to predetermined sites in the MST channels 90. Transportation of cells with sizes greater than 20 microns (for example, certain leukocytes) requires channel dimensions greater than 20 microns, and therefore a cross sectional area transverse to the flow of greater than 400 square microns. MST channels, particularly at locations in the LOC where transport of cells is not required, can be significantly smaller.
It will be appreciated that cap channel 94 and MST channel 90 are generic references and particular MST channels 90 may also be referred to as (for example) heated microchannels or dialysis MST channels in light of their particular function. MST channels 90 are formed by etching through a MST channel layer 100 deposited on the passivation layer 88 and patterned with photoresist. The MST channels 90 are enclosed by a roof layer 66 which forms the top (with respect to the orientation shown in the figures) of the CMOS + MST device 48.
Despite sometimes being shown as separate layers, the cap channel layer 80 and the reservoir layer 78 are formed from a unitary piece of material. Of course, the piece of material may also be non-unitary. This piece of material is etched from both sides in order to form a cap channel layer 80 in which the cap channels 94 are etched and the reservoir layer 78 in which the reservoirs 54, 56, 58, 60 and 62 are etched. Alternatively, the reservoirs and the cap channels are formed by a micromolding process. Both etching and micromolding techniques are used to produce channels with cross sectional areas transverse to the flow as large as 20,000 square microns, and as small as 8 square microns.
At different locations in the LOC device, there can be a range of appropriate choices for the cross sectional area of the channel transverse to the flow. Where large quantities of sample, or samples with large constituents, are contained in the channel, a cross-sectional area of up to 20,000 square microns (for example, a 200 micron wide channel in a 100 micron thick layer) is suitable. Where small quantities of liquid, or mixtures without large cells present, are contained in the channel, a very small cross sectional area transverse to the flow is preferable.
A lower seal 64 encloses the cap channels 94 and the upper seal layer 82 encloses the reservoirs 54, 56, 58, 60 and 62.
The five reservoirs 54, 56, 58, 60 and 62 are preloaded with assay-specific reagents. In the embodiment described here, the reservoirs are preloaded with the following reagents, but other reagents can easily be substituted: · reservoir 54: anticoagulant with option to include erythrocyte lysis buffer
• reservoir 56: lysis reagent
• reservoir 58: restriction enzymes, ligase and linkers (for linker-primed PCR (see Figure 69, extracted from T. Stachan et al, Human Molecular Genetics 2, Garland Science, NY and London, 1999))
· reservoir 60: amplification mix (dNTPs, primers, buffer) and
• reservoir 62: DNA polymerase.
The cap 46 and the CMOS+MST layers 48 are in fluid communication via corresponding openings in the lower seal 64 and the roof layer 66. These openings are referred to as uptakes 96 and downtakes 92 depending on whether fluid is flowing from the MST channels 90 to the cap channels 94 or vice versa.
LOC DEVICE OPERATION
The operation of the LOC device 301 is described below in a step-wise fashion with reference to analysing pathogenic DNA in a blood sample. Of course, other types of biological or non-biological fluid are also analysed using an appropriate set, or combination, of reagents, test protocols, LOC variants and detection systems. Referring back to Figure 4, there are five major steps involved in analysing a biological sample, comprising sample input and preparation 288, nucleic acid extraction 290, nucleic acid incubation 291, nucleic acid amplification 292 and detection and analysis 294.
The sample input and preparation step 288 involves mixing the blood with an anticoagulant 116 and then separating pathogens from the leukocytes and erythrocytes with the pathogen dialysis section 70. As best shown in Figures 7 and 12, the blood sample enters the device via the sample inlet 68. Capillary action draws the blood sample along the cap channel 94 to the reservoir 54. Anticoagulant is released from the reservoir 54 as the sample blood flow opens its surface tension valve 118 (see Figures 15 and 22). The anticoagulant prevents the formation of clots which would block the flow.
As best shown in Figure 22, the anticoagulant 1 16 is drawn out of the reservoir 54 by capillary action and into the MST channel 90 via the downtake 92. The downtake 92
has a capillary initiation feature (CIF) 102 to shape the geometry of the meniscus such that it does not anchor to the rim of the downtake 92. Vent holes 122 in the upper seal 82 allows air to replace the anticoagulant 1 16 as it is drawn out of the reservoir 54.
The MST channel 90 shown in Figure 22 is part of a surface tension valve 1 18. The anticoagulant 1 16 fills the surface tension valve 118 and pins a meniscus 120 to the uptake 96 to a meniscus anchor 98. Prior to use, the meniscus 120 remains pinned at the uptake 96 so the anticoagulant does not flow into the cap channel 94. When the blood flows through the cap channel 94 to the uptake 96, the meniscus 120 is removed and the anticoagulant is drawn into the flow.
Figures 15 to 21 show Inset AE which is a portion of Inset AA shown in Figure 13.
As shown in Figures 15, 16 and 17, the surface tension valve 118 has three separate MST channels 90 extending between respective downtakes 92 and uptakes 96. The number of MST channels 90 in a surface tension valve can be varied to change the flow rate of the reagent into the sample mixture. As the sample mixture and the reagents mix together by diffusion, the flow rate out of the reservoir determines the concentration of the reagent in the sample flow. Hence, the surface tension valve for each of the reservoirs is configured to match the desired reagent concentration.
The blood passes into a pathogen dialysis section 70 (see Figures 4 and 15) where target cells are concentrated from the sample using an array of apertures 164 sized according to a predetermined threshold. Cells smaller than the threshold pass through the apertures while larger cells do not pass through the apertures. Unwanted cells, which may be either the larger cells withheld by the array of apertures 164 or the smaller cells that pass through the apertures, are redirected to a waste unit 76 while the target cells continue as part of the assay.
In the pathogen dialysis section 70 described here, the pathogens from the whole blood sample are concentrated for microbial DNA analysis. The array of apertures is formed by a multitude of 3 micron diameter holes 164 fluidically connecting the input flow in the cap channel 94 to a target channel 74. The 3 micron diameter apertures 164 and the dialysis uptake holes 168 for the target channel 74 are connected by a series of dialysis MST channels 204 (best shown in Figures 15 and 21). Pathogens are small enough to pass through the 3 micron diameter apertures 164 and fill the target channel 74 via the dialysis MST channels 204. Cells larger than 3 microns, such as erythrocytes and leukocytes, stay in the waste channel 72 in the cap 46 which leads to a waste reservoir 76 (see Figure 7).
Other aperture shapes, sizes and aspect ratios can be used to isolate specific pathogens or other target cells such as leukocytes for human DNA analysis. Greater detail on the dialysis section and dialysis variants is provided later.
Referring again to Figures 6 and 7, the flow is drawn through the target channel 74 to the surface tension valve 128 of the lysis reagent reservoir 56. The surface tension valve 128 has seven MST channels 90 extending between the lysis reagent reservoir 56 and the target channel 74. When the menisci are unpinned by the sample flow, the flow rate from all seven of the MST channels 90 will be greater than the flow rate from the anticoagulant reservoir 54 where the surface tension valve 118 has three MST channels 90 (assuming the physical characteristics of the fluids are roughly equivalent). Hence the proportion of lysis reagent in the sample mixture is greater than that of the anticoagulant.
The lysis reagent and target cells mix by diffusion in the target channel 74 within the chemical lysis section 130. A boiling-initiated valve 126 stops the flow until sufficient time has passed for diffusion and lysis to take place, releasing the genetic material from the target cells (see Figures 6 and 7). The structure and operation of the boiling-initiated valves are described in greater detail below with reference to Figures 31 and 32. Other active valve types (as opposed to passive valves such as the surface tension valve 118) have also been developed by the Applicant which may be used here instead of the boiling- initiated valve. These alternative valve designs are also described later.
When the boiling-initiated valve 126 opens, the lysed cells flow into a mixing section 131 for pre-amplification restriction digestion and linker ligation.
Referring to Figure 13, restriction enzymes, linkers and ligase are released from the reservoir 58 when the flow unpins the menisci at the surface tension valve 132 at the start of the mixing section 131. The mixture flows the length of the mixing section 131 for diffusion mixing. At the end of the mixing section 131 is downtake 134 leading into the incubator inlet channel 133 of the incubation section 114 (see Figure 13). The incubator inlet channel 133 feeds the mixture into a serpentine configuration of heated microchannels 210 which provides an incubation chamber for holding the sample during restriction digestion and ligation of the linkers (see Figures 13 and 14).
Figures 23, 24, 25, 26, 27, 28 and 29 show the layers of the LOC device 301 within
Inset AB of Figure 6. Each figure shows the sequential addition of layers forming the structures of the CMOS + MST layer 48 and the cap 46. Inset AB shows the end of the incubation section 114 and the start of the amplification section 112. As best shown in Figures 14 and 23, the flow fills the microchannels 210 of the incubation section 1 14 until
reaching the boiling-initiated valve 106 where the flow stops while diffusion takes place. As discussed above, the microchannel 210 upstream of the boiling-initiated valve 106 becomes an incubation chamber containing the sample, restriction enzymes, ligase and linkers. The heaters 154 are then activated and held at constant temperature for a specified time for restriction digestion and linker ligation to occur.
The skilled worker will appreciate that this incubation step 291 (see Figure 4) is optional and only required for some nucleic acid amplification assay types. Furthermore, in some instances, it may be necessary to have a heating step at the end of the incubation period to spike the temperature above the incubation temperature. The temperature spike inactivates the restriction enzymes and ligase prior to entering the amplification section 1 12. Inactivation of the restriction enzymes and ligase has particular relevance when isothermal nucleic acid amplification is being employed.
Following incubation, the boiling-initiated valve 106 is activated (opened) and the flow resumes into the amplification section 112. Referring to Figures 31 and 32, the mixture fills the serpentine configuration of heated microchannels 158, which form one or more amplification chambers, until it reaches the boiling-initiated valve 108. As best shown in the schematic section view of Figure 30, amplification mix (dNTPs, primers, buffer) is released from reservoir 60 and polymerase is subsequently released from reservoir 62 into the intermediate MST channel 212 connecting the incubation and amplification sections (114 and 112 respectively).
Figures 35 to 51 show the layers of the LOC device 301 within Inset AC of Figure 6. Each figure shows the sequential addition of layers forming the structures of the CMOS + MST device 48 and the cap 46. Inset AC is at the end of the amplification section 1 12 and the start of the hybridization and detection section 52. The incubated sample, amplification mix and polymerase flow through the microchannels 158 to the boiling- initiated valve 108. After sufficient time for diffusion mixing, the heaters 154 in the microchannels 158 are activated for thermal cycling or isothermal amplification. The amplification mix goes through a predetermined number of thermal cycles or a preset amplification time to amplify sufficient target DNA. After the nucleic acid amplification process, the boiling-initiated valve 108 opens and flow resumes into the hybridization and detection section 52. The operation of boiling- initiated valves is described in more detail later.
As shown in Figure 52, the hybridization and detection section 52 has an array of hybridization chambers 1 10. Figures 52, 53, 54 and 56 show the hybridization chamber
array 110 and individual hybridization chambers 180 in detail. At the entrance to the hybridization chamber 180 is a diffusion barrier 175 which prevents diffusion of the target nucleic acid, probe strands and hybridized probes between the hybridization chambers 180 during hybridization so as to prevent erroneous hybridization detection results. The diffusion barriers 175 present a flow-path-length that is long enough to prevent the target sequences and probes diffusing out of one chamber and contaminating another chamber within the time taken for the probes and nucleic acids to hybridize and the signal to be detected, thus avoiding an erroneous result.
Another mechanism to prevent erroneous readings is to have identical probes in a number of the hybridization chambers. The CMOS circuitry 86 derives a single result from the photodiodes 184 corresponding to the hybridization chambers 180 that contain identical probes. Anomalous results can be disregarded or weighted differently in the derivation of the single result.
The thermal energy required for hybridization is provided by CMOS-controlled heaters 182 (described in more detail below). After the heater is activated, hybridization occurs between complementary target-probe sequences. The LED driver 29 in the CMOS circuitry 86 signals the LED 26 located in the test module 10 to illuminate. These probes only fluoresce when hybridization has occurred thereby avoiding washing and drying steps that are typically required to remove unbound strands. Hybridization forces the stem-and- loop structure of the FRET probes 186 to open, which allows the fluorophore to emit fluorescent energy in response to the LED excitation light, as discussed in greater detail later. Fluorescence is detected by a photodiode 184 in the CMOS circuitry 86 underlying each hybridization chamber 180 (see hybridization chamber description below). The photodiodes 184 for all hybridization chambers and associated electronics collectively form the photosensor 44 (see Figure 64). In other embodiments, the photosensor may be an array of charge coupled devices (CCD array). The detected signal from the photodiodes 184 is amplified and converted to a digital output which is analyzed by the test module reader 12. Further details of the detection method are described later.
ADDITIONAL DETAILS FOR THE LOC DEVICE MODULARITY OF THE DESIGN
The LOC device 301 has many functional sections, including the reagent reservoirs 54, 56, 58, 60 and 62, the dialysis section 70, lysis section 130, incubation section 1 14, and
amplification section 112, valve types, the humidifier and humidity sensor. In other embodiments of the LOC device, these functional sections can be omitted, additional functional sections can be added or the functional sections can be used for alternative purposes to those described above.
For example, the incubation section 1 14 can be used as the first amplification section 112 of a tandem amplification assay system, with the chemical lysis reagent reservoir 56 being used to add the first amplification mix of primers, dNTPs and buffer and reagent reservoir 58 being used for adding the reverse transcriptase and/or polymerase. A chemical lysis reagent can also be added to the reservoir 56 along with the amplification mix if chemical lysis of the sample is desired or, alternatively, thermal lysis can occur in the incubation section by heating the sample for a predetermined time. In some embodiments, an additional reservoir can be incorporated immediately upstream of reservoir 58 for the mix of primers, dNTPs and buffer if there is a requirement for chemical lysis and a separation of this mix from the chemical lysis reagent is desired.
In some circumstances it may be desirable to omit a step, such as the incubation step 291. In this case, a LOC device can be specifically fabricated to omit the reagent reservoir 58 and incubation section 1 14, or the reservoir can simply not be loaded with reagents or the active valves, if present, not activated to dispense the reagents into the sample flow, and the incubation section then simply becomes a channel to transport the sample from the lysis section 130 to the amplification section 112. The heaters are independently operable and therefore, where reactions are dependent on heat, such as thermal lysis, programming the heaters not to activate during this step ensures thermal lysis does not occur in LOC devices that do not require it. The dialysis section 70 can be located at the beginning of the fluidic system within the micro fluidic device as shown in Figure 4 or can be located anywhere else within the microfluidic device. For example, dialysis after the amplification phase 292 to remove cellular debris prior to the
hybridization and detection step 294 may be beneficial in some circumstances.
Alternatively, two or more dialysis sections can be incorporated at any location throughout the LOC device. Similarly, it is possible to incorporate additional amplification sections 1 12 to enable multiple targets to be amplified in parallel or in series prior to being detected in the hybridization chamber arrays 110 with specific nucleic acid probes. For analysis of samples like whole blood, in which dialysis is not required, the dialysis section 70 is simply omitted from the sample input and preparation section 288 of the LOC design. In some cases, it is not necessary to omit the dialysis section 70 from the LOC device even if
the analysis does not require dialysis. If there is no geometric hindrance to the assay by the existence of a dialysis section, a LOC with the dialysis section 70 in the sample input and preparation section can still be used without a loss of the required functionality.
Furthermore, the detection section 294 may encompass proteomic chamber arrays which are identical to the hybridization chamber arrays but are loaded with probes designed to conjugate or hybridize with sample target proteins present in non-amplified sample instead of nucleic acid probes designed to hybridize to target nucleic acid sequences.
It will be appreciated that the LOC devices fabricated for use in this diagnostic system are different combinations of functional sections selected in accordance with the particular LOC application. The vast majority of functional sections are common to many of the LOC devices and the design of additional LOC devices for new application is a matter of compiling an appropriate combination of functional sections from the extensive selection of functional sections used in the existing LOC devices.
Only a small number of the LOC devices are shown in this description and some more are shown schematically to illustrate the design flexibility of the LOC devices fabricated for this system. The person skilled in the art will readily recognise that the LOC devices shown in this description are not an exhaustive list and many additional LOC designs are a matter of compiling the appropriate combination of functional sections. SAMPLE TYPES
LOC variants can accept and analyze the nucleic acid or protein content of a variety of sample types in liquid form including, but not limited to, blood and blood products, saliva, cerebrospinal fluid, urine, semen, amniotic fluid, umbilical cord blood, breast milk, sweat, pleural effusion, tear, pericardial fluid, peritoneal fluid, environmental water samples and drink samples. Amplicon obtained from macroscopic nucleic acid amplification can also be analysed using the LOC device; in this case, all the reagent reservoirs will be empty or configured not to release their contents, and the dialysis, lysis, incubation and amplification sections will be used solely to transport the sample from the sample inlet 68 to the hybridization chambers 180 for nucleic acid detection, as described above.
For some sample types, a pre-processing step is required, for example semen may need to be liquefied and mucus may need to be pre-treated with an enzyme to reduce the viscosity prior to input into the LOC device.
SAMPLE INPUT
Referring to Figures 1 and 12, the sample is added to the macroreceptacle 24 of the test module 10. The macroreceptacle 24 is a truncated cone which feeds into the inlet 68 of the LOC device 301 by capillary action. Here it flows into the 64 μηι wide x 60 μιη deep cap channel 94 where it is drawn towards the anticoagulant reservoir 54, also by capillary action.
REAGENT RESERVOIRS
The small volumes of reagents required by the assay systems using microfluidic devices, such as LOC device 301, permit the reagent reservoirs to contain all reagents necessary for the biochemical processing with each of the reagent reservoirs having a small volume. This volume is easily less than 1,000,000,000 cubic microns, in the vast majority of cases less than 300,000,000 cubic microns, typically less than 70,000,000 cubic microns and in the case of the LOC device 301 shown in the drawings, less than 20,000,000 cubic microns. DIALYSIS SECTION
Referring to Figures 15 to 21, 33 and 34, the pathogen dialysis section 70 is designed to concentrate pathogenic target cells from the sample. As previously described, a plurality of apertures in the form of 3 micron diameter holes 164 in the roof layer 66 filter the target cells from the bulk of the sample. As the sample flows past the 3 micron diameter apertures 164, microbial pathogens pass through the holes into a series of dialysis MST channels 204 and flow back up into the target channel 74 via 16μιη dialysis uptake holes 168 (see Figures 33 and 34). The remainder of the sample (erythrocytes and so on) stay in the cap channel 94. Downstream of the pathogen dialysis section 70, the cap channel 94 becomes the waste channel 72 leading to the waste reservoir 76. For biological samples of the type that generate a substantial amount of waste, a foam insert or other porous element 49 within the outer casing 13 of the test module 10 is configured to be in fluid communication with the waste reservoir 76 (see Figure 1).
The pathogen dialysis section 70 functions entirely on capillary action of the fluid sample. The 3 micron diameter apertures 164 at the upstream end of the pathogen dialysis section 70 have capillary initiation features (CIFs) 166 (see Figure 33) so that the fluid is drawn down into the dialysis MST channel 204 beneath. The first uptake hole 198 for the
target channel 74 also has a CIF 202 (see Figure 15) to avoid the flow simply pinning a meniscus across the dialysis uptake holes 168.
The small constituents dialysis section 682 schematically shown in Figure 79 can have a similar structure to the pathogen dialysis section 70. The small constituents dialysis section separates any small target cells or molecules from a sample by sizing (and, if necessary, shaping) apertures suitable for allowing the small target cells or molecules to pass into the target channel and continue for further analysis. Larger sized cells or molecules are removed to a waste reservoir 766. Thus, the LOC device 30 (see Figures 1 and 109) is not limited to separating pathogens that are less than 3 μιη in size, but can be used to separate cells or molecules of any size desired.
LYSIS SECTION
Referring back to Figures 7, 1 1 and 13, the genetic material in the sample is released from the cells by a chemical lysis process. As described above, a lysis reagent from the lysis reservoir 56 mixes with the sample flow in the target channel 74 downstream of the surface tension valve 128 for the lysis reservoir 56. However, some diagnostic assays are better suited to a thermal lysis process, or even a combination of chemical and thermal lysis of the target cells. The LOC device 301 accommodates this with the heated microchannels 210 of the incubation section 1 14. The sample flow fills the incubation section 114 and stops at the boiling-initiated valve 106. The incubation microchannels 210 heat the sample to a temperature at which the cellular membranes are disrupted.
In some thermal lysis applications, an enzymatic reaction in the chemical lysis section 130 is not necessary and the thermal lysis completely replaces the enzymatic reaction in the chemical lysis section 130. BOILING-INITIATED VALVE
As discussed above, the LOC device 301 has three boiling-initiated valves 126, 106 and 108. The location of these valves is shown in Figure 6. Figure 31 is an enlarged plan view of the boiling-initiated valve 108 in isolation at the end of the heated microchannels 158 of the amplification section 1 12.
The sample flow 1 19 is drawn along the heated microchannels 158 by capillary action until it reaches the boiling-initiated valve 108. The leading meniscus 120 of the
sample flow pins at a meniscus anchor 98 at the valve inlet 146. The geometry of the meniscus anchor 98 stops the advancing meniscus to arrest the capillary flow. As shown in Figures 31 and 32, the meniscus anchor 98 is an aperture provided by an uptake opening from the MST channel 90 to the cap channel 94. Surface tension in the meniscus 120 keeps the valve closed. An annular heater 152 is at the periphery of the valve inlet 146. The annular heater 152 is CMOS-controlled via the boiling- initiated valve heater contacts 153.
To open the valve, the CMOS circuitry 86 sends an electrical pulse to the valve heater contacts 153. The annular heater 152 resistively heats until the liquid sample 1 19 boils. The boiling unpins the meniscus 120 from the valve inlet 146 and initiates wetting of the cap channel 94. Once wetting the cap channel 94 begins, capillary flow resumes. The fluid sample 119 fills the cap channel 94 and flows through the valve downtake 150 to the valve outlet 148 where capillary driven flow continues along the amplification section exit channel 160 into the hybridization and detection section 52. Liquid sensors 174 are placed before and after the valve for diagnostics.
It will be appreciated that once the boiling-initiated valves are opened, they cannot be re-closed. However, as the LOC device 301 and the test module 10 are single-use devices, re-closing the valves is unnecessary.
INCUBATION SECTION AND NUCLEIC ACID AMPLIFICATION SECTION Figures 6, 7, 13, 14, 23, 24, 25, 35 to 45, 50 and 51 show the incubation section 114 and the amplification section 112. The incubation section 114 has a single, heated incubation microchannel 210 etched in a serpentine pattern in the MST channel layer 100 from the downtake opening 134 to the boiling-initiated valve 106 (see Figures 13 and 14). Control over the temperature of the incubation section 114 enables enzymatic reactions to take place with greater efficiency. Similarly, the amplification section 112 has a heated amplification microchannel 158 in a serpentine configuration leading from the boiling- initiated valve 106 to the boiling-initiated valve 108 (see Figures 6 and 14). These valves arrest the flow to retain the target cells in the heated incubation or amplification microchannels 210 or 158 while mixing, incubation and nucleic acid amplification takes place. The serpentine pattern of the microchannels also facilitates (to some extent) mixing of the target cells with reagents.
In the incubation section 114 and the amplification section 1 12, the sample cells and the reagents are heated by the heaters 154 controlled by the CMOS circuitry 86 using
pulse width modulation (PWM). Each meander of the serpentine configuration of the heated incubation microchannel 210 and amplification microchannel 158 has three separately operable heaters 154 extending between their respective heater contacts 156 (see Figure 14) which provides for the two-dimensional control of input heat flux density. As best shown in Figure 51 , the heaters 154 are supported on the roof layer 66 and embedded in the lower seal 64. The heater material is TiAl but many other conductive metals would be suitable. The elongate heaters 154 are parallel with the longitudinal extent of each channel section that forms the wide meanders of the serpentine shape. In the amplification section 112, each of the wide meanders can operate as separate PC chambers via individual heater control.
The small volumes of amplicon required by the assay systems using microfluidic devices, such as LOC device 301, permit low amplification mixture volumes for amplification in amplification section 112. This volume is easily less than 400 nanoliters, in the vast majority of cases less than 170 nanoliters, typically less than 70 nanoliters and in the case of the LOC device 301, between 2 nanoliters and 30 nanoliters.
INCREASED RATES OF HEATING AND GREATER DIFFUSIVE MIXING
The small cross section of each channel section increases the heating rate of the amplification fluid mix. All the fluid is kept a relatively short distance from the heater 154. Reducing the channel cross section (that is the amplification microchannel 158 cross section) to less than 100,000 square microns achieves appreciably higher heating rates than that provided by more 'macro-scale' equipment. Lithographic fabrication techniques allow the amplification microchannel 158 to have a cross sectional area transverse to the flow- path less than 16,000 square microns which gives substantially higher heating rates.
Feature sizes on the order of 1 micron are readily achievable with lithographic techniques. If very little amplicon is needed (as is the case in the LOC device 301), the cross sectional area can be reduced to less than 2,500 square microns. For diagnostic assays with 1,000 to 2,000 probes on the LOC device, and a requirement of 'sample-in, answer out' in less than 1 minute, a cross sectional area transverse to the flow of between 400 square microns and 1 square micron is adequate.
The heater element in the amplification microchannel 158 heats the nucleic acid sequences at a rate more than 80 Kelvin (K) per second, in the vast majority of cases at a rate greater than 100 K per second. Typically, the heater element heats the nucleic acid sequences at a rate more than 1,000 K per second and in many cases, the heater element
heats the nucleic acid sequences at a rate more than 10,000 per second. Commonly, based on the demands of the assay system, the heater element heats the nucleic acid sequences at a rate more than 100,000 K per second, more than 1,000,000 K per second more than 10,000,000 K per second, more than 20,000,000 per second, more than 40,000,000 K per second, more than 80,000,000 K per second and more than 160,000,000 K per second.
A small cross-sectional area channel is also beneficial for diffusive mixing of any reagents with the sample fluid. Before diffusive mixing is complete, diffusion of one liquid into the other is greatest near the interface between the two. Concentration decreases with distance from the interface. Using microchannels with relatively small cross sections transverse to the flow direction, keeps both fluid flows close to the interface for more rapid diffusive mixing. Reducing the channel cross section to less than 100,000 square microns achieves appreciably higher mixing rates than that provided by more 'macro-scale' equipment. Lithographic fabrication techniques allows microchannels with a cross sectional area transverse to the flow-path less than 16000 square microns which gives significantly higher mixing rates. If small volumes are needed (as is the case in the LOC device 301), the cross sectional area can be reduced to less than 2500 square microns. For diagnostic assays with 1000 to 2000 probes on the LOC device, and a requirement of 'sample-in, answer out' in less than 1 minute, a cross sectional area transverse to the flow of between 400 square microns and 1 square micron is adequate.
SHORT THERMAL CYCLE TIMES
Keeping the sample mixture proximate to the heaters, and using very small fluid volumes allows rapid thermal cycling during the nucleic acid amplification process. Each thermal cycle (i.e. denaturing, annealing and primer extension) is completed in less than 30 seconds for target sequences up to 150 base pairs (bp) long. In the vast majority of diagnostic assays, the individual thermal cycle times are less than 11 seconds, and a large proportion are less than 4 seconds. LOC devices 30 with some of the most common diagnostic assays have thermal cycles time between 0.45 seconds to 1.5 seconds for target sequences up to 150 bp long. Thermal cycling at this rate allows the test module to complete the nucleic acid amplification process in much less than 10 minutes; often less than 220 seconds. For most assays, the amplification section generates sufficient amplicon in less than 80 seconds from the sample fluid entering the sample inlet. For a great many assays, sufficient amplicon is generated in 30 seconds.
Upon completion of a preset number of amplification cycles, the amplicon is fed into the hybridization and detection section 52 via the boiling-initiated valve 108.
HYBRIDIZATION CHAMBERS
Figures 52, 53, 54, 56 and 57 show the hybridization chambers 180 in the hybridization chamber array 1 10. The hybridization and detection section 52 has a 24 x 45 array 110 of hybridization chambers 180, each with hybridization-responsive FRET probes 186, heater element 182 and an integrated photodiode 184. The photodiode 184 is incorporated for detection of fluorescence resulting from the hybridization of a target nucleic acid sequence or protein with the FRET probes 186. Each photodiode 184 is independently controlled by the CMOS circuitry 86. Any material between the FRET probes 186 and the photodiode 184 must be transparent to the emitted light. Accordingly, the wall section 97 between the probes 186 and the photodiode 184 is also optically transparent to the emitted light. In the LOC device 301, the wall section 97 is a thin (approximately 0.5 micron) layer of silicon dioxide.
Incorporation of a photodiode 184 directly beneath each hybridization chamber 180 allows the volume of probe-target hybrids to be very small while still generating a detectable fluorescence signal (see Figure 54). The small amounts permit small volume hybridization chambers. A detectable amount of probe-target hybrid requires a quantity of probe, prior to hybridization, which is easily less than 270 picograms (corresponding to 900,000 cubic microns), in the vast majority of cases less than 60 picograms
(corresponding to 200,000 cubic microns), typically less than 12 picograms (corresponding to 40,000 cubic microns) and in the case of the LOC device 301 shown in the
accompanying figures, less than 2.7 picograms (corresponding to a chamber volume of 9,000 cubic microns). Of course, reducing the size of the hybridization chambers allows a higher density of chambers and therefore more probes on the LOC device. In LOC device 301, the hybridization section has more than 1,000 chambers in an area of 1,500 microns by 1,500 microns (i.e. less than 2,250 square microns per chamber). Smaller volumes also reduce the reaction times so that hybridization and detection is faster. An additional advantage of the small amount of probe required in each chamber is that only very small quantities of probe solution need to be spotted into each chamber during production of the LOC device. Embodiments of the LOC device according to the invention can be spotted using a probe solution volume of 1 picoliter or less.
After nucleic acid amplification, boiling-initiated valve 108 is activated and the amplicon flows along the flow-path 176 and into each of the hybridization chambers 180 (see Figures 52 and 56). An end-point liquid sensor 178 indicates when the hybridization chambers 180 are filled with amplicon and the heaters 182 can be activated.
After sufficient hybridization time, the LED 26 (see Figure 2) is activated. The opening in each of the hybridization chambers 180 provides an optical window 136 for exposing the FRET probes 186 to the excitation radiation (see Figures 52, 54 and 56). The LED 26 is illuminated for a sufficiently long time in order to induce a fluorescence signal from the probes with high intensity. During excitation, the photodiode 184 is shorted. After a pre-programmed delay 300 (see Figure 2), the photodiode 184 is enabled and fluorescence emission is detected in the absence of the excitation light. The incident light on the active area 185 of the photodiode 184 (see Figure 54) is converted into a photocurrent which can then be measured using CMOS circuitry 86.
The hybridization chambers 180 are each loaded with probes for detecting a single target nucleic acid sequence. Each hybridization chambers 180 can be loaded with probes to detect over 1,000 different targets if desired. Alternatively, many or all the
hybridization chambers can be loaded with the same probes to detect the same target nucleic acid repeatedly. Replicating the probes in this way throughout the hybridization chamber array 1 10 leads to increased confidence in the results obtained and the results can be combined by the photodiodes adjacent those hybridization chambers to provide a single result if desired. The person skilled in the art will recognise that it is possible to have from one to over 1,000 different probes on the hybridization chamber array 1 10, depending on the assay specification.
HUMIDIFIER AND HUMIDITY SENSOR Inset AG of Figure 6 indicates the position of the humidifier 196. The humidifier prevents evaporation of the reagents and probes during operation of the LOC device 301. As best shown in the enlarged view of Figure 55, a water reservoir 188 is fluidically connected to three evaporators 190. The water reservoir 188 is filled with molecular biology-grade water and sealed during manufacturing. As best shown in Figures 55 and 67, water is drawn into three downtakes 194 and along respective water supply channels 192 by capillary action to a set of three uptakes 193 at the evaporators 190. A meniscus pins at each uptake 193 to retain the water. The evaporators have annular shaped heaters 191 which encircle the uptakes 193. The annular heaters 191 are connected to the CMOS
circuitry 86 by the conductive columns 376 to the top metal layer 195 (see Figure 37). Upon activation, the annular heaters 191 heat the water causing evaporation and humidifying the device surrounds.
The position of the humidity sensor 232 is also shown in Figure 6. However, as best shown in the enlarged view of Inset AH in Figure 63, the humidity sensor has a capacitive comb structure. A lithographically etched first electrode 296 and a
lithographically etched second electrode 298 face each other such that their teeth are interleaved. The opposed electrodes form a capacitor with a capacitance that can be monitored by the CMOS circuitry 86. As the humidity increases, the permittivity of the air gap between the electrodes increases, so that the capacitance also increases. The humidity sensor 232 is adjacent the hybridization chamber array 110 where humidity measurement is most important to slow evaporation from the solution containing the exposed probes.
FEEDBACK SENSORS
Temperature and liquid sensors are incorporated throughout the LOC device 301 to provide feedback and diagnostics during device operation. Referring to Figure 35, nine temperature sensors 170 are distributed throughout the amplification section 1 12.
Likewise, the incubation section 114 also has nine temperature sensors 170. These sensors each use a 2x2 array of bipolar junction transistors (BJTs) to monitor the fluid temperature and provide feedback to the CMOS circuitry 86. The CMOS circuitry 86 uses this to precisely control the thermal cycling during the nucleic acid amplification process and any heating during thermal lysis and incubation.
In the hybridization chambers 180, the CMOS circuitry 86 uses the hybridization heaters 182 as temperature sensors (see Figure 56). The electrical resistance of the hybridization heaters 182 is temperature dependent and the CMOS circuitry 86 uses this to derive a temperature reading for each of the hybridization chambers 180.
The LOC device 301 also has a number of MST channel liquid sensors 174 and cap channel liquid sensors 208. Figure 35 shows a line of MST channel liquid sensors 174 at one end of every other meander in the heated microchannel 158. As best shown in Figure 37, the MST channel liquid sensors 174 are a pair of electrodes formed by exposed areas of the top metal layer 195 in the CMOS structure 86. Liquid closes the circuit between the electrodes to indicate its presence at the sensor's location.
Figure 25 shows an enlarged perspective of cap channel liquid sensors 208.
Opposing pairs of TiAl electrodes 218 and 220 are deposited on the roof layer 66.
Between the electrodes 218 and 220 is a gap 222 to hold the circuit open in the absence of liquid. The presence of liquid closes the circuit and the CMOS circuitry 86 uses this feedback to monitor the flow.
GRAVITATIONAL INDEPENDENCE The test modules 10 are orientation independent. They do not need to be secured to a flat stable surface in order to operate. Capillary driven fluid flows and a lack of external plumbing into ancillary equipment allow the modules to be truly portable and simply plugged into a similarly portable hand held reader such as a mobile telephone. Having a gravitationally independent operation means the test modules are also accelerationally independent to all practical extents. They are resistant to shock and vibration and will operate on moving vehicles or while the mobile telephone is being carried around.
DIALYSIS VARIANTS
DIALYSIS SECTION WITH FLOW CHANNEL TO PREVENT TRAPPED AIR BUBBLES Described below is an embodiment of the LOC device referred to as LOC variant
VIII 518 and shown in Figures 72, 73, 74 and 75. This LOC device has a dialysis section that fills with the fluid sample without leaving air bubbles trapped in the channels. LOC variant VIII 518 also has an additional layer of material referred to as an interface layer 594. The interface layer 594 is positioned between the cap channel layer 80 and the MST channel layer 100 of the CMOS + MST device 48. The interface layer 594 allows a more complex fluidic interconnection between the reagent reservoirs and the MST layer 87 without increasing the size of the silicon substrate 84.
Referring to Figure 73, the bypass channel 600 is designed to introduce a time delay in the fluid sample flow from the interface waste channel 604 to the interface target channel 602. This time delay allows the fluid sample to flow through the dialysis MST channel 204 to the dialysis uptake 168 where it pins a meniscus. With a capillary initiation feature (CIF) 202 at the uptake from the bypass channel 600 to the interface target channel 602, the sample fluid fills the interface target channel 602 from a point upstream of all the dialysis uptakes 168 from the dialysis MST channels 204.
Without the bypass channel 600, the interface target channel 602 still starts filling from the upstream end, but eventually the advancing meniscus reaches and passes over an
uptake belonging to an MST channel that has not yet filled, leading into air entrapment at that point. Trapped air reduces the sample flow rate through the leukocyte dialysis section 328.
P RE-HYBRIDIZATION FILTERING A variant of the LOC device, LOC variant XII 758, uses a small constituents dialysis section 682 placed at the outlet of the amplification section 112 (see Figures 93 to 100). The small constituents dialysis section 682 provides a pre-hybridization filter purification phase 293 (see Figure 93). Pre-hybridization filtering removes cell debris remaining in the sample flow following cell lysis. Hybridization efficiency can be affected by cell debris, so it is advantageous to reduce the concentration of cell debris prior to hybridization.
Referring to Figures 98, 99 and 100, the small constituents dialysis section 682 has three adjacent channels fabricated in the bottom channel layer 100; a large constituents channel 760 flanked by two small constituents channels 762. A series of stoma in the form of inverse tapered openings 764 along both sides of the large constituents channel 760 provide a fluidic connection to the small constituents channels 762. In most practical applications, the stoma will be between 1 to 8 microns wide and 1 to 8 microns high. As the sample flows down the large constituents channel 760, particles small enough to pass through the inverse tapered openings (e.g. the amplicon) flow through to the small constituents channels 762, while the larger particles (e.g. cell debris) remain in the large constituents channel which eventually terminates at a blind end 766. The smaller particles continue along the small constituents channels to opposite sides of the hybridization chamber array 1 10 where they both follow serpentine paths through the array to respective blind ends 768 (see Figure 100). The small constituents amplicons fill all the individual hybridization chambers 180 prior to detection.
NUCLEIC ACID AMPLIFICATION VARIANTS
DIRECT PCR
Traditionally, PCR requires extensive purification of the target DNA prior to preparation of the reaction mixture. However, with appropriate changes to the chemistry and sample concentration, it is possible to perform nucleic acid amplification with minimal DNA purification, or direct amplification. When the nucleic acid amplification process is
PCR, this approach is called direct PCR. In LOC devices where nucleic acid amplification is performed at a controlled, constant temperature, the approach is direct isothermal amplification. Direct nucleic acid amplification techniques have considerable advantages for use in LOC devices, particularly relating to simplification of the required fluidic design. Adjustments to the amplification chemistry for direct PCR or direct isothermal amplification include increased buffer strength, the use of polymerases which have high activity and processivity, and additives which chelate with potential polymerase inhibitors. Dilution of inhibitors present in the sample is also important.
To take advantage of direct nucleic acid amplification techniques, the LOC device designs incorporate two additional features. The first feature is reagent reservoirs (for example reservoir 58 in Figure 8) which are appropriately dimensioned to supply a sufficient quantity of amplification reaction mix, or diluent, so that the final concentrations of sample components which might interfere with amplification chemistry are low enough to permit successful nucleic acid amplification. The desired dilution of non-cellular sample components is in the range of 5X to 20X. Different LOC structures, for example the pathogen dialysis section 70 in Figure 4, are used when appropriate to ensure that the concentration of target nucleic acid sequences is maintained at a high enough level for amplification and detection. In this embodiment, further illustrated in Figure 6, a dialysis section which effectively concentrates pathogens small enough to be passed into the amplification section 292 is employed upstream of the sample extraction section 290, and rejects larger cells to a waste receptacle 76. In another embodiment, a dialysis section is used to selectively deplete proteins and salts in blood plasma while retaining cells of interest.
The second LOC structural feature which supports direct nucleic acid amplification is design of channel aspect ratios to adjust the mixing ratio between the sample and the amplification mix components. For example, to ensure dilution of inhibitors associated with the sample in the preferred 5X - 20X range through a single mixing step, the length and cross-section of the sample and reagent channels are designed such that the sample channel, upstream of the location where mixing is initiated, constitutes a flow impedance 4X - 19X higher than the flow impedance of the channels through which the reagent mixture flows. Control over flow impedances in microchannels is readily achieved through control over the design geometry. The flow impedance of a microchannel increases linearly with the channel length, for a constant cross-section. Importantly for mixing designs, flow impedance in microchannels depends more strongly on the smallest
cross-sectional dimension. For example, the flow impedance of a microchannel with rectangular cross-section is inversely proportional to the cube of the smallest perpendicular dimension, when the aspect ratio is far from unity.
REVERSE-TRANSCRIPTASE PCR (RT-PCR) Where the sample nucleic acid species being analysed or extracted is RNA, such as from RNA viruses or messenger RNA, it is first necessary to reverse transcribe the RNA into complementary DNA (cDNA) prior to PCR amplification. The reverse transcription reaction can be performed in the same chamber as the PCR (one-step RT-PCR) or it can be performed as a separate, initial reaction (two-step RT-PCR). In the LOC variants described herein, a one-step RT-PCR can be performed simply by adding the reverse transcriptase to reagent reservoir 62 along with the polymerase and programming the heaters 154 to cycle firstly for the reverse transcription step and then progress onto the nucleic acid amplification step. A two-step RT-PCR could also be easily achieved by utilizing the reagent reservoir 58 to store and dispense the buffers, primers, dNTPs and reverse transcriptase and the incubation section 1 14 for the reverse transcription step followed by amplification in the normal way in the amplification section 1 12.
ISOTHERMAL NUCLEIC ACID AMPLIFICATION
For some applications, isothermal nucleic acid amplification is the preferred method of nucleic acid amplification, thus avoiding the need to repetitively cycle the reaction components through various temperature cycles but instead maintaining the amplification section at a constant temperature, typically around 37°C to 41°C. A number of isothermal nucleic acid amplification methods have been described, including Strand Displacement Amplification (SDA), Transcription Mediated Amplification (TMA), Nucleic Acid Sequence Based Amplification (NASBA), Recombinase Polymerase Amplification (RPA), Helicase-Dependent isothermal DNA Amplification (HDA), Rolling Circle Amplification (RCA), Ramification Amplification (RAM) and Loop-mediated Isothermal Amplification (LAMP), and any of these, or other isothermal amplification methods, can be employed in particular embodiments of the LOC device described herein.
In order to perform isothermal nucleic acid amplification, the reagent reservoirs 60 and 62 adjoining the amplification section will be loaded with the appropriate reagents for the specified isothermal method instead of PCR amplification mix and polymerase. For example, for SDA, reagent reservoir 60 contains amplification buffer, primers and dNTPs
and reagent reservoir 62 contains an appropriate nickase enzyme and Exo- DNA polymerase. For RPA, reagent reservoir 60 contains the amplification buffer, primers, dNTPs and recombinase proteins, with reagent reservoir 62 containing a strand displacing DNA polymerase such as Bsu. Similarly, for HDA, reagent reservoir 60 contains amplification buffer, primers and dNTPs and reagent reservoir 62 contains an appropriate DNA polymerase and a helicase enzyme to unwind the double stranded DNA strand instead of using heat. The skilled person will appreciate that the necessary reagents can be split between the two reagent reservoirs in any manner appropriate for the nucleic acid amplification process.
For amplification of viral nucleic acids from RNA viruses such as HIV or hepatitis
C virus, NASBA or TMA is appropriate as it is unnecessary to first transcribe the RNA to cDNA. In this example, reagent reservoir 60 is filled with amplification buffer, primers and dNTPs and reagent reservoir 62 is filled with RNA polymerase, reverse transcriptase and, optionally, RNase H.
For some forms of isothermal nucleic acid amplification it may be necessary to have an initial denaturation cycle to separate the double stranded DNA template, prior to maintaining the temperature for the isothermal nucleic acid amplification to proceed. This is readily achievable in all embodiments of the LOC device described herein, as the temperature of the mix in the amplification section 112 can be carefully controlled by the heaters 154 in the amplification microchannels 158 (see Figure 14).
Isothermal nucleic acid amplification is more tolerant of potential inhibitors in the sample and, as such, is generally suitable for use where direct nucleic acid amplification from the sample is desired. Therefore, isothermal nucleic acid amplification is sometimes useful in LOC variant XLIII 673, LOC variant XLIV 674 and LOC variant XLVII 677, amongst others, shown in Figures 80, 81 and 82, respectively. Direct isothermal amplification may also be combined with one or more pre-amplification dialysis steps 70, 686 or 682 as shown in Figures 80 and 82 and/or a pre-hybridization dialysis step 682 as indicated in Figure 81 to help partially concentrate the target cells in the sample before nucleic acid amplification or remove unwanted cellular debris prior to the sample entering the hybridization chamber array 110, respectively. The person skilled in the art will appreciate that any combination of pre-amplification dialysis and pre-hybridization dialysis can be used.
Isothermal nucleic acid amplification can also be performed in parallel amplification sections such as those schematically represented in Figures 71, 76 and 77,
multiplexed and some methods of isothermal nucleic acid amplification, such as LAMP, are compatible with an initial reverse transcription step to amplify RNA.
ADDITIONAL DETAILS ON THE FLUORESCENCE DETECTION SYSTEM
Figures 58 and 59 show the hybridization-responsive FRET probes 236. These are often referred to as molecular beacons and are stem-and-loop probes, generated from a single strand of nucleic acid, that fluoresce upon hybridization to complementary nucleic acids. Figure 58 shows a single FRET probe 236 prior to hybridization with a target nucleic acid sequence 238. The probe has a loop 240, stem 242, a fluorophore 246 at the 5' end, and a quencher 248 at the 3' end. The loop 240 consists of a sequence complementary to the target nucleic acid sequence 238. Complementary sequences on either side of the probe sequence anneal together to form the stem 242.
In the absence of a complementary target sequence, the probe remains closed as shown in Figure 58. The stem 242 keeps the fluorophore-quencher pair in close proximity to each other, such that significant resonant energy transfer can occur between them, substantially eliminating the ability of the fluorophore to fluoresce when illuminated with the excitation light 244.
Figure 59 shows the FRET probe 236 in an open or hybridized configuration. Upon hybridization to a complementary target nucleic acid sequence 238, the stem-and- loop structure is disrupted, the fluorophore and quencher are spatially separated, thus restoring the ability of the fluorophore 246 to fluoresce. The fluorescence emission 250 is optically detected as an indication that the probe has hybridized.
The probes hybridize with very high specificity with complementary targets, since the stem helix of the probe is designed to be more stable than a probe-target helix with a single nucleotide that is not complementary. Since double-stranded DNA is relatively rigid, it is sterically impossible for the probe-target helix and the stem helix to coexist.
PRIMER-LINKED PROBES
Primer-linked, stem-and-loop probes and primer-linked, linear probes, otherwise known as scorpion probes, are an alternative to molecular beacons and can be used for real-time and quantitative nucleic acid amplification in the LOC device. Real-time amplification could be performed directly in the hybridization chambers of the LOC device. The benefit of using primer-linked probes is that the probe element is physically linked to the primer, thus only requiring a single hybridization event to occur during the
nucleic acid amplification rather than separate hybridizations of the primers and probes being required. This ensures that the reaction is effectively instantaneous and results in stronger signals, shorter reaction times and better discrimination than when using separate primers and probes. The probes (along with polymerase and the amplification mix) would be deposited into the hybridization chambers 180 during fabrication and there would be no need for a separate amplification section on the LOC device. Alternatively, the amplification section is left unused or used for other reactions.
PRIMER-LINKED LINEAR PROBE
Figures 83 and 84 show a primer-linked linear probe 692 during the initial round of nucleic acid amplification and in its hybridized configuration during subsequent rounds of nucleic acid amplification, respectively. Referring to Figure 83, the primer-linked linear probe 692 has a double-stranded stem segment 242. One of the strands incorporates the primer linked probe sequence 696 which is homologous to a region on the target nucleic acid 696 and is labelled on its 5' end with fluorophore 246, and linked on its 3' end to an oligonucleotide primer 700 via an amplification blocker 694. The other strand of the stem 242 is labelled at its 3□ end with a quencher moiety 248. After an initial round of nucleic acid amplification has completed, the probe can loop around and hybridize to the extended strand with the, now complementary, sequence 698. During the initial round of nucleic acid amplification, the oligonucleotide primer 700 anneals to the target DNA 238 (Figure 83) and is then extended, forming a DNA strand containing both the probe sequence and the amplification product. The amplification blocker 694 prevents the polymerase from reading through and copying the probe region 696. Upon subsequent denaturation, the extended oligonucleotide primer 700/template hybrid is dissociated and so is the double stranded stem 242 of the primer-linked linear probe, thus releasing the quencher 248. Once the temperature decreases for the annealing and extension steps, the primer linked probe sequence 696 of the primer-linked linear probe curls around and hybridizes to the amplified complementary sequence 698 on the extended strand and fluorescence is detected indicating the presence of the target DNA. Non-extended primer- linked linear probes retain their double-stranded stem and fluorescence remains quenched. This detection method is particularly well suited for fast detection systems as it relies on a single-molecule process.
PRIMER-LINKED STEM-AND-LOOP PROBES
Figures 85A to 85F show the operation of a primer-linked stem-and-loop probe 704. Referring to Figure 85A, the primer-linked stem-and-loop probe 704 has a stem 242 of complementary double-stranded DNA and a loop 240 which incorporates the probe sequence. One of the stem strands 708 is labelled at its 5' end with fluorophore 246. The other strand 710 is labelled with a 3 '-end quencher 248 and carries both the amplification blocker 694 and oligonucleotide primer 700. During the initial denaturation phase (see Figure 85B), the strands of the target nucleic acid 238 separate, as does the stem 242 of the primer-linked, stem-and-loop probe 704. When the temperature cools for the annealing phase (see Figure 85C), the oligonucleotide primer 700 on the primer-linked stem-and-loop probe 704 hybridizes to the target nucleic acid sequence 238. During extension (see Figure 85D) the complement 706 to the target nucleic acid sequence 238 is synthesized forming a DNA strand containing both the probe sequence 704 and the amplified product. The amplification blocker 694 prevents the polymerase from reading through and copying the probe region 704. When the probe next anneals, following denaturation, the probe sequence of the loop segment 240 of the primer-linked stem-and-loop probe (see Figure 85F) anneals to the complementary sequence 706 on the extended strand. This configuration leaves the fluorophore 246 relatively remote from the quencher 248, resulting in a significant increase in fluorescence emission.
CONTROL PROBES The hybridization chamber array 110 includes some hybridization chambers 180 with positive and negative control probes used for assay quality control. Figures 105 and
106 schematically illustrate negative control probes without a fluorophore 796, and Figures
107 and 108 are sketches of positive control probes without a quencher 798. The positive and negative control probes have a stem-and-loop structure like the FRET probes described above. However, a fluorescence signal 250 will always be emitted from positive control probes 798 and no fluorescence signal 250 is ever emitted from negative control probes 796, regardless of whether the probes hybridize into an open configuration or remain closed.
Referring to Figures 105 and 106, the negative control probe 796 has no fluorophore (and may or may not have a quencher 248). Hence, whether the target nucleic acid sequence 238 hybridizes with the probe (see Figure 106), or the probe remains in its stem-and-loop configuration (see Figure 105), the response to the excitation light 244 is negligible. Alternatively, the negative control probe 796 could be designed so that it
always remains quenched. For example, by synthesizing the loop 240 to have a probe sequence that will not hybridize to any nucleic acid sequence within the sample under investigation, the stem 242 of the probe molecule will re-hybridize to itself and the fluorophore and quencher will remain in close proximity and no appreciable fluorescence signal will be emitted. This negative control signal would correspond to low level emissions from hybridization chambers 180 in which the probes has not hybridized but the quencher does not quench all emissions from the reporter.
Conversely, the positive control probe 798 is constructed without a quencher as illustrated in Figures 107 and 108. Nothing quenches the fluorescence emission 250 from the fluorophore 246 in response to the excitation light 244 regardless of whether the positive control probe 798 hybridizes with the target nucleic acid sequence 238.
Figure 52 shows a possible distribution of the positive and negative control probes (378 and 380 respectively) throughout the hybridization chamber array 1 10. The control probes 378 and 380 are placed in hybridization chambers 180 positioned in a line across the hybridization chamber array 1 10. However, the arrangement of the control probes within the array is arbitrary (as is the configuration of the hybridization chamber array 1 10).
FLUOROPHORE DESIGN
Fluorophores with long fluorescence lifetimes are required in order to allow enough time for the excitation light to decay to an intensity below that of the fluorescence emission at which time the photosensor 44 is enabled, thereby providing a sufficient signal to noise ratio. Also, longer fluorescence lifetime translates into larger integrated fluorescence photon count.
The fluorophores 246 (see Figure 59) have a fluorescence lifetime greater than 100 nanoseconds, often greater than 200 nanoseconds, more commonly greater than 300 nanoseconds and in most cases greater than 400 nanoseconds.
The metal-ligand complexes based on the transition metals or lanthanides have long lifetimes (from hundreds of nanoseconds to milliseconds), adequate quantum yields, and high thermal, chemical and photochemical stability, which are all favourable properties with respect to the fluorescence detection system requirements.
A particularly well-studied metal-ligand complex based on the transition metal ion Ruthenium (Ru (II)) is tris(2,2'-bipyridine) ruthenium (II) ([Ru(bpy)3]2+) which has a
lifetime of approximately 1μ8. This complex is available commercially from Biosearch Technologies under the brand name Pulsar 650.
Table 1 : Photophysical properties of Pulsar 650 (Ruthenium chelate)
Terbium chelate, a lanthanide metal-ligand complex has been successfully demonstrated as a fluorescent reporter in a FRET probe system, and also has a Ion:
lifetime of 1600 8.
Table 2: Photophysical properties of terbium chelate
The fluorescence detection system used by the LOC device 301 does not utilize filters to remove unwanted background fluorescence. It is therefore advantageous if the quencher 248 has no native emission in order to increase the signal-to-noise ratio. With no native emission, there is no contribution to background fluorescence from the quencher 248. High quenching efficiency is also important so that fluorescence is prevented until a hybridization event occurs. The Black Hole Quenchers (BHQ), available from Biosearch
Technologies, Inc. of Novato California, have no native emission and high quenching efficiency, and are suitable quenchers for the system. BHQ- 1 has an absorption maximum at 534 nm, and a quenching range of 480-580 nm, making it a suitable quencher for the Tb- chelate fluorophore. BHQ-2 has an absorption maximum at 579 nm, and a quenching range of 560-670 nm, making it a suitable quencher for Pulsar 650.
Iowa Black Quenchers (Iowa Black FQ and RQ), available from Integrated DNA Technologies of Coralville, Iowa, are suitable alternative quenchers with little or no background emission. Iowa Black FQ has a quenching range from 420-620 nm, with an absorption maximum at 531 nm and would therefore be a suitable quencher for the Tb- chelate fluorophore. Iowa Black RQ has an absorption maximum at 656 nm, and a quenching range of 500-700 nm, making it an ideal quencher for Pulsar 650.
In the embodiments described here, the quencher 248 is a functional moiety which is initially attached to the probe, but other embodiments are possible in which the quencher is a separate molecule free in solution. EXCITATION SOURCE
In the fluorescence detection based embodiments described herein, a LED is chosen as the excitation source instead of a laser diode, high power lamp or laser due to the low power consumption, low cost and small size. Referring to Figure 86, the LED 26 is positioned directly above the hybridization chamber array 110 on an external surface of the LOC device 301. On the opposing side of the hybridization chamber array 110, is the photosensor 44, made up of an array of photodiodes 184 (see Figures 53, 54 and 64) for detection of fluorescence signals from each of the chambers.
Figures 87, 88 and 89 schematically illustrate other embodiments for exposing the probes to excitation light. In the LOC device 30 shown in Figure 87, the excitation light 244 generated by the excitation LED 26 is directed onto the hybridization chamber array 1 10 by the lens 254. The excitation LED 26 is pulsed and the fluorescence emissions are detected by the photosensor 44.
In the LOC device 30 shown in Figure 88, the excitation light 244 generated by the excitation LED 26 is directed onto the hybridization chamber array 1 10 by the lens 254, a first optical prism 712 and second optical prism 714. The excitation LED 26 is pulsed and the fluorescence emissions are detected by the photosensor 44.
Similarly, the LOC device 30 shown in Figure 89, the excitation light 244 generated by the excitation LED 26 is directed onto the hybridization chamber array 1 10
by the lens 254, a first mirror 716 and second mirror 718. Again, the excitation LED 26 is pulsed and the fluorescence emissions are detected by the photosensor 44.
The excitation wavelength of the LED 26 is dependent on the choice of fluorescent dye. The Philips LXK2-PR14-R00 is a suitable excitation source for the Pulsar 650 dye. The SET UVTOP335T039BL LED is a suitable excitation source for the Tb-chelate label.
Table 3: Philips LXK2-PR14-R00 LED specifications
Table 4: SET UVTOP334T039BL LED Specifications
ULTRA VIOLET EXCITATION LIGHT
Silicon absorbs little light in the UV spectrum. Accordingly, it is advantageous to use UV excitation light. A UV LED excitation source can be used but the broad spectrum of the LED 26 reduces the effectiveness of this method. To address this, a filtered UV LED can be used. Optionally, a UV laser can be the excitation source unless the relatively high cost of the laser is impractical for the particular test module market.
LED DRIVER
The LED driver 29 drives the LED 26 at a constant current for the required duration. A lower power USB 2.0-certifiable device can draw at most 1 unit load (100 mA), with a minimum operating voltage of 4.4 V. A standard power conditioning circuit is used for this purpose.
PHOTODIODE
Figure 54 shows the photodiode 184 integrated into the CMOS circuitry 86 of the LOC device 301. The photodiode 184 is fabricated as part of the CMOS circuitry 86 without additional masks or steps. This is one significant advantage of a CMOS photodiode over a CCD, an alternate sensing technology which could be integrated on the same chip using non-standard processing steps, or fabricated on an adjacent chip. On-chip detection is low cost and reduces the size of the assay system. The shorter optical path length reduces noise from the surrounding environment for efficient collection of the fluorescence signal and eliminates the need for a conventional optical assembly of lenses and filters.
Quantum efficiency of the photodiode 184 is the fraction of photons impinging on its active area 185 that are effectively converted to photo-electrons. For standard silicon processes, the quantum efficiency is in the range of 0.3 to 0.5 for visible light, depending on process parameters such as the amount and absorption properties of the cover layers.
The detection threshold of the photodiode 184 determines the smallest intensity of the fluorescence signal that can be detected. The detection threshold also determines the size of the photodiode 184 and hence the number of hybridization chambers 180 in the hybridization and detection section 52 (see Figure 52). The size and number of chambers are technical parameters that are limited by the dimensions of the LOC device (in the case of the LOC device 301, the dimensions are 1760 μηι x 5824 μηι) and the real estate available after other functional modules such as the pathogen dialysis section 70 and amplification section(s) 1 12 are incorporated.
For standard silicon processes, the photodiode 184 detects a minimum of 5 photons. However, to ensure reliable detection, the minimum can be set to 10 photons. Therefore with the quantum efficiency range being 0.3 to 0.5 (as discussed above), the fluorescence emission from the probes should be a minimum of 17 photons but 30 photons would incorporate a suitable margin of error for reliable detection.
CALIBRATION CHAMBERS
The non-uniformity of the electrical characteristic of the photodiode 184, autofluorescence, and residual excitation photon flux that has not yet completely decayed, introduce background noise and offset into the output signal. This background is removed from each output signal using one or more calibration signals. Calibration signals are
generated by exposing one or more calibration photodiodes 184 in the array to respective calibration sources. A low calibration source is used for determining a negative result in which a target has not reacted with a probe. A high calibration source is indicative of a positive result from a probe-target complex. In the embodiment described here, the low calibration light source is provided by calibration chambers 382 in the hybridization chamber array 1 10 which:
do not contain any probes;
contain probes that have no fluorescent reporter; or,
contain probes with a reporter and quencher configured such that quenching is always expected to occur.
The output signal from such calibration chambers 382 closely approximates the noise and offset in the output signal from all the hybridization chambers in the LOC device. Subtracting the calibration signal from the output signals generated by the other hybridization chambers substantially removes the background and leaves the signal generated by the fluorescence emission (if any). Signals arising from ambient light in the region of the chamber array are also subtracted.
It will be appreciated that the negative control probes described above with reference to Figures 105 to 108 can be be used in calibration chambers. However, as shown in Figures 91 and 92, which are enlarged views of insets DG and DH of LOC variant X 728 shown in Figure 90, another option is to fluidically isolate the calibration chambers 382 from the amplicon. The background noise and offset can be determined by leaving the fluidically isolated chambers empty, or containing reporterless probes, or indeed any of the 'normal' probes with both reporter and quencher as hybridization is precluded by fluidic isolation.
The calibration chambers 382 can provide a high calibration source to generate a high signal in the corresponding photodiodes. The high signal corresponds to all probes in a chamber having hybridized. Spotting probes with reporters and no quenchers, or just reporters will consistently provide a signal approximating that of a hybridization chamber in which a predominant number of the probes have hybridized. It will also be appreciated that calibration chambers 382 can be used instead of control probes, or in addition to control probes.
The number and arrangement of the calibration chambers 382 throughout the hybridization chamber array is arbitrary. However, the calibration is more accurate if
photodiodes 184 are calibrated by a calibration chamber 382 that is relatively proximate. Referring to Figure 56, the hybridization chamber array 110 has one calibration chamber 382 for every eight hybridization chambers 180. That is, a calibration chamber 382 is positioned in the middle of every three by three square of hybridization chambers 180. In this configuration, the hybridization chambers 180 are calibrated by a calibration chamber 382 that is immediately adjacent.
Figure 104 shows a differential imager circuit 788 used to substract the signal from the photodiode 184 corresponding to the calibration chamber 382 as a result of excitation light, from the fluorescence signal from the surrounding hybridization chambers 180. The differential imager circuit 788 samples the signal from the pixel 790 and a "dummy" pixel 792. In one embodiment, the "dummy" pixel 792 is shielded from light, so its output signal provides a dark reference. Alternatively, the "dummy" pixel 792 can be exposed to the excitation light along with the rest of the array. In the embodiment where the
"dummy" pixel 792 is open to light, signals arising from ambient light in the region of the chamber array are also subtracted.The signals from the pixel 790 are small (i.e. close to dark signal), and without a reference to a dark level it is hard to differentiate between the background and a very small signal.
During use, the "read_row" 794 and "read row d" 795 are activated and M4 797 and MD4 801 transistors are turned on. Switches 807 and 809 are closed such that the outputs from the pixel 790 and "dummy" pixel 792 are stored on pixel capacitor 803 and dummy pixel capacitor 805 respectively. After the pixel signals have been stored, switches 807 and 809 are deactivated. Then the "read_col" switch 81 1 and dummy "read col" switch 813 are closed, and the switched capacitor amplifier 815 at the output amplifies the differential signal 817. SUPPRESSION AND ENABLEMENT OF THE PHOTODIODE
The photodiode 184 needs to be suppressed during excitation by the LED 26 and enabled during fluorescence. Figure 65 is a circuit diagram for a single photodiode 184 and Figure 66 is a timing diagram for the photodiode control signals. The circuit has photodiode 184 and six MOS transistors, Mshunt 394, M^ 396, Mreset 398, Msf 400, Mread 402 and Mbias 404. At the beginning of the excitation cycle, tl, the transistors Mshunt 394, and Mreset 398 are turned on by pulling the MsriUnt gate 384 and the reset gate 388 high. During this period, the excitation photons generate carriers in the photodiode 184. These carriers have to be removed, as the amount of generated carriers can be sufficient to
saturate the photodiode 184. During this cycle, Mshunt 394 directly removes the carriers generated in photodiode 184, while Mreset 398 resets any carriers that have accumulated on node 'NS' 406 due to leakage in transistors or due to diffusion of excitation-produced carriers in the substrate. After excitation, a capture cycle commences at t4. During this cycle, the emitted response from the fluorophore is captured and integrated in the circuit on node 'NS' 406. This is achieved by pulling tx gate 386 high, which turns on the transistor Mtx 396 and transfers any accumulated carriers on the photodiode 184 to node 'NS' 406. The duration of the capture cycle can be as long as the fluorophore emits. The outputs from all photodiodes 184 in the hybridization chamber array 110 are captured
simultaneously.
There is a delay between the end of the capture cycle t5 and the start of the read cycle t6. This delay is due to the requirement to read each photodiode 184 in the hybridization chamber array 110 (see Figure 52) separately following the capture cycle. The first photodiode 184 to be read will have the shortest delay before the read cycle, while the last photodiode 184 will have the longest delay before the read cycle. During the read cycle, transistor Mread 402 is turned on by pulling the read gate 393 high. The 'NS' node 406 voltage is buffered and read out using the source-follower transistor Msf 400.
There are additional, optional methods of enabling or suppressing the photodiode as discussed below:
1. Suppression Methods
Figures 101, 102 and 103 show three possible configurations 778, 780, 782 for the shunt transistor 394. The Mshunt transistor 394 has a very high off ratio at maximum | GS| =
5 V which is enabled during excitation. As shown in Figure 101, the Mshunt gate 384 is configured to be on the edge of the photodiode 184. Optionally, as shown in Figure 102, the Mshunt gate 384 may be configured to surround the photodiode 184. A third option is to configure the Msnunt gate 384 inside the photodiode 184, as shown in Figure 103. Under this third option there would be less photodiode active area 185.
These three configurations 778, 780 and 782 reduce the average path length from all locations in the photodiode 184 to the Mshunt gate 384. In Figure 101, the Mshunt gate 384 is on one side of the photodiode 184. This configuration is simplest to fabricate and impinges the least on the photodiode active area 185. However, any carriers lingering on the remote side of the photodiode 184 would take longer to propagate through to the Mshunt gate 384.
In Figure 102, the Mshunt gate 384 surrounds the photodiode 184. This further reduces the average path length for carriers in the photodiode 184 to the Mshunt gate 384. However, extending the Mshunt gate 384 about the periphery of the photodiode 184 imposes a greater reduction of the photodiode active area 185. The configuration 782 in Figure 103 positions the Mshunt gate 384 within the active area 185. This provides the shortest average path length to the Mshunt gate 384 and hence the shortest transition time. However, the impingement on the active area 185 is greatest. It also poses a wider leakage path.
Enabling Methods
A trigger photodiode drives the shunt transistor with a fixed delay.
A trigger photodiode drives the shunt transistor with programmable delay.
The shunt transistor is driven from the LED drive pulse with a fixed delay.
The shunt transistor is driven as in 2c but with programmable delay. Figure 68 is a schematic section view through a hybridization chamber 180 showing a photodiode 184 and trigger photodiode 187 embedded in the CMOS circuitry 86. A small area in the corner of the photodiode 184 is replaced with the trigger photodiode 187. A trigger photodiode 187 with a small area is sufficient as the intensity of the excitation light will be high in comparison with the fluorescence emission. The trigger photodiode 187 is sensitive to the excitation light 244. The trigger photodiode 187 registers that the excitation light 244 has extinguished and activates the photodiode 184 after a short time delay At 300 (see Figure 2). This delay allows the fluorescence photodiode 184 to detect the fluorescence emission from the FRET probes 186 in the absence of the excitation light 244. This enables detection and improves the signal to noise ratio.
Both photodiodes 184 and trigger photodiodes 187 are located in the CMOS circuitry 86 under each hybridization chamber 180. The array of photodiodes combines, along with appropriate electronics, to form the photosensor 44 (see Figure 64). The photodiodes 184 are pn-junction fabricated during CMOS structure manufacturing without additional masks or steps. During MST fabrication, the dielectric layer (not shown) above the photodiodes 184 is optionally thinned using the standard MST photolithography techniques to allow more fluorescent light to illuminate the active area 185 of the photodiode 184. The photodiode 184 has a field of view such that the fluorescence signal from the probe-target hybrids within the hybridization chamber 180 is incident on the
sensor face. The fluorescent light is converted into a photocurrent which can then be measured using CMOS circuitry 86.
Alternatively, one or more hybridization chambers 180 can be dedicated to a trigger photodiode 187 only. These options can be used in these in combination with 2a and 2b above.
DELAYED DETECTION OF FLUORESCENCE
The following derivations elucidate the delayed detection of fluorescence using a long-lifetime fluorophore for the LED/fluorophore combinations described above. The fluorescence intensity is derived as a function of time after excitation by an ideal pulse of constant intensity Ie between time t\ and ¾ as shown in Figure 60.
Let [51]( equal the density of excited states at time t, then during and after excitation, the number of excited states per unit time per unit volume is described by the following differential equation: dt Tf h ve
where c is the molar concentration of fluorophores, ε is the molar extinction coefficient, ve is the excitation frequency, and h = 6.62606896(10)"34 Js is the Planck constant.
This differential equation has the general form:
^ + p{x)y = q(x)
dx
which has the solution:
e' q(x)dx + k
y(x) = ± r— ...(2)
e1
Now at time h, [Sl](h) = 0, and from (3): k =-—— f-eh '-f ...(4)
h ve
Substituting (4) into (3):
[S\](t) = -—f—-— L
h ve h ve
At time h.
[Sl](t2) = - f-— f-e-«^' ...(5)
hve hve
For t > t2, the excited states decay exponentially and this is described by:
[S\](t) = [SY\(t2)e-(t-h)'T! ...(6)
The fluorescence intensity is given by the following equation:
d[Sl](t) .
If(t) = - L^ Jhvf l ...(8) where V/is the fluorescence frequency, η is the quantum yield and 1 is the optical path length.
Substituting (9) into (8):
If (t) = Iesclri—W - e (h-h)lT< (ί- )1τ> ...(10)
For— →∞, I f(t)→ ΙεεοΙη
Therefore, we can write the following approximate equation which describes the fluorescence intensity decay after a sufficiently long excitation pulse (h-t\ » if):
I f(t) = I escl ^e '~'2>'Tf ior t≥t2 ...(11)
From the above equation, we can derive the following:
¾ ( = ¾ /J7e"('"'2) T ...(12)
where
J f it)
n f (t) =—— is the number of fluorescent photons per unit time per unit area and
h vf is the number of excitation photons per unit time per unit area.
Consequently, nf (t) = nf (t)dt ...(13) where nf is the number of fluorescent photons per unit area and ?3 is the instant of time at which the photodiode is turned on. Substituting (12) into (13): εοΙηβ ('~ )'τ* dt ...(14)
Now, the number of fluorescent photons that reach the photodiode per unit time per unit area, ns (t) , is given by the following:
where φ0 is the light gathering efficiency of the optical system.
Substituting (12) into (1 ) we find
η^) = φ ήεεεΙηβ ^ )'τ' ...(16)
Similarly, the number of fluorescence photons that reach the photodiode per unit fluorescent area « , will be as follows: ns = ns {t)dt and substituting in (16) and integrating: hs = φ0ηεεεΙητ fe~ 3~ 2 T/
Therefore,
ns = φϋήεεοΙητ fe~kt'Tf - - -(lV)
The optimal value of h is when the rate of electrons generated in the photodiode 184 due to fluorescence photons becomes equal to the rate of electrons generated in the photodiode 184 by the excitation photons, as the flux of the excitation photons decays much faster than that of the fluorescence photons.
where φ/ is the quantum efficiency of the sensor at the fluorescence wavelength.
Substituting in (17) we have:
Similarly, the rate of sensor output electrons per unit fluorescent area due to the excitation photons is:
¾( = ^¾ -('-¾)/T- ...(19)
where φε is the quantum efficiency of the sensor at the excitation wavelength, and xe is the time-constant corresponding to the "off characteristics of the excitation LED. After time t2, the LED's decaying photon flux would increase the intensity of the fluorescence signal and extend its decay time, but we are assuming that this has a negligible effect on ¾t), thus we are taking a conservative approach.
Now, as mentioned earlier, the optimal value of t3 is when:
'<?} <¾) = ¾ <¾ )
Therefore, from (18) and (19) we have:
and rearranging we find:
...(20)
From the previous two sections, we have the following two working equations: i>0neFT e ...(21)
where F = εοΐη and At = t3 - t2. We also know that, in practice, t2 - tx » τ f .
The optimal time for fluorescence detection and the number of fluorescence photons detected using the Philips LXK2-P 14-R00 LED and Pulsar 650 dye are determined as follows.
The optimum detection time is determined using equation (22):
Recalling the concentration of amplicon, and assuming that all amplicons hybridize, then the concentration of fluorescent fluorophores is: c = 2.89(10)"6 mol/L
The height of the chamber is the optical path length 1 = 8(10)~6 m.
We have taken the fluorescence area to be equal to our photodiode area, yet our actual fluorescence area is substantially larger than our photodiode area; consequently we can approximately assume 0 = 0.5 for the light gathering efficiency of our optical system.
<j)f
From the photodiode characteristics,— = 10 is a very conservative value for the ratio of the photodiode quantum efficiency at the fluorescence wavelength to its quantum efficiency at the excitation wavelength.
With a typical LED decay lifetime of ze = 0.5 ns and using Pulsar 650
specifications, At can be determined:
F = [1.48(10)6 ][2.89(10) 6 ] [8(10) 6 ](1)
= 3.42(10)"5
_ ln([3.42(10)-5](10)(0.5))
_J 1_
1(10) 6 0.5(10)-9
= 4.34(10)"9 s
The number of photons detected is determined using equation (21). First, the number of excitation photons emitted per unit time «e is determined by examining the illumination geometry.
The Philips LXK2-P 14-R00 LED has a Lambertian radiation pattern, therefore: nl = 'ri cos(6>) . . .(23) where n) is the number of photons emitted per unit time per unit solid angle at an angle of Θ off the LED's forward axial direction, and nm is the valve of n) in the forward axial direction.
The total number of photons emitted by the LED per unit time is:
Now,
ΔΩ = 2π[1 - cos(6> + Δ 0)] - 2π[1 - cos(0)]
ΔΩ = 2π[οο$(θ) - cos(# + Δ6>)]
Αθ . ( Αθ ,( Αθ
■■ 4 z-sin(6>)cos sinl— | + 4 rcos(6>)sin
2 j 2
άΩ = 2πύη(θ)άθ
Substituting this into (24): h, = ^2πηιο οο$(θ)ήη(θ)άθ
Rearranging, we have: - = - •••(26)
71
The LED's output power is 0.515 W and ve = 6.52(10)14 Hz, therefore: ή, = ~ ...(27)
h ve
0.515
[6.63(10r34][6.52(10)14]
= 1.19(10)18 photons/s
Substituting this value into (26) we have:
... 1.19(10)18
¾ =
π
= 3.79(10)17 photons/s/sr
Referring to Figure 61, the optical centre 252 and the lens 254 of the LED 26 are schematically shown. The photodiodes are 16 μιη x 16 μηι, and for the photodiode in the middle of the array, the solid angle (Ω) of the cone of light emitted from the LED 26 to the photodiode 184 is approximately:
Ω = area of sensor/r2
[16(10) 6][16(10) 6]
[2.825(10) 3f
= 3.21(10)"5 sr
It will be appreciated that the central photodiode 184 of the photodiode array 44 is used for the purpose of these calculations. A sensor located at the edge of the array would only receive 2% less photons upon a hybridization event for a Lambertian excitation source intensity distribution.
he = η,Ω
[3.79(10)17 ][3.21(10r5]
1.22(10)13 hotons/s
Now referring to equation (29):
s = <f>0neFrfe
, = (0.5)[1.22(10)13 ][3.42(10)-5 ][l(10)-6 ]e^34 10r9 /1(10r6
208 photons per sensor.
Therefore, using the Philips LXK2-PR14- 00 LED and Pulsar 650 fluorophi can easily detect any hybridization events which results in this number of photons being emitted.
The SET LED illumination geometry is shown in Figure 62. At ID = 20 mA, the LED has a minimum optical power output of pi = 240 μW centred at λβ = 340 nm (the absorption wavelength of the terbium chelate). Driving the LED at ID = 200 mA would increase the output power linearly to pi = 2.4 mW. By placing the LED's optical centre 252, 17.5 mm away from the hybridization chamber array 110, we would approximately concentrate this output flux in a circular spot size which has a maximum diameter of 2 mm.
2.4(10Γ3
[6.63(10n4 ][8.82(10)14]
4.10(10)15 photons/s
Using equation 28, we have:
Ω
[16(10)-6 ]2
4.10(10)15
[ΐ(ΐθ)-3 ]2
3.34(10)u photons/s
Now, recalling equation 22 and using the Tb chelate properties listed previously,
ln[(6.94(10)-5 )(10)(0.5)]
1 1
1(10) 3 0.5(10)"9
= 3.98(10)"9 s
Now from equation 21 :
ns = (0.5)[3.34(10)n ][6.94(10)-5 ][l(10)-3 ]e-3-98(10r9 /1(10r3
= 11 ,600 photons per sensor.
The theoretical number of photons emitted by hybridization events using the SET LED and terbium chelate system are easily detectable and well over the minimum of 30 photons required for reliable detection by the photosensor as indicated above.
MAXIMUM SPACING BETWEEN PROBES AND PHOTODIODE The on-chip detection of hybridization avoids the needs for detection via confocal microscopy (see Background of the Invention). This departure from traditional detection techniques is a significant factor in the time and cost savings associated with this system. Traditional detection requires imaging optics which necessarily uses lenses or curved mirrors. By adopting non-imaging optics, the diagnostic system avoids the need for a complex and bulky optical train. Positioning the photodiode very close to the probes has the advantage of extremely high collection efficiency: when the thickness of the material between the probes and the photodiode is of the order of 1 micron, the angle of collection of emission light is up to 173°. This angle is calculated by considering light emitted from a probe at the centroid of the face of the hybridization chamber closest to the photodiode, which has a planar active surface area parallel to that chamber face. The cone of emission angles within which light is able to be absorbed by the photodiode is defined as having the emitting probe at its vertex and the corner of the sensor on the perimeter of its planar face. For a 16 micron x 16 micron sensor, the vertex angle of this cone is 170°; in the limiting case where the photodiode is expanded so that its area matches that of the 29 micron x 19.75 micron hybridization chamber, the vertex angle is 173°. A separation between the chamber face and the photodiode active surface of 1 micron or less is readily achievable.
Employing a non-imaging optics scheme does require the photodiode 184 to be very close to the hybridization chamber in order to collect sufficient photons of fluorescence emission. The maximum spacing between the photodiode and probes is determined as follows with reference to Figure 54.
Utilizing a terbium chelate fluorophore and a SET UVTOP335T039BL LED, we calculated 11600 photons reaching our 16 micron x 16 micron photodiode 184 from the respective hybridization chamber 180. In performing this calculation we assumed that the light-collecting region of our hybridization chamber 180 has a base area which is the same as our photodiode active area 185, and half of the total number of the hybridization photons reaches the photodiode 184. That is, the light gathering efficiency of the optical system is 0 = 0.5 .
More accurately we can write φ0 = [(base area of the light-collecting region of the hybridization chamber)/(photodiode area)][Q/4n], where Ω = solid angle subtended by the photodiode at a representative point on the base of the hybridization chamber. For a right square pyramid geometry:
Ω = 4arcsin(a2/(4do2+a2)), where do = distance between the chamber and the photodiode, and a is the photodiode dimension.
Each hybridization chamber releases 23200 photons. The selected photodiode has a detection threshold of 17 photons; therefore, the minimum optical efficiency required is: φ0= 17/23200 = 7.33xl0"4
The base area of the light-collecting region of the hybridization chamber 180 is 29 micron x 19.75 micron.
Solving for do, we will get the maximum limiting distance between the bottom of our hybridization chamber and our photodiode 184 to be do = 249 microns. In this limit, the collection cone angle as defined above is only 0.8°. It should be noted this analysis ignores the negligible effect of refraction.
LOC VARIANTS
The LOC device 301 described and illustrated above in full is just one of many possible LOC device designs. Variations of the LOC device that use different
combinations of the various functional sections described above will now be described and/or shown as schematic flow-charts, from sample inlet to detection, to illustrate some of the combinations possible. The flow-charts have been divided, where appropriate, into sample input and preparation stage 288, extraction stage 290, incubation stage 291, amplification stage 292, pre-hybridization stage 293 and detection stage 294. For all the LOC variants that are briefly described or shown only in schematic form, the
accompanying full layouts are not shown for reasons of clarity and succinctness. Also in
the interests of clarity, smaller functional units such as liquid sensors and temperature sensors are not shown but it will be appreciated that these have been incorporated into the appropriate locations in each of the following LOC device designs.
LOC VARIANT XII LOC variant XII 758 is shown in Figures 93 to 100. This LOC device extracts 290, incubates 291, amplifies 292 and detects 294 pathogenic DNA, and uses a pre- hybridization purification step 293 to increase hybridization efficiency. The sample (such as whole blood) is added to the sample inlet 68 (see Figure 95) and capillary action draws the sample to the surface tension valve 118 where anticoagulant is added from reservoir 54. The sample continues in the cap channel 94 to the pathogen dialysis section 70. The dialysis section 70 has a bypass channel 600 to prevent trapped air bubbles (see Figure 95).
After dialysis in the pathogen dialysis section 70, the erythrocyte and leukocyte stream is directed to a waste reservoir 76 while the pathogens continue in the sample flow to surface tension valve 128 where a lysis reagent is added from reservoir 56. The sample fills the chemical lysis chamber 130 where it is retained by boiling-initiated valve 206 until the lysis reagent has diffused through the sample to release most, if not all, of the pathogenic DNA. When the boiling-initiated valve 206 opens, the sample flows to surface tension valve 132 where restriction enzymes, ligase and linker primers are added from reservoir 58. The sample fills the incubation section 114 and is heated while restriction digestion and linker ligation of the pathogenic DNA occurs (see Figure 95).
After restriction digestion and linker ligation, the boiling-initiated valve 207 opens for the sample to flow into the amplification sectionl 12. Amplification mix from reservoir 60 is added via surface tension valve 138 and polymerase from reservoir 62 through surface tension valve 140 as the sample flows into the amplification section 112. The pathogenic DNA is amplified by thermal cycling before the boiling-initiated valve 108 opens for the amplicon to flow to the small constituents dialysis section 682 where large components are removed (see Figure 95).
As best shown in Figures 98 and 99, the small constituents dialysis section 682 has a large constituents channel 760 between two small constituents channels 762 formed in the bottom channel layer 100 (see Figure 94). The large constituents channel 760 is connected to the small constituents channels 762 by stoma in the form of a series of inverse tapered openings 764 (smaller at the large constituents channel end). In most practical applications, the stoma will be between 1 to 8 microns wide and 1 to 8 microns high. As
the amplicon flows into the large constituents channel 760, small constituents (smaller than the inverse tapered openings 764) start to diffuse into the small constituents channels 762. The concentration of small constituents in the large constituents channel 760 reduces as the flow progresses to the downstream end of the small constituents dialysis section 682. An additional advantage of microfabricated stoma is that the number of stoma per unit length along the channel is very high, so that the separation is more efficient. For efficient separation of constituents with the sizes of interest, the spacing between adjacent stoma is between 1 micron and 10 microns; in the embodiment shown in Figure 99, the spacing between adjacent stoma is 8 microns.
Figure 100 shows the downstream end of the small constituents dialysis section
682. The large constituents channel 760 diverts into a wide meander ending at a blind end 766 which provides a waste reservoir. The two small constituents channels 762 lead to opposite sides of the hybridization chamber array 110 where they both follow serpentine paths through the array to respective blind ends 768. The small constituents amplicon fills all the individual hybridization chambers 180 prior to timed initiation of the hybridization heaters and subsequent probe-target hybrid detection (as described previously).
The small constituents dialysis section 682 removes cell debris which may still remain in the sample flow following cell lysis. Cell debris may interfere with
hybridization efficiency. LOC VARIANT XIX
The LOC variant XIX 646 shown in Figure 78 has pathogen dialysis section 70 and thermal lysis section 638 of the sample prior to nucleic acid amplification (amplification section 112), but also adds a pre-hybridization purification step 293 between the amplification 292 and detection phases 294. The pre-hybridization, small constituents dialysis section 682 removes cell debris in the sample flow resulting from cell lysis. Most nucleic acid amplification protocols are sufficiently tolerant of cell debris in the sample. However, hybridization can be affected by cell debris and so pre-hybridization dialysis via the small constituents dialysis section 682 is used to substantially reduce the concentration of debris in the amplicon immediately prior to filling the hybridization chamber array 110. CONCLUSION
The devices, systems and methods described here facilitate molecular diagnostic tests at low cost with high speed and at the point-of-care.
The system and its components described above are purely illustrative and the skilled worker in this field will readily recognize many variations and modifications which do not depart from the spirit and scope of the broad inventive concept.
Claims
1. A lab-on-a-chip (LOC) device for detecting pathogens in a biological sample, the LOC device comprising:
an inlet for receiving the sample;
a supporting substrate;
a first dialysis section for separating pathogens from larger constituents in the sample;
a lysis section downstream of the dialysis section for lysing the pathogens to release genetic material therein, the lysis section having a lysis chamber and a heater for lysing the pathogens while the sample is in the lysis chamber;
a nucleic acid amplification section downstream of the lysis section for amplifying nucleic acid sequences in the genetic material; and,
a second dialysis section downstream of the nucleic acid amplification section for prehybridization filtration of amplicon produced by the nucleic acid amplification section, the second dialysis section being configured to remove cell debris from the amplicon; wherein,
the first dialysis section, the lysis section, the nucleic acid amplification section and the second dialysis section are all supported on the supporting substrate.
2. The LOC device according to claim 1 wherein the lysis section has a heater for thermally lysing the pathogens.
3. The LOC device according to claim 2 further comprising a hybridization section downstream of the second dialysis section that has an array of probes for hybridization with target nucleic acid sequences in the sample and, a photosensor for detecting hybridization of any probes within the array.
4. The LOC device according to claim 3 wherein the first dialysis section has a first channel in fluid communication with the inlet, a second channel in fluid communication with the lysis section and a plurality of first apertures that are larger than the pathogens and smaller than the larger constituents, the second channel being in fluid communication with the first channel via the first apertures such that the pathogens flow into the second channel while the larger constituents are retained in the first channel.
5. The LOC device according to claim 4 wherein the first channel and the second channel are configured to fill with the sample by capillary action.
6. The LOC device according to claim 1 wherein the second dialysis section has a large component channel, a small component channel and a plurality of second apertures fluidically connecting the large component channel to the small component channel, the second apertures being sized to allow nucleic acid sequences to flow from the large component channel to the small component channel while cell debris larger than the second apertures is retained in the large component channel, the small component channel being in fluid communication with the hybridization section.
7. The LOC device according to claim 1 wherein the nucleic acid amplification section is an isothermal nucleic acid amplification section.
8. The LOC device according to claim 7 further comprising a reagent reservoir for holding a reagent used for isothermal nucleic acid amplification; and,
a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus and the reagent flows out of the reagent reservoir.
9. The LOC device according to claim 1 wherein the nucleic acid amplification section is polymerase chain reaction (PCR) amplification section.
10. The LOC device according to claim 9 further comprising CMOS circuitry, a temperature sensor and a microsystems technology (MST) layer which incorporates the PCR section, wherein the CMOS circuitry is positioned between the supporting substrate and the MST layer, the CMOS circuitry being configured to use the temperature sensor output for feedback control of the PCR section.
1 1. The LOC device according to claim 10 wherein the PCR section has a PCR microchannel for thermally cycling the sample to amplify the nucleic acid sequences, the PCR microchannel defining part of the flow-path for the sample and has a cross sectional area transverse to the flow less than 100,000 square microns.
12. The LOC device according to claim 11 wherein the PC section further comprises at least one elongate heater element for heating the nucleic acid sequences within the elongate PCR microchannel, the elongate heater element extending parallel to the PCR microchannel.
13. The LOC device according to claim 12 wherein at least one section of the PCR microchannel forms an elongate PCR chamber. 14. The LOC device according to claim 13 wherein the PCR section has a plurality of the elongate PCR chambers each formed by respective sections of the PCR microchannel, the PCR microchannel having a serpentine configuration formed by a series of wide meanders, each of the wide meanders being a channel section that forms one of the elongate PCR chambers.
1 . The LOC device according to claim 14 further comprising a reagent reservoir for holding a reagent used for PCR; and,
a surface tension valve having an aperture configured to pin a meniscus of the reagent such that the meniscus retains the reagent in the reagent reservoir until contact with the fluid sample removes the meniscus and the reagent flows out of the reagent reservoir.
16. The LOC device according to claim 15 further comprising a hybridization chamber array for containing the probes such that the probes within each hybridization chamber are configured to hybridize with one of the target nucleic acid sequences.
17. The LOC device according to claim 16 wherein the photosensor is an array of photodiodes positioned in registration with the hybridization chambers.
18. The LOC device according to claim 16 wherein the CMOS circuitry has a digital memory for storing hybridization data from the photosensor output and a data interface for transmission of the hybridization data to an external device.
19. The LOC device according to claim 16 wherein the PCR section has an active valve for retaining liquid in the PCR section during thermal cycling and allowing flow to the hybridization chambers in response to an activation signal from the CMOS circuitry.
20. The LOC device according to claim 19 wherein the active valve is a boiling- initiated valve with a meniscus anchor configured to pin a meniscus that arrests capillary driven flow of the liquid, and a heater for boiling the liquid to unpin the meniscus from the meniscus anchor such that capillary driven flow resumes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35601810P | 2010-06-17 | 2010-06-17 | |
US61/356,018 | 2010-06-17 | ||
US201161437686P | 2011-01-30 | 2011-01-30 | |
US61/437,686 | 2011-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011156837A1 true WO2011156837A1 (en) | 2011-12-22 |
Family
ID=45327470
Family Applications (23)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2011/000673 WO2011156850A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with pcr section and diffusion mixer |
PCT/AU2011/000679 WO2011156856A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic thermal bend actuated surface tension valve |
PCT/AU2011/000675 WO2011156852A1 (en) | 2010-06-17 | 2011-06-01 | Genetic analysis loc with non-specific nucleic acid amplification section and subsequent specific amplification of particular sequences in a separate section |
PCT/AU2011/000667 WO2011156844A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for genetic analysis which performs nucleic acid amplification before removing non-nucleic acid constituents in a dialysis section |
PCT/AU2011/000663 WO2011156840A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection and genetic analysis with chemical lysis, incubation and tandem nucleic acid amplification |
PCT/AU2011/000672 WO2011156849A1 (en) | 2010-06-17 | 2011-06-01 | Test module with microfluidic device having loc and dialysis device for separating pathogens from other constituents in a biological sample |
PCT/AU2011/000665 WO2011156842A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection and genetic analysis with dialysis and nucleic acid amplification |
PCT/AU2011/000664 WO2011156841A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection with dialysis, thermal lysis, nucleic acid amplification and prehybridization filtering |
PCT/AU2011/000666 WO2011156843A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for genetic analysis which performs nucleic acid amplification after sample preparation in a dialysis section |
PCT/AU2011/000668 WO2011156845A1 (en) | 2010-06-17 | 2011-06-01 | Loc device with parallel incubation and parallel dna and rna amplification functionality |
PCT/AU2011/000671 WO2011156848A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with flow-channel structure having active valve for capillary-driven fluidic propulsion without trapped air bubbles |
PCT/AU2011/000659 WO2011156836A1 (en) | 2010-06-17 | 2011-06-01 | Apparatus for loading oligonucleotide spotting devices and spotting oligonucleotide probes |
PCT/AU2011/000658 WO2011156835A1 (en) | 2010-06-17 | 2011-06-01 | Test module incorporating spectrometer |
PCT/AU2011/000670 WO2011156847A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device for genetic and mitochondrial analysis of a biological sample |
PCT/AU2011/000661 WO2011156838A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection with dialysis, chemical lysis and tandem nucleic acid amplification |
PCT/AU2011/000676 WO2011156853A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic test module with flexible membrane for internal microenvironment pressure-relief |
PCT/AU2011/000662 WO2011156839A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for genetic analysis with dialysis, chemical lysis and tandem nucleic acid amplification |
PCT/AU2011/000669 WO2011156846A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device for simultaneous detection of multiple conditions in a patient |
PCT/AU2011/000680 WO2011156857A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with dialysis section having stomata tapering counter to flow direction |
PCT/AU2011/000678 WO2011156855A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with reagent mixing proportions determined by number of active outlet valves |
PCT/AU2011/000677 WO2011156854A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with conductivity sensor |
PCT/AU2011/000674 WO2011156851A1 (en) | 2010-06-17 | 2011-06-01 | Test module with diffusive mixing in small cross section area microchannel |
PCT/AU2011/000660 WO2011156837A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection with dialysis, thermal lysis, nucleic acid amplification and prehybridization filtering |
Family Applications Before (22)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2011/000673 WO2011156850A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with pcr section and diffusion mixer |
PCT/AU2011/000679 WO2011156856A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic thermal bend actuated surface tension valve |
PCT/AU2011/000675 WO2011156852A1 (en) | 2010-06-17 | 2011-06-01 | Genetic analysis loc with non-specific nucleic acid amplification section and subsequent specific amplification of particular sequences in a separate section |
PCT/AU2011/000667 WO2011156844A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for genetic analysis which performs nucleic acid amplification before removing non-nucleic acid constituents in a dialysis section |
PCT/AU2011/000663 WO2011156840A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection and genetic analysis with chemical lysis, incubation and tandem nucleic acid amplification |
PCT/AU2011/000672 WO2011156849A1 (en) | 2010-06-17 | 2011-06-01 | Test module with microfluidic device having loc and dialysis device for separating pathogens from other constituents in a biological sample |
PCT/AU2011/000665 WO2011156842A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection and genetic analysis with dialysis and nucleic acid amplification |
PCT/AU2011/000664 WO2011156841A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection with dialysis, thermal lysis, nucleic acid amplification and prehybridization filtering |
PCT/AU2011/000666 WO2011156843A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for genetic analysis which performs nucleic acid amplification after sample preparation in a dialysis section |
PCT/AU2011/000668 WO2011156845A1 (en) | 2010-06-17 | 2011-06-01 | Loc device with parallel incubation and parallel dna and rna amplification functionality |
PCT/AU2011/000671 WO2011156848A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with flow-channel structure having active valve for capillary-driven fluidic propulsion without trapped air bubbles |
PCT/AU2011/000659 WO2011156836A1 (en) | 2010-06-17 | 2011-06-01 | Apparatus for loading oligonucleotide spotting devices and spotting oligonucleotide probes |
PCT/AU2011/000658 WO2011156835A1 (en) | 2010-06-17 | 2011-06-01 | Test module incorporating spectrometer |
PCT/AU2011/000670 WO2011156847A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device for genetic and mitochondrial analysis of a biological sample |
PCT/AU2011/000661 WO2011156838A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for pathogen detection with dialysis, chemical lysis and tandem nucleic acid amplification |
PCT/AU2011/000676 WO2011156853A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic test module with flexible membrane for internal microenvironment pressure-relief |
PCT/AU2011/000662 WO2011156839A1 (en) | 2010-06-17 | 2011-06-01 | Loc device for genetic analysis with dialysis, chemical lysis and tandem nucleic acid amplification |
PCT/AU2011/000669 WO2011156846A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device for simultaneous detection of multiple conditions in a patient |
PCT/AU2011/000680 WO2011156857A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with dialysis section having stomata tapering counter to flow direction |
PCT/AU2011/000678 WO2011156855A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with reagent mixing proportions determined by number of active outlet valves |
PCT/AU2011/000677 WO2011156854A1 (en) | 2010-06-17 | 2011-06-01 | Microfluidic device with conductivity sensor |
PCT/AU2011/000674 WO2011156851A1 (en) | 2010-06-17 | 2011-06-01 | Test module with diffusive mixing in small cross section area microchannel |
Country Status (3)
Country | Link |
---|---|
US (355) | US20110312712A1 (en) |
TW (1) | TW201213798A (en) |
WO (23) | WO2011156850A1 (en) |
Families Citing this family (265)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790028B1 (en) * | 2005-09-28 | 2010-09-07 | The Charles Stark Draper Laboratory, Inc. | Systems, methods, and devices relating to a cellularized nephron unit |
CA2646309C (en) | 2006-04-21 | 2016-07-26 | Nanobiosym, Inc. | Single-molecule platform for drug discovery: methods and apparatuses for drug discovery, including discovery of anticancer and antiviral agents |
US11001881B2 (en) | 2006-08-24 | 2021-05-11 | California Institute Of Technology | Methods for detecting analytes |
WO2008014485A2 (en) | 2006-07-28 | 2008-01-31 | California Institute Of Technology | Multiplex q-pcr arrays |
US11525156B2 (en) | 2006-07-28 | 2022-12-13 | California Institute Of Technology | Multiplex Q-PCR arrays |
US11560588B2 (en) | 2006-08-24 | 2023-01-24 | California Institute Of Technology | Multiplex Q-PCR arrays |
US8498695B2 (en) | 2006-12-22 | 2013-07-30 | Novadaq Technologies Inc. | Imaging system with a single color image sensor for simultaneous fluorescence and color video endoscopy |
US7993292B2 (en) * | 2007-05-22 | 2011-08-09 | Bellacure, Inc. | Orthotic apparatus and method of operation |
US9598737B2 (en) * | 2012-05-09 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Next generation genomic sequencing methods |
US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
US8707452B1 (en) * | 2008-04-14 | 2014-04-22 | Avaya Inc. | Secure data management device |
EP2927350A1 (en) * | 2014-04-02 | 2015-10-07 | Beatrice Sala | Electrochemical cell for the electrolysis of water in steam or liquid form, manufacturing method and uses |
US8304185B2 (en) * | 2009-07-17 | 2012-11-06 | Canon U.S. Life Sciences, Inc. | Methods and systems for DNA isolation on a microfluidic device |
EP2437887B1 (en) | 2009-06-04 | 2016-05-11 | Lockheed Martin Corporation | Multiple-sample microfluidic chip for dna analysis |
EP2493597B1 (en) * | 2009-10-29 | 2017-03-29 | The Charles Stark Draper Laboratory, Inc. | Microfluidic device for blood dialysis |
EP2565616B1 (en) * | 2010-04-28 | 2020-08-05 | Panasonic Intellectual Property Management Co., Ltd. | Chemical sensor |
US20110312712A1 (en) * | 2010-06-17 | 2011-12-22 | Geneasys Pty Ltd | Genetic analysis loc for pcr amplification of nucleic acids from whole blood |
US10161928B2 (en) | 2010-07-26 | 2018-12-25 | Wellmetris, Llc | Wellness panel |
US20120044339A1 (en) * | 2010-08-19 | 2012-02-23 | Stith Curtis W | Opto-fluidic microscope system with evaluation chambers |
US20120045786A1 (en) * | 2010-08-19 | 2012-02-23 | Stith Curtis W | Opto-fluidic microscope diagnostic system |
EP2609742A4 (en) * | 2010-08-27 | 2015-07-08 | Univ Leland Stanford Junior | Microscopy imaging device with advanced imaging properties |
WO2012040050A1 (en) | 2010-09-23 | 2012-03-29 | Bayer Healthcare Llc | System and method for determining ambient temperatures for a fluid analyte system |
AU2011315951B2 (en) | 2010-10-15 | 2015-03-19 | Lockheed Martin Corporation | Micro fluidic optic design |
EP2648609B1 (en) | 2010-12-09 | 2018-05-30 | Zoll Medical Corporation | Electrode with redundant impedance reduction |
FR2968532B1 (en) * | 2010-12-14 | 2013-04-26 | Commissariat Energie Atomique | DEVICE AND METHOD FOR DETERMINING AN EXCRETION RATE OF A BODILY FLUID BY AN INDIVIDUAL OR ANIMAL |
CN102564576B (en) * | 2010-12-17 | 2013-11-06 | 鸿富锦精密工业(深圳)有限公司 | Light intensity testing device |
US9068566B2 (en) * | 2011-01-21 | 2015-06-30 | Biodot, Inc. | Piezoelectric dispenser with a longitudinal transducer and replaceable capillary tube |
US8794050B2 (en) | 2011-01-27 | 2014-08-05 | Nanoscopia (Cayman), Inc. | Fluid sample analysis systems |
US9469871B2 (en) | 2011-04-14 | 2016-10-18 | Corporos Inc. | Methods and apparatus for point-of-care nucleic acid amplification and detection |
TWI441940B (en) * | 2011-06-09 | 2014-06-21 | Shih Hua Technology Ltd | Method for making pattern conductive element |
US9657261B2 (en) | 2011-06-15 | 2017-05-23 | The Charles Stark Draper Laboratory, Inc. | Systems, methods, and devices relating to a biomimetic cellularized nephron unit |
ITTO20110567A1 (en) * | 2011-06-28 | 2012-12-29 | St Microelectronics Srl | CARTRIDGE FOR BIOCHEMICAL ANALYSIS, BIOCHEMICAL ANALYSIS SYSTEM AND METHOD TO PERFORM A BIOCHEMICAL PROCESS |
TW201301141A (en) * | 2011-06-29 | 2013-01-01 | Walton Advanced Eng Inc | Storage device having graphs and recognition system thereof |
US8717556B2 (en) | 2011-07-27 | 2014-05-06 | Aptina Imaging Corporation | Microfluidic systems with chemical pumps |
WO2013021687A1 (en) * | 2011-08-11 | 2013-02-14 | オリンパス株式会社 | Method for detecting target particles |
WO2013031365A1 (en) | 2011-08-30 | 2013-03-07 | オリンパス株式会社 | Method for detecting target particles |
US8988684B1 (en) | 2011-09-08 | 2015-03-24 | Lawrence Livermore National Security, Llc | System and method for measuring fluorescence of a sample |
US9372135B1 (en) | 2011-09-08 | 2016-06-21 | Lawrence Livermore National Security, Llc | Fluidics platform and method for sample preparation |
WO2013040058A1 (en) * | 2011-09-12 | 2013-03-21 | Jian Guo | Imaging fluorescence or luminescence lifetime |
USD753311S1 (en) | 2011-10-12 | 2016-04-05 | Alere Switzerland Gmbh | Isothermal nucleic acid amplification meter |
GB201119032D0 (en) | 2011-11-03 | 2011-12-14 | Isis Innovation | Multisomes: encapsulated droplet networks |
US9689029B2 (en) | 2011-12-02 | 2017-06-27 | Caliper Life Sciences, Inc. | Systems and methods for sampling of amplification products |
WO2013102150A1 (en) * | 2011-12-28 | 2013-07-04 | Ricardo Mancebo | Reagents and methods for autoligation chain reaction |
US20130211289A1 (en) | 2012-01-25 | 2013-08-15 | Tasso, Inc. | Handheld Device for Drawing, Collecting, and Analyzing Bodily Fluid |
CN104115003B (en) | 2012-02-22 | 2016-03-23 | 奥林巴斯株式会社 | The detection method of intended particle |
TWI484154B (en) * | 2012-02-24 | 2015-05-11 | Optical detecting apparatus and operating method thereof | |
JP6095645B2 (en) | 2012-03-21 | 2017-03-15 | オリンパス株式会社 | Method for detecting target nucleic acid molecule |
US9150907B2 (en) | 2012-04-27 | 2015-10-06 | General Electric Company | Microfluidic flow cell assemblies and method of use |
US9354159B2 (en) | 2012-05-02 | 2016-05-31 | Nanoscopia (Cayman), Inc. | Opto-fluidic system with coated fluid channels |
US9258536B2 (en) * | 2012-05-03 | 2016-02-09 | Semiconductor Components Industries, Llc | Imaging systems with plasmonic color filters |
US9625465B2 (en) | 2012-05-15 | 2017-04-18 | Defined Diagnostics, Llc | Clinical diagnostic systems |
US9081001B2 (en) | 2012-05-15 | 2015-07-14 | Wellstat Diagnostics, Llc | Diagnostic systems and instruments |
US9213043B2 (en) | 2012-05-15 | 2015-12-15 | Wellstat Diagnostics, Llc | Clinical diagnostic system including instrument and cartridge |
CN102649931A (en) * | 2012-05-28 | 2012-08-29 | 上海理工大学 | Preparation method for microarray biochip |
KR20130136623A (en) * | 2012-06-05 | 2013-12-13 | 인제대학교 산학협력단 | Apparatus for detecting liquid electric conductivity |
US10278585B2 (en) | 2012-06-21 | 2019-05-07 | Novadaq Technologies ULC | Quantification and analysis of angiography and perfusion |
JP6312670B2 (en) * | 2012-07-23 | 2018-04-18 | タッソ インコーポレイテッド | Methods, systems, and apparatus for open microfluidic channels |
US20140200167A1 (en) | 2012-08-01 | 2014-07-17 | Nanomdx, Inc. | Functionally integrated device for multiplex genetic identification |
US9310300B2 (en) * | 2012-08-03 | 2016-04-12 | Ingeneron Incorporated | Compact portable apparatus for optical assay |
WO2014025861A1 (en) * | 2012-08-07 | 2014-02-13 | Netanel Avner | Sim card based medical testing and data transmission system |
US20140073013A1 (en) * | 2012-08-07 | 2014-03-13 | California Institute Of Technology | Ultrafast thermal cycler |
WO2014047523A2 (en) * | 2012-09-21 | 2014-03-27 | California Institute Of Technology | Methods and devices for sample lysis |
US9518914B2 (en) * | 2012-09-24 | 2016-12-13 | Brigham And Women's Hospital, Inc. | Portal and method for management of dialysis therapy |
DE102012109317A1 (en) * | 2012-10-01 | 2014-04-03 | Astrium Gmbh | Device for carrying out a biochemical analysis, in particular in space |
US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
GB201219201D0 (en) | 2012-10-25 | 2012-12-12 | Isis Innovation | Hydrogel network |
JPWO2014077029A1 (en) * | 2012-11-13 | 2017-01-05 | 株式会社村田製作所 | Droplet quantification method and measuring apparatus |
US9885655B2 (en) | 2012-11-13 | 2018-02-06 | Viavi Solutions Inc. | Spectrometer with a relay lightpipe |
TWI659198B (en) * | 2012-11-13 | 2019-05-11 | 美商唯亞威方案公司 | Portable spectrometer, method of generating a spectrum, andportable spectrometer system |
CN103852105A (en) * | 2012-12-04 | 2014-06-11 | 昆山平成电子科技有限公司 | Multi-functional tester |
JP6416772B2 (en) * | 2012-12-07 | 2018-10-31 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | Droplet collection by 3D printing |
US9239328B2 (en) | 2012-12-17 | 2016-01-19 | Taiwan Semiconductor Manufacturing Company, Ltd. | Systems and methods for an integrated bio-entity manipulation and processing semiconductor device |
US9495332B2 (en) * | 2012-12-21 | 2016-11-15 | International Business Machines Corporation | Detection and repositioning of pop-up dialogs |
BR112015015236A2 (en) | 2012-12-27 | 2017-07-11 | Medi Physics Inc | Dual Filter Dual Integrity Test Duct Assembly, and Method for Dispensing Product Liquid |
GB201301178D0 (en) | 2013-01-23 | 2013-03-06 | Dynamic Biosensors Gmbh | Method for sequencing a template nucleic acid immobilized on a substrate |
US9999393B2 (en) | 2013-01-29 | 2018-06-19 | Zoll Medical Corporation | Delivery of electrode gel using CPR puck |
US8880196B2 (en) | 2013-03-04 | 2014-11-04 | Zoll Medical Corporation | Flexible therapy electrode |
KR20150134357A (en) * | 2013-03-12 | 2015-12-01 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Microfluidic device for immunoblotting |
WO2014153216A2 (en) * | 2013-03-14 | 2014-09-25 | Alfred E. Mann Foundation For Scientific Research | Microfluidic flow rate sensor |
GB201304797D0 (en) * | 2013-03-15 | 2013-05-01 | Diagnostics For The Real World Ltd | Apparatus and method for automated sample preparation and adaptor for use in the apparatus |
EP2972402B1 (en) | 2013-03-15 | 2023-12-20 | Abbott Laboratories | Diagnostic analyzers with pretreatment carousels and related methods |
EP2972404B1 (en) | 2013-03-15 | 2021-11-24 | Abbott Laboratories | Automated diagnostic analyzers having rear accessible track systems and related methods |
US10933417B2 (en) | 2013-03-15 | 2021-03-02 | Nanobiosym, Inc. | Systems and methods for mobile device analysis of nucleic acids and proteins |
JP6351703B2 (en) | 2013-03-15 | 2018-07-04 | アボット・ラボラトリーズAbbott Laboratories | Automatic diagnostic analyzer with vertically arranged carousel and related methods |
EP2969218A2 (en) * | 2013-03-15 | 2016-01-20 | Nanobiosym, Inc. | Systems and methods for mobile device analysis of nucleic acids and proteins |
KR101483493B1 (en) * | 2013-03-22 | 2015-01-19 | 나노바이오시스 주식회사 | PCR device for detecting food-borne bacteria, and and method for detecting food-borne bacteria using the same |
US20140323819A1 (en) * | 2013-04-29 | 2014-10-30 | Elwha LLC, a limited liability company of the State of Delaware | Multi-parameter test units for initial indication of medical symptoms |
WO2014194042A2 (en) * | 2013-05-29 | 2014-12-04 | Gnubio, Inc. | Low cost optical high speed discrete measurement system |
GB2516669B (en) * | 2013-07-29 | 2015-09-09 | Atlas Genetics Ltd | A method for processing a liquid sample in a fluidic cartridge |
US9347962B2 (en) | 2013-08-05 | 2016-05-24 | Nanoscopia (Cayman), Inc. | Handheld diagnostic system with chip-scale microscope and automated image capture mechanism |
WO2015031351A1 (en) | 2013-08-26 | 2015-03-05 | Diagenetix, Inc. | Hardware and mobile software for operation of portable instruments for nucleic acid amplification |
US9597441B2 (en) | 2013-09-16 | 2017-03-21 | Johnson & Johnson Innovation LLC | Microfluidic organ assist device incorporating boundary layer disrupters |
ITMI20131541A1 (en) * | 2013-09-19 | 2015-03-20 | Eugenio Iannone | DIAGNOSIS DEVICE, PARTICULARLY OF THE LAB-ON-CHIP TYPE. |
US20160215254A1 (en) | 2013-09-27 | 2016-07-28 | Deirdre Meldrum | System and method for laser lysis |
US9604214B2 (en) * | 2013-10-01 | 2017-03-28 | Owl biomedical, Inc. | Cell sorting system using microfabricated components |
WO2015070173A1 (en) * | 2013-11-08 | 2015-05-14 | Isis Pharmaceuticals, Inc. | Compounds and methods for detecting oligonucleotides |
US9059337B1 (en) * | 2013-12-24 | 2015-06-16 | Christie Digital Systems Usa, Inc. | Method, system and apparatus for dynamically monitoring and calibrating display tiles |
US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
US20180135108A1 (en) * | 2014-01-20 | 2018-05-17 | Board Of Trustees Of Michigan State University | Method for detecting bacterial and fungal pathogens |
WO2015123603A1 (en) * | 2014-02-14 | 2015-08-20 | Beth Israel Deaconess Medical Center, Inc. | Electrical impedance myography |
KR20160125993A (en) * | 2014-02-28 | 2016-11-01 | 비디비씨 싸이언시스 코프. | A system for tissue manipulation |
KR20240017103A (en) | 2014-03-07 | 2024-02-06 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Devices for integrating analyte extraction, concentration and detection |
WO2015138343A1 (en) | 2014-03-10 | 2015-09-17 | Click Diagnostics, Inc. | Cartridge-based thermocycler |
EP3116651B1 (en) | 2014-03-11 | 2020-04-22 | Illumina, Inc. | Disposable, integrated microfluidic cartridge and methods of making it |
BR112016020664A8 (en) * | 2014-03-12 | 2019-12-31 | Basf Corp | catalyzed soot filter, process for manufacturing a catalyzed soot filter, system for treating a diesel engine exhaust stream, method for treating a diesel engine exhaust stream, use of a catalyzed soot filter and use cuo |
US8820538B1 (en) * | 2014-03-17 | 2014-09-02 | Namocell LLC | Method and apparatus for particle sorting |
US10318878B2 (en) | 2014-03-19 | 2019-06-11 | Numenta, Inc. | Temporal processing scheme and sensorimotor information processing |
GB2524730A (en) * | 2014-03-30 | 2015-10-07 | Robert Faulkner | Predicting application user behaviour and interests in real-time using predictive analytics as a service |
SG11201608600YA (en) | 2014-04-14 | 2016-11-29 | Stanford Res Inst Int | Portable nucleic acid analysis system and high-performance microfluidic electroactive polymer actuators |
BR112016022867A2 (en) * | 2014-04-25 | 2018-07-03 | Hewlett Packard Development Co | diagnostic cassette. |
CN104668002B (en) * | 2014-05-22 | 2016-03-16 | Imec非营利协会 | Compact fluid analysis device and manufacture method thereof |
CA2991918A1 (en) * | 2014-07-11 | 2016-01-14 | Advanced Theranostics Inc. | Point of care polymerase chain reaction device for disease detection |
JP2016023994A (en) * | 2014-07-17 | 2016-02-08 | セイコーエプソン株式会社 | Electronic component conveyance device and electronic component inspection device |
EP3769682B1 (en) | 2014-08-01 | 2024-01-03 | Tasso, Inc. | Systems for gravity-enhanced microfluidic collection, handling and transferring of fluids |
US10352899B2 (en) | 2014-10-06 | 2019-07-16 | ALVEO Technologies Inc. | System and method for detection of silver |
US9506908B2 (en) | 2014-10-06 | 2016-11-29 | Alveo Technologies, Inc. | System for detection of analytes |
US9921182B2 (en) | 2014-10-06 | 2018-03-20 | ALVEO Technologies Inc. | System and method for detection of mercury |
US10196678B2 (en) | 2014-10-06 | 2019-02-05 | ALVEO Technologies Inc. | System and method for detection of nucleic acids |
US10627358B2 (en) | 2014-10-06 | 2020-04-21 | Alveo Technologies, Inc. | Method for detection of analytes |
WO2016062788A1 (en) | 2014-10-24 | 2016-04-28 | Ait Austrian Institute Of Technology Gmbh | Microfluidic chip for biological analysis |
US10022718B2 (en) * | 2014-10-24 | 2018-07-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Microfluidic device and array disk |
CN104374903B (en) * | 2014-11-08 | 2016-07-06 | 东莞博识生物科技有限公司 | A kind of in-vitro diagnosis test card |
MX2017008618A (en) | 2014-12-31 | 2018-03-23 | Click Diagnostics Inc | Devices and methods for molecular diagnostic testing. |
RU2016151351A (en) * | 2015-01-28 | 2019-02-28 | КАБУСИКИ КАЙСЯ ДиЭнЭйФОРМ | ANALYSIS DEVICE, ANALYSIS CHIP, ANALYSIS KIT AND METHOD OF ANALYSIS WITH THEIR APPLICATION |
EP3234549A4 (en) | 2015-01-30 | 2018-08-08 | Hewlett-Packard Development Company, L.P. | Diagnostic chip |
DE102015001998B3 (en) * | 2015-02-20 | 2016-02-04 | Friz Biochem Gesellschaft Für Bioanalytik Mbh | Microfluidic cartridge for the detection of biomolecules |
US10279352B2 (en) * | 2015-03-18 | 2019-05-07 | Optolane Technologies Inc. | PCR module, PCR system having the same, and method of inspecting using the same |
CA2979864A1 (en) * | 2015-03-23 | 2016-09-29 | Wellmetris, Llc | Smartphone enabled urinalysis device, software, and test platform |
US9708647B2 (en) | 2015-03-23 | 2017-07-18 | Insilixa, Inc. | Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays |
WO2016175848A1 (en) * | 2015-04-30 | 2016-11-03 | Hewlett-Packard Development Company, L.P. | Drop ejection based flow sensor calibration |
EP3233498B1 (en) * | 2015-04-30 | 2019-06-26 | Hewlett-Packard Development Company, L.P. | Microfluidic flow sensor |
WO2016188738A1 (en) * | 2015-05-26 | 2016-12-01 | F. Hoffmann-La Roche Ag | Point of care testing poct system |
CN104833747B (en) * | 2015-05-06 | 2016-08-24 | 华东理工大学 | A kind of preparative hplc UV-detector using deep ultraviolet LED light source |
US9855555B2 (en) * | 2015-05-20 | 2018-01-02 | University Of Maryland | Generation and trapping of aqueous droplets in a microfluidic chip with an air continuous phase |
KR20180052122A (en) | 2015-09-04 | 2018-05-17 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Methods and apparatus for clinical analyte collection, extraction, concentration and detection |
US9499861B1 (en) | 2015-09-10 | 2016-11-22 | Insilixa, Inc. | Methods and systems for multiplex quantitative nucleic acid amplification |
US9735305B2 (en) | 2015-09-21 | 2017-08-15 | International Business Machines Corporation | Monolithically integrated fluorescence on-chip sensor |
WO2017059094A2 (en) * | 2015-09-29 | 2017-04-06 | Adi Mashiach | System and method for detection of disease in bodily fluids |
ES2830154T3 (en) * | 2015-10-01 | 2021-06-03 | Dnanudge Ltd | Method, apparatus and system to transfer biological information safely |
JP6989496B2 (en) * | 2015-10-16 | 2022-01-05 | オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーOpko Diagnostics, Llc | Articles and methods for preparing the surface to obtain a patient's sample |
AU2016351730B2 (en) | 2015-11-13 | 2019-07-11 | Novadaq Technologies Inc. | Systems and methods for illumination and imaging of a target |
WO2017087703A1 (en) * | 2015-11-17 | 2017-05-26 | Nanoscopia (Cayman), Inc. | Sample processing and smearing apparatus and methods |
WO2017090427A1 (en) * | 2015-11-26 | 2017-06-01 | 富士フイルム株式会社 | Solution deposition device and solution deposition method |
CN109068979B (en) | 2015-12-21 | 2021-08-20 | 塔索公司 | Devices, systems, and methods for actuation and retraction in fluid collection |
EP3394293B1 (en) * | 2015-12-22 | 2021-05-26 | Canon U.S. Life Sciences, Inc. | Sample-to-answer system for microorganism detection featuring target enrichment, amplification and detection |
US11371075B2 (en) | 2016-01-08 | 2022-06-28 | Advanced Theranostics Inc. | Fully integrated hand-held device to detect specific nucleic acid sequences |
JP1565699S (en) * | 2016-01-12 | 2016-12-19 | ||
US10436773B2 (en) | 2016-01-18 | 2019-10-08 | Jana Care, Inc. | Mobile device based multi-analyte testing analyzer for use in medical diagnostic monitoring and screening |
EP3408654B1 (en) | 2016-01-26 | 2022-08-03 | Stryker European Operations Limited | Fluorescence imaging system and method for fluorescence imaging |
US9643181B1 (en) | 2016-02-08 | 2017-05-09 | International Business Machines Corporation | Integrated microfluidics system |
JP6274233B2 (en) * | 2016-02-23 | 2018-02-07 | 住友ベークライト株式会社 | Clip cartridge system |
WO2017155858A1 (en) | 2016-03-07 | 2017-09-14 | Insilixa, Inc. | Nucleic acid sequence identification using solid-phase cyclic single base extension |
CN105675371B (en) * | 2016-03-29 | 2018-09-25 | 广东江门生物技术开发中心有限公司 | A kind of Multifunctional inspection sample extraction separator |
WO2017181069A1 (en) * | 2016-04-15 | 2017-10-19 | University Of Maryland, College Park | Integrated thermoplastic chip for rapid pcr and hrma |
WO2017185067A1 (en) * | 2016-04-22 | 2017-10-26 | Click Diagnostics, Inc. | Printed circuit board heater for an amplification module |
WO2017197040A1 (en) | 2016-05-11 | 2017-11-16 | Click Diagnostics, Inc. | Devices and methods for nucleic acid extraction |
CN107400628B (en) * | 2016-05-19 | 2021-03-02 | 深圳市华因康高通量生物技术研究院 | Sequencing reaction cell, sequencing reaction clamp and sequencing reaction equipment |
CN106018389A (en) * | 2016-05-20 | 2016-10-12 | 华南师范大学 | Handheld POCT (Point of Care Testing) bipolar electrode-electrochemical light emitting device and application thereof |
CN116083539A (en) | 2016-06-09 | 2023-05-09 | 加利福尼亚大学董事会 | Method for purifying and amplifying nucleic acid |
US10869645B2 (en) | 2016-06-14 | 2020-12-22 | Stryker European Operations Limited | Methods and systems for adaptive imaging for low light signal enhancement in medical visualization |
JP6729027B2 (en) * | 2016-06-15 | 2020-07-22 | ウシオ電機株式会社 | Micro channel chip |
WO2018005710A1 (en) * | 2016-06-29 | 2018-01-04 | Click Diagnostics, Inc. | Devices and methods for the detection of molecules using a flow cell |
CA3029682A1 (en) * | 2016-06-30 | 2018-01-04 | Click Diagnostics, Inc. | Devices and methods for nucleic acid extraction |
CN106026006B (en) * | 2016-06-30 | 2019-07-16 | 成绎半导体技术(上海)有限公司 | A kind of USB Type-C interface female intelligent measurement and protection circuit |
JP6632487B2 (en) * | 2016-07-13 | 2020-01-22 | キヤノン株式会社 | Continuum robot, method of correcting kinematics, and control method of continuum robot |
US11008214B2 (en) * | 2016-07-22 | 2021-05-18 | Hewlett-Packard Development Company, L.P. | Substrate assembly and related methods |
US10889854B2 (en) * | 2016-08-08 | 2021-01-12 | Universiti Brunei Darussalam | System and method for immobilization free electrochemiluminescence DNA detection using a luminophore dye for multi-species detection |
CN106323353B (en) * | 2016-08-12 | 2019-02-12 | Oppo广东移动通信有限公司 | A kind of calibration method of proximity sensor, device and terminal |
WO2018039139A1 (en) | 2016-08-22 | 2018-03-01 | The Regents Of The University Of California | Hydrogel platform for aqueous two-phase concentration of a target to enhance its detection |
JP7146743B2 (en) | 2016-09-23 | 2022-10-04 | アルヴェオ テクノロジーズ インコーポレイテッド | Methods and compositions for detecting analytes |
JP7453664B2 (en) * | 2016-10-11 | 2024-03-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Integrated Molecular Diagnostic System (iMDx) and Methods for Dengue Fever |
US10809176B2 (en) | 2016-10-24 | 2020-10-20 | The Trustees Of The University Of Pennsylvania | Ultra-high throughput detection of fluorescent droplets using time domain encoded optofluidics |
US11067535B2 (en) * | 2016-10-27 | 2021-07-20 | Sharp Kabushiki Kaisha | Fluorescent testing system, dielectrophoresis device, and molecular testing method |
US10650312B2 (en) | 2016-11-16 | 2020-05-12 | Catalog Technologies, Inc. | Nucleic acid-based data storage |
EP3542295A4 (en) | 2016-11-16 | 2020-10-21 | Catalog Technologies, Inc. | Systems for nucleic acid-based data storage |
PL235210B1 (en) * | 2016-12-21 | 2020-06-15 | Genomtec Spolka Akcyjna | Method for detection of genetic material in a biological specimen the device for the execution of this method |
GB201704754D0 (en) | 2017-01-05 | 2017-05-10 | Illumina Inc | Kinetic exclusion amplification of nucleic acid libraries |
US11786899B2 (en) | 2017-02-02 | 2023-10-17 | University Of Maryland, College Park | Trap arrays for robust microfluidic sample digitization |
AU2018215821B2 (en) * | 2017-02-06 | 2023-02-02 | Efa - Engineering For All Ltd. | Portable digital diagnostic device |
EP4242743A3 (en) | 2017-02-10 | 2023-10-18 | Stryker European Operations Limited | Open-field handheld fluorescence imaging systems and methods |
WO2018183211A1 (en) | 2017-03-27 | 2018-10-04 | The Regents Of The University Of California | Semi-quantitative lateral-flow immunoassay for the detection of csf leaks |
CN106895908B (en) * | 2017-03-29 | 2018-10-16 | 中国汽车技术研究中心 | Check device during a kind of high stability laser positioning luminosity probe |
USD849265S1 (en) * | 2017-04-21 | 2019-05-21 | Precision Nanosystems Inc | Microfluidic chip |
US11441701B2 (en) | 2017-07-14 | 2022-09-13 | Hewlett-Packard Development Company, L.P. | Microfluidic valve |
US11590495B2 (en) | 2017-07-28 | 2023-02-28 | Hewlett-Packard Development Company, L.P. | Ionic species interrogation and sensing |
JP2019024453A (en) * | 2017-08-02 | 2019-02-21 | 株式会社リコー | Rna concentration quantitative method, rna concentration quantitative device, and rna concentration quantitative apparatus |
CN208016344U (en) * | 2017-08-30 | 2018-10-30 | 苏州宝时得电动工具有限公司 | Automatic running device |
WO2019066804A1 (en) * | 2017-09-27 | 2019-04-04 | Hewlett-Packard Development Company, L.P. | Reuse of dispensers during alignment procedures |
US11402400B2 (en) | 2017-10-13 | 2022-08-02 | Hewlett-Packard Development Company, L.P. | Partition liquid into samples |
WO2019094784A1 (en) * | 2017-11-09 | 2019-05-16 | Click Diagnostics, Inc. | Portable molecular diagnostic device and methods for the detection of target viruses |
US11383236B2 (en) * | 2017-11-10 | 2022-07-12 | Christopher Walker | Polymerase chain reaction using a microfluidic chip fabricated with printed circuit board techniques |
CN107967380B (en) * | 2017-11-15 | 2021-09-07 | 晶晨半导体(上海)股份有限公司 | Layout design method of printed circuit board |
US10854251B2 (en) * | 2017-12-15 | 2020-12-01 | Google Llc | Physical identifiers for authenticating an identity of a semiconductor component |
CN108221844B (en) * | 2017-12-31 | 2023-01-10 | 浙江大学 | Dynamic response test device for near-sea foundation pit under effect of simulated tidal load |
WO2019148013A2 (en) * | 2018-01-29 | 2019-08-01 | The Texas A&M University System | Integrated modular on-chip droplet microfluidic screening platform |
CN108195728A (en) * | 2018-02-01 | 2018-06-22 | 山东诺方电子科技有限公司 | A kind of control system and its control method based on multinuclear particulate matter sensors technology |
CA3092684A1 (en) * | 2018-03-02 | 2019-09-06 | Teleflex Medical Incorporated | Infection detection systems and methods |
JP7364604B2 (en) | 2018-03-16 | 2023-10-18 | カタログ テクノロジーズ, インコーポレイテッド | Chemical methods for nucleic acid-based data storage |
US20200193301A1 (en) | 2018-05-16 | 2020-06-18 | Catalog Technologies, Inc. | Compositions and methods for nucleic acid-based data storage |
EP3758844B1 (en) * | 2018-06-11 | 2023-03-29 | Hewlett-Packard Development Company, L.P. | Microfluidic valves |
US10307755B1 (en) * | 2018-07-19 | 2019-06-04 | Bioceryx Inc. | Apparatuses and methods for sample-specific self-configuration |
US10883914B2 (en) | 2018-08-07 | 2021-01-05 | Blaire Biomedical, LLC | Flow cytometry systems including an optical analysis box for interfacing with an imaging device |
CN110819522B (en) * | 2018-08-13 | 2023-09-22 | 上海新微技术研发中心有限公司 | Digital PCR system and digital PCR liquid drop forming method |
CA3112327A1 (en) * | 2018-09-14 | 2020-03-19 | William Marsh Rice University | Apparatus and methods for multiplexed amplification and detection of dna using convectional heating and label-free microarray |
CN111657965B (en) | 2018-09-14 | 2024-03-22 | 塔索公司 | Body fluid collection device and related methods |
US11486814B2 (en) * | 2018-10-01 | 2022-11-01 | Hewlett-Packard Development Company, L.P. | Particle sorting using microfluidic ejectors |
EP3861316B1 (en) * | 2018-10-01 | 2023-08-30 | Hewlett-Packard Development Company, L.P. | Batch particle sorting |
WO2020072030A1 (en) * | 2018-10-01 | 2020-04-09 | Hewlett-Packard Development Company, L.P. | Microscopy systems |
JP6795019B2 (en) * | 2018-10-04 | 2020-12-02 | カシオ計算機株式会社 | Case and watch |
US11946902B2 (en) * | 2018-10-11 | 2024-04-02 | Hewlett-Packard Development Company, L.P. | Dielectrophoresis separator cross-over frequency measurement systems |
US10760936B2 (en) * | 2018-11-02 | 2020-09-01 | Nanya Technology Corporation | Semiconductor device and method of sensing a change in a level of a liquid therein |
FR3088534A1 (en) * | 2018-11-16 | 2020-05-22 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | DEVICE FOR PREPARING A CALIBRATED VOLUME OF BLOOD PLASMA |
US20210354126A1 (en) * | 2018-12-07 | 2021-11-18 | Ultima Genomics, Inc. | Implementing barriers for controlled environments during sample processing and detection |
WO2020122922A1 (en) * | 2018-12-13 | 2020-06-18 | Hewlett-Packard Development Company, L.P. | Multiplex nucleic acid detection |
CN113508179A (en) * | 2018-12-20 | 2021-10-15 | 阿尔韦奥科技公司 | Impedance-based handheld diagnostic test system for detecting analytes |
WO2020149926A1 (en) * | 2019-01-17 | 2020-07-23 | Siemens Healthcare Diagnostics Inc. | Flow cell using peltier module as prime mover for polymerase chain reaction |
US11815430B2 (en) | 2019-02-22 | 2023-11-14 | Hewlett-Packard Development Company, L.P. | Nucleic acid detection |
EP3937780A4 (en) | 2019-03-14 | 2022-12-07 | InSilixa, Inc. | Methods and systems for time-gated fluorescent-based detection |
CN110180811A (en) * | 2019-05-07 | 2019-08-30 | 王海山 | A kind of chip detecting equipment that the clarity with dehumidification function is high |
JP2022531790A (en) | 2019-05-09 | 2022-07-11 | カタログ テクノロジーズ, インコーポレイテッド | Data structures and behaviors for search, calculation, and indexing in DNA-based data storage |
CN113557432A (en) * | 2019-06-04 | 2021-10-26 | 惠普发展公司,有限责任合伙企业 | Integrated microfluidic ejector chip |
EP3941624A4 (en) * | 2019-07-24 | 2022-04-06 | Hewlett-Packard Development Company, L.P. | Device with microfluidic channels |
EP3769840A1 (en) * | 2019-07-26 | 2021-01-27 | LEX Diagnostics Ltd | Systems and modules for nucleic acid amplification testing |
GB201911386D0 (en) * | 2019-08-09 | 2019-09-25 | Stratec Se | Calibration tool for planar chip applications |
CN110333272A (en) * | 2019-08-21 | 2019-10-15 | 业成科技(成都)有限公司 | Humidity sensor and its manufacturing method |
WO2021046506A1 (en) * | 2019-09-06 | 2021-03-11 | Teleflex Medical Incorporated | Infection detection systems and methods including intermediate filtering and metering |
WO2021046504A1 (en) * | 2019-09-06 | 2021-03-11 | Teleflex Medical Incorporated | Infection detection systems and methods including a sample processor having integrated sample filter and meter |
CA3157359A1 (en) | 2019-10-10 | 2021-04-15 | 1859, Inc. | Methods and systems for microfluidic screening |
WO2021072398A1 (en) | 2019-10-11 | 2021-04-15 | Catalog Technologies, Inc. | Nucleic acid security and authentication |
USD954573S1 (en) * | 2019-11-06 | 2022-06-14 | Fluxergy, Llc | Test card |
US11352675B2 (en) | 2020-01-03 | 2022-06-07 | Visby Medical, Inc. | Devices and methods for antibiotic susceptability testing |
US11136543B1 (en) | 2020-02-11 | 2021-10-05 | Edward R. Flynn | Magnetic cell incubation device |
US11536732B2 (en) | 2020-03-13 | 2022-12-27 | Jana Care, Inc. | Devices, systems, and methods for measuring biomarkers in biological fluids |
KR20210128632A (en) * | 2020-04-17 | 2021-10-27 | 커넥타젠(주) | Apparatus for Detecting Potable Isothermal Amplification |
TWI749529B (en) * | 2020-04-20 | 2021-12-11 | 關鍵禾芯科技股份有限公司 | Ribonucleic acid test panel and ribonucleic acid test device |
CN111534430B (en) * | 2020-04-28 | 2023-12-29 | 港岫科技(上海)有限公司 | Ribonucleic acid detection panel and ribonucleic acid detection device |
JP2023524117A (en) * | 2020-04-30 | 2023-06-08 | スタブ ヴィーダ - インヴェスティガサォン エ セルヴィソス エム シエンシアス バイオロジカス エルディーエー | Method and portable device for detecting nucleic acid sequences in suspected coronavirus samples |
US11306353B2 (en) | 2020-05-11 | 2022-04-19 | Catalog Technologies, Inc. | Programs and functions in DNA-based data storage |
US20210354127A1 (en) * | 2020-05-13 | 2021-11-18 | Keycore Technology Corp. | Ribonucleic acid test panel and ribonucleic acid test device |
US11654436B2 (en) | 2020-08-11 | 2023-05-23 | Seagate Technology Llc | Microwave heating device for lab on a chip |
TWI781660B (en) * | 2020-09-30 | 2022-10-21 | 富佳生技股份有限公司 | Nucleic acid detection disc and nucleic acid detection device |
JP2022058244A (en) * | 2020-09-30 | 2022-04-11 | 富佳生技股▲ふん▼有限公司 | Nucleic acid detection box and nucleic acid detection device |
CN112275335B (en) * | 2020-10-16 | 2022-06-28 | 吉林大学 | Self-suction valve separation type chip, preparation method and detection method of Listeria monocytogenes |
CN112255397B (en) * | 2020-10-16 | 2022-06-07 | 吉林大学 | Kit for detecting Listeria monocytogenes, Vibrio parahaemolyticus and Salmonella typhimurium and preparation method thereof |
GB2600103B (en) * | 2020-10-19 | 2024-01-10 | Quantumdx Group Ltd | Integrated thermal conditioning and PCR in a molecular POC diagnostic system |
EP3992613A1 (en) * | 2020-10-28 | 2022-05-04 | Koninklijke Philips N.V. | Sputum analysis method and system |
WO2022099087A1 (en) * | 2020-11-05 | 2022-05-12 | President And Fellows Of Harvard College | An airborne pathogen diagnostic platform |
CN112553054A (en) * | 2020-12-10 | 2021-03-26 | 上海艾众生物科技有限公司 | Cell separation apparatus for bioreactor |
TR202021833A2 (en) * | 2020-12-26 | 2021-10-21 | Bilkent Holding A S | DISPOSABLE PATHOGEN DETECTION CHIP AND A RELATED PRODUCTION METHOD |
CN112858085B (en) * | 2021-01-19 | 2021-11-02 | 竹简云(天津)生物科技有限公司 | Food drug solubility detection and analysis device |
WO2022177558A1 (en) * | 2021-02-17 | 2022-08-25 | Hewlett-Packard Development Company, L.P. | Microfluidic nucleic acid amplification |
US11891671B1 (en) * | 2021-03-24 | 2024-02-06 | A9.Com, Inc. | Virus detection system |
KR102423154B1 (en) * | 2021-04-13 | 2022-07-20 | 주식회사 시큐어메드 | Conductive plastic diagnostic device and manufacturing method thereof |
WO2022232056A1 (en) * | 2021-04-26 | 2022-11-03 | Chan Zuckerberg Biohub, Inc. | Testing devices |
CN113340332B (en) * | 2021-05-27 | 2022-07-12 | 西安交通大学 | Photoelectric sensor calibration device and method |
US11630428B2 (en) * | 2021-08-06 | 2023-04-18 | Trimble Inc. | Real-time analysis of vibration samples for operating environment classification and anomaly detection |
KR20230049323A (en) * | 2021-10-06 | 2023-04-13 | 경희대학교 산학협력단 | Diagnostic microfluidic chip, system and IoT-based genetic analysis system including the same |
TWI797820B (en) * | 2021-11-08 | 2023-04-01 | 財團法人工業技術研究院 | Pcr rapid detection device and method thereof |
CN114308162B (en) * | 2021-12-31 | 2023-05-05 | 北京百奥纳芯生物科技有限公司 | Device for assisting combination and fixation of gene chip probe and substrate |
WO2023152599A1 (en) | 2022-02-08 | 2023-08-17 | Universita' Degli Studi Magna Graecia Di Catanzaro | Platform for screening static and dynamic cell culture supports |
GB202204431D0 (en) * | 2022-03-29 | 2022-05-11 | Enzyre Bv | A sensor for testing biomakers in nano litre volumes of plasma based on luminescence |
WO2024006245A1 (en) * | 2022-07-01 | 2024-01-04 | Owl biomedical, Inc. | Illumination and imaging system in tdi-based continuous line scanning microscopy |
GB2621159A (en) * | 2022-08-04 | 2024-02-07 | Wobble Genomics Ltd | Methods of preparing processed nucleic acid samples and detecting nucleic acids and devices therefor |
CN116188510B (en) * | 2023-04-25 | 2023-07-07 | 安徽皖欣环境科技有限公司 | Enterprise emission data acquisition system based on multiple sensors |
CN116854551B (en) * | 2023-06-29 | 2024-03-29 | 武汉大学 | Solid working medium for improving laser micro-propulsion performance and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055198A2 (en) * | 2002-12-12 | 2004-07-01 | Chiron Corporation | Device and method for in-line blood testing using biochips |
WO2004065010A2 (en) * | 2003-01-21 | 2004-08-05 | Micronics Inc. | Method and system for microfluidic manipulation, amplification and analysis of fluids, for example, bacteria assays and antiglobulin testing |
US20040265182A1 (en) * | 2003-06-24 | 2004-12-30 | Chien-Hua Chen | Fluidic MEMS device |
US20090325276A1 (en) * | 2006-09-27 | 2009-12-31 | Micronics, Inc. | Integrated microfluidic assay devices and methods |
Family Cites Families (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3283560A (en) * | 1962-12-24 | 1966-11-08 | Du Pont | Differential thermal analysis apparatus |
DE3110879A1 (en) * | 1981-03-20 | 1982-09-30 | Philips Patentverwaltung Gmbh, 2000 Hamburg | ELECTROCHEMOLUMINESCENT CELL |
US4407290A (en) * | 1981-04-01 | 1983-10-04 | Biox Technology, Inc. | Blood constituent measuring device and method |
US5187990A (en) * | 1984-02-16 | 1993-02-23 | Rainin Instrument Co., Inc. | Method for dispensing liquids with a pipette with compensation for air pressure and surface tension |
US5075447A (en) * | 1984-09-17 | 1991-12-24 | Hoffmann-La Roche Inc. | Ruthenium complexes useful as carriers for immunologically active materials |
US4713347A (en) * | 1985-01-14 | 1987-12-15 | Sensor Diagnostics, Inc. | Measurement of ligand/anti-ligand interactions using bulk conductance |
US5038852A (en) * | 1986-02-25 | 1991-08-13 | Cetus Corporation | Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps |
US4929426A (en) * | 1987-11-02 | 1990-05-29 | Biologix, Inc. | Portable blood chemistry measuring apparatus |
DE4113033A1 (en) * | 1991-04-20 | 1992-10-22 | Fraunhofer Ges Forschung | INTEGRATED CONDUCTIVITY MEASURING DEVICE |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5304487A (en) * | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US5726026A (en) * | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US6315953B1 (en) * | 1993-11-01 | 2001-11-13 | Nanogen, Inc. | Devices for molecular biological analysis and diagnostics including waveguides |
US5965452A (en) * | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6071699A (en) * | 1996-06-07 | 2000-06-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US6015880A (en) * | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5700695A (en) * | 1994-06-30 | 1997-12-23 | Zia Yassinzadeh | Sample collection and manipulation method |
US5610635A (en) * | 1994-08-09 | 1997-03-11 | Encad, Inc. | Printer ink cartridge with memory storage capacity |
US6635226B1 (en) * | 1994-10-19 | 2003-10-21 | Agilent Technologies, Inc. | Microanalytical device and use thereof for conducting chemical processes |
JPH08122247A (en) * | 1994-10-24 | 1996-05-17 | Hitachi Ltd | Analyzer |
US5527710A (en) * | 1994-12-02 | 1996-06-18 | Igen, Inc. | Rate measurements of biomolecular reactions using electrochemiluminescence |
US6673533B1 (en) * | 1995-03-10 | 2004-01-06 | Meso Scale Technologies, Llc. | Multi-array multi-specific electrochemiluminescence testing |
US6207369B1 (en) * | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5633724A (en) * | 1995-08-29 | 1997-05-27 | Hewlett-Packard Company | Evanescent scanning of biochemical array |
US6130098A (en) * | 1995-09-15 | 2000-10-10 | The Regents Of The University Of Michigan | Moving microdroplets |
US6114122A (en) * | 1996-03-26 | 2000-09-05 | Affymetrix, Inc. | Fluidics station with a mounting system and method of using |
US5707589A (en) * | 1996-04-12 | 1998-01-13 | Merlin Instrument Company | Funnel-shaped sample-vial septum with membrane covered diffusion-barrier section |
US5798502A (en) * | 1996-05-10 | 1998-08-25 | Oak Frequency | Temperature controlled substrate for VLSI construction having minimal parasitic feedback |
FR2750999B1 (en) * | 1996-07-10 | 1998-11-20 | Appligene Oncor | THERMOSTABLE DNA POLYMERASE OF ARCHAEBACTERIA OF THE GENUS PYROCOCCUS SP |
US6136212A (en) * | 1996-08-12 | 2000-10-24 | The Regents Of The University Of Michigan | Polymer-based micromachining for microfluidic devices |
WO1998022625A1 (en) * | 1996-11-20 | 1998-05-28 | The Regents Of The University Of Michigan | Microfabricated isothermal nucleic acid amplification devices and methods |
US6027459A (en) * | 1996-12-06 | 2000-02-22 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US6529446B1 (en) * | 1996-12-20 | 2003-03-04 | Telaric L.L.C. | Interactive medication container |
EP0970101A2 (en) * | 1997-03-20 | 2000-01-12 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
US7314711B2 (en) * | 1997-05-23 | 2008-01-01 | Bioveris Corporation | Assays employing electrochemiluminescent labels and electrochemiluminescence quenchers |
US7160687B1 (en) * | 1997-05-29 | 2007-01-09 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US7328975B2 (en) * | 1997-07-15 | 2008-02-12 | Silverbrook Research Pty Ltd | Injet printhead with thermal bend arm exposed to ink flow |
AUPO793797A0 (en) * | 1997-07-15 | 1997-08-07 | Silverbrook Research Pty Ltd | A method of manufacture of an image creation apparatus (IJM03) |
US6440725B1 (en) * | 1997-12-24 | 2002-08-27 | Cepheid | Integrated fluid manipulation cartridge |
US5965410A (en) * | 1997-09-02 | 1999-10-12 | Caliper Technologies Corp. | Electrical current for controlling fluid parameters in microchannels |
US6287776B1 (en) * | 1998-02-02 | 2001-09-11 | Signature Bioscience, Inc. | Method for detecting and classifying nucleic acid hybridization |
US6184040B1 (en) * | 1998-02-12 | 2001-02-06 | Polaroid Corporation | Diagnostic assay system and method |
US6200531B1 (en) * | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
US20050244954A1 (en) * | 1998-06-23 | 2005-11-03 | Blackburn Gary F | Binding acceleration techniques for the detection of analytes |
US6761816B1 (en) * | 1998-06-23 | 2004-07-13 | Clinical Micro Systems, Inc. | Printed circuit boards with monolayers and capture ligands |
US6494614B1 (en) * | 1998-07-27 | 2002-12-17 | Battelle Memorial Institute | Laminated microchannel devices, mixing units and method of making same |
US5936730A (en) * | 1998-09-08 | 1999-08-10 | Motorola, Inc. | Bio-molecule analyzer with detector array and filter device |
US6116717A (en) * | 1998-09-15 | 2000-09-12 | Lexmark International, Inc. | Method and apparatus for customized control of a print cartridge |
US6203683B1 (en) * | 1998-11-09 | 2001-03-20 | Princeton University | Electrodynamically focused thermal cycling device |
US6638760B1 (en) * | 1998-11-25 | 2003-10-28 | Pe Corporation (Ny) | Method and apparatus for flow-through hybridization |
US20040053290A1 (en) * | 2000-01-11 | 2004-03-18 | Terbrueggen Robert Henry | Devices and methods for biochip multiplexing |
US20020177135A1 (en) * | 1999-07-27 | 2002-11-28 | Doung Hau H. | Devices and methods for biochip multiplexing |
US6878540B2 (en) * | 1999-06-25 | 2005-04-12 | Cepheid | Device for lysing cells, spores, or microorganisms |
US6453431B1 (en) * | 1999-07-01 | 2002-09-17 | International Business Machines Corporation | System technique for detecting soft errors in statically coupled CMOS logic |
US7078167B2 (en) * | 1999-09-17 | 2006-07-18 | Agilent Technologies, Inc. | Arrays having background features and methods for using the same |
US6699384B1 (en) * | 1999-09-21 | 2004-03-02 | Battelle Memorial Institute | Compact electrochemical sensor system and method for field testing for metals in saliva or other fluids |
WO2001026813A2 (en) * | 1999-10-08 | 2001-04-19 | Micronics, Inc. | Microfluidics without electrically of mechanically operated pumps |
US6576460B1 (en) * | 1999-10-28 | 2003-06-10 | Cornell Research Foundation, Inc. | Filtration-detection device and method of use |
US6553844B2 (en) * | 1999-10-29 | 2003-04-29 | Metasensors, Inc. | Property-independent volumetric flowmeter and sonic velocimeter |
US6867851B2 (en) * | 1999-11-04 | 2005-03-15 | Regents Of The University Of Minnesota | Scanning of biological samples |
US6875619B2 (en) * | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
AU2788101A (en) * | 2000-01-11 | 2001-07-24 | Maxygen, Inc. | Integrated systems and methods for diversity generation and screening |
AU2001238011A1 (en) | 2000-01-31 | 2001-08-07 | Board Of Regents, The University Of Texas System | System for transferring fluid samples through a sensor array |
JP3871846B2 (en) * | 2000-03-10 | 2007-01-24 | 日立ソフトウエアエンジニアリング株式会社 | Hybridization reaction detection method and detection apparatus |
US7867763B2 (en) * | 2004-01-25 | 2011-01-11 | Fluidigm Corporation | Integrated chip carriers with thermocycler interfaces and methods of using the same |
CH695166A5 (en) * | 2000-04-25 | 2005-12-30 | Sensirion Ag | Method and apparatus for measuring the flow of a liquid. |
EP1297179B1 (en) * | 2000-05-12 | 2008-09-24 | Caliper Life Sciences, Inc. | Detection of nucleic acid hybridization by fluorescence polarization |
CA2408574A1 (en) * | 2000-05-24 | 2001-11-29 | Micronics, Inc. | Microfluidic concentration gradient loop |
US8071051B2 (en) * | 2004-05-14 | 2011-12-06 | Honeywell International Inc. | Portable sample analyzer cartridge |
US7351376B1 (en) * | 2000-06-05 | 2008-04-01 | California Institute Of Technology | Integrated active flux microfluidic devices and methods |
AU2001255518A1 (en) * | 2000-06-07 | 2001-12-17 | Baylor College Of Medicine | Compositions and methods for array-based nucleic acid hybridization |
CA2311622A1 (en) * | 2000-06-15 | 2001-12-15 | Moussa Hoummady | Sub-nanoliter liquid drop dispensing system and method therefor |
KR100481305B1 (en) * | 2000-07-21 | 2005-04-07 | 박용덕 | Apparatus for controling a door using a mobile communications system |
FR2812306B1 (en) * | 2000-07-28 | 2005-01-14 | Gabriel Festoc | POLYMERSIS CHAIN AMPLIFICATION SYSTEM OF TARGET NUCLEIC SEQUENCES |
NL1016298C2 (en) * | 2000-09-29 | 2002-04-03 | Sgt Exploitatie Bv | Vial, method for using a vial for analysis on a sample, as well as a system for performing the method according to the invention using a vial according to the invention. |
AU2002213043A1 (en) * | 2000-10-06 | 2002-04-15 | Protasis Corporation | Fluid separation conduit cartridge |
US6827095B2 (en) * | 2000-10-12 | 2004-12-07 | Nanostream, Inc. | Modular microfluidic systems |
US7374881B2 (en) * | 2000-10-31 | 2008-05-20 | Hitachi Chemical Research Center, Inc. | Method for collecting and using nuclear mRNA |
AU2002230524A1 (en) * | 2000-11-16 | 2002-05-27 | California Institute Of Technology | Apparatus and methods for conducting assays and high throughput screening |
US20020094528A1 (en) * | 2000-11-29 | 2002-07-18 | Salafsky Joshua S. | Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations |
US6382254B1 (en) * | 2000-12-12 | 2002-05-07 | Eastman Kodak Company | Microfluidic valve and method for controlling the flow of a liquid |
US7157232B2 (en) * | 2000-12-13 | 2007-01-02 | The Regents Of The University Of California | Method to detect the end-point for PCR DNA amplification using an ionically labeled probe and measuring impedance change |
WO2002061392A2 (en) * | 2001-01-31 | 2002-08-08 | Board Of Regents, The University Of Texas System | Method and apparatus for the confinement of materials in a micromachined chemical sensor array |
US20020160363A1 (en) * | 2001-01-31 | 2002-10-31 | Mcdevitt John T. | Magnetic-based placement and retention of sensor elements in a sensor array |
US6386219B1 (en) * | 2001-02-01 | 2002-05-14 | Agilent Technologies, Inc. | Fluid handling system and method of manufacture |
EP1360479A4 (en) * | 2001-02-15 | 2005-03-23 | Caliper Life Sciences Inc | Methods and systems for enhanced delivery of electrical currents to fluidic systems |
US20020165675A1 (en) * | 2001-03-03 | 2002-11-07 | Golovlev Valeri V. | Method and microelectronic device for multi-site molecule detection |
WO2002074372A2 (en) * | 2001-03-15 | 2002-09-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nebulizer having cooling chamber |
DE10114540A1 (en) * | 2001-03-21 | 2002-10-02 | Francotyp Postalia Ag | Consumption module for an electronic device |
US7323140B2 (en) * | 2001-03-28 | 2008-01-29 | Handylab, Inc. | Moving microdroplets in a microfluidic device |
US20020142318A1 (en) * | 2001-03-30 | 2002-10-03 | Cattell Herbert F. | Chemical array reading |
GB0110501D0 (en) * | 2001-04-30 | 2001-06-20 | Secr Defence Brit | Amplification process |
WO2002089972A1 (en) * | 2001-05-03 | 2002-11-14 | Commissariat A L'energie Atomique | Microfluidic device for analyzing nucleic acids and/or proteins, methods of preparation and uses thereof |
US6573734B2 (en) * | 2001-05-08 | 2003-06-03 | The Board Of Trustees Of The University Of Illinois | Integrated thin film liquid conductivity sensor |
US20050009101A1 (en) * | 2001-05-17 | 2005-01-13 | Motorola, Inc. | Microfluidic devices comprising biochannels |
US7214300B2 (en) * | 2001-06-04 | 2007-05-08 | Epocal Inc. | Integrated electrokinetic devices and methods of manufacture |
WO2002099410A1 (en) * | 2001-06-04 | 2002-12-12 | Aclara Biosciences, Inc. | Sensor device and method for indicating oxygen consumption |
US20030015425A1 (en) * | 2001-06-20 | 2003-01-23 | Coventor Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US20030186222A1 (en) | 2001-06-27 | 2003-10-02 | Paul John H. | Rapid detection of enteroviruses in environmental samples by NASBA |
US20030032172A1 (en) * | 2001-07-06 | 2003-02-13 | The Regents Of The University Of California | Automated nucleic acid assay system |
FR2827199B1 (en) * | 2001-07-10 | 2004-07-09 | Centre Nat Rech Scient | PROCESS AND MACHINE FOR THE EX SITU MANUFACTURE OF LOW AND MEDIUM INTEGRATION BIOPE NETWORKS |
DE10133844B4 (en) * | 2001-07-18 | 2006-08-17 | Micronas Gmbh | Method and device for detecting analytes |
EP1439910A2 (en) * | 2001-07-26 | 2004-07-28 | Motorola, Inc. | System and methods for mixing within a microfluidic device |
US6726820B1 (en) * | 2001-09-19 | 2004-04-27 | Applera Corporation | Method of separating biomolecule-containing samples with a microdevice with integrated memory |
US6995841B2 (en) * | 2001-08-28 | 2006-02-07 | Rice University | Pulsed-multiline excitation for color-blind fluorescence detection |
US7075162B2 (en) * | 2001-08-30 | 2006-07-11 | Fluidigm Corporation | Electrostatic/electrostrictive actuation of elastomer structures using compliant electrodes |
DE10145701A1 (en) * | 2001-09-17 | 2003-04-10 | Infineon Technologies Ag | Fluorescence biosensor chip and fluorescence biosensor chip arrangement |
US6969843B1 (en) * | 2001-10-19 | 2005-11-29 | Beach James M | Light standard for microscopy |
US6902900B2 (en) | 2001-10-19 | 2005-06-07 | Prolico, Llc | Nucleic acid probes and methods to detect and/or quantify nucleic acid analytes |
US20030175947A1 (en) * | 2001-11-05 | 2003-09-18 | Liu Robin Hui | Enhanced mixing in microfluidic devices |
US6622746B2 (en) * | 2001-12-12 | 2003-09-23 | Eastman Kodak Company | Microfluidic system for controlled fluid mixing and delivery |
US20030148391A1 (en) * | 2002-01-24 | 2003-08-07 | Salafsky Joshua S. | Method using a nonlinear optical technique for detection of interactions involving a conformational change |
US8114349B2 (en) * | 2002-01-28 | 2012-02-14 | Qiagen Sciences, Llc | Bio-analysis cartridge tracking and protection mechanism |
US7318902B2 (en) * | 2002-02-04 | 2008-01-15 | Colorado School Of Mines | Laminar flow-based separations of colloidal and cellular particles |
US20060164533A1 (en) * | 2002-08-27 | 2006-07-27 | E-Phocus, Inc | Electronic image sensor |
US20040109793A1 (en) * | 2002-02-07 | 2004-06-10 | Mcneely Michael R | Three-dimensional microfluidics incorporating passive fluid control structures |
US7195986B1 (en) * | 2002-03-08 | 2007-03-27 | Caliper Life Sciences, Inc. | Microfluidic device with controlled substrate conductivity |
JP3722367B2 (en) * | 2002-03-19 | 2005-11-30 | ソニー株式会社 | Manufacturing method of solid-state imaging device |
US6639313B1 (en) | 2002-03-20 | 2003-10-28 | Analog Devices, Inc. | Hermetic seals for large optical packages and the like |
US7312085B2 (en) * | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US7156484B2 (en) * | 2002-04-12 | 2007-01-02 | Silverbrook Research Pty Ltd | Inkjet printhead with CMOS drive circuitry close to ink supply passage |
US7157274B2 (en) * | 2002-06-24 | 2007-01-02 | Cytonome, Inc. | Method and apparatus for sorting particles |
US6877528B2 (en) * | 2002-04-17 | 2005-04-12 | Cytonome, Inc. | Microfluidic system including a bubble valve for regulating fluid flow through a microchannel |
US20050033525A1 (en) * | 2002-05-21 | 2005-02-10 | Corson John F. | Method and system for computing and applying a user-defined, global, multi-channel background correction to a feature-based data set obtained from reading a microarray |
US7229838B2 (en) * | 2002-07-08 | 2007-06-12 | Innovative Micro Technology | MEMS actuator and method of manufacture for MEMS particle sorting device |
US20040018635A1 (en) * | 2002-07-26 | 2004-01-29 | Peck Bill J. | Fabricating arrays with drop velocity control |
US7214348B2 (en) * | 2002-07-26 | 2007-05-08 | Applera Corporation | Microfluidic size-exclusion devices, systems, and methods |
US6777662B2 (en) * | 2002-07-30 | 2004-08-17 | Freescale Semiconductor, Inc. | System, circuit and method providing a dynamic range pixel cell with blooming protection |
US7118676B2 (en) * | 2003-09-04 | 2006-10-10 | Arryx, Inc. | Multiple laminar flow-based particle and cellular separation with laser steering |
US20040197845A1 (en) * | 2002-08-30 | 2004-10-07 | Arjang Hassibi | Methods and apparatus for pathogen detection, identification and/or quantification |
EP1545740A2 (en) * | 2002-09-07 | 2005-06-29 | Arizona Board of Regents | Integrated apparatus and methods for treating liquids |
US7595883B1 (en) * | 2002-09-16 | 2009-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Biological analysis arrangement and approach therefor |
ITTO20020808A1 (en) * | 2002-09-17 | 2004-03-18 | St Microelectronics Srl | INTEGRATED DNA ANALYSIS DEVICE. |
AU2003267255A1 (en) * | 2002-09-20 | 2004-04-08 | Novus Molecular, Inc. | Methods and devices for active bioassay |
WO2004029217A2 (en) * | 2002-09-26 | 2004-04-08 | Vanderbilt University | Method for screening molecular interactions |
US7635762B2 (en) * | 2002-10-21 | 2009-12-22 | Biosearch Technologies, Inc. | Luminescent metal ion complexes |
TWI324684B (en) * | 2002-10-25 | 2010-05-11 | Nat Univ Tsing Hua | Micro-array system for micro amount reaction |
US20040086872A1 (en) * | 2002-10-31 | 2004-05-06 | Childers Winthrop D. | Microfluidic system for analysis of nucleic acids |
US7932098B2 (en) * | 2002-10-31 | 2011-04-26 | Hewlett-Packard Development Company, L.P. | Microfluidic system utilizing thin-film layers to route fluid |
US7264723B2 (en) * | 2002-11-01 | 2007-09-04 | Sandia Corporation | Dialysis on microchips using thin porous polymer membranes |
EP1419818B1 (en) * | 2002-11-14 | 2013-10-30 | Boehringer Ingelheim microParts GmbH | Device for sequential transport of liquids by capillary forces |
US6755509B2 (en) * | 2002-11-23 | 2004-06-29 | Silverbrook Research Pty Ltd | Thermal ink jet printhead with suspended beam heater |
JP3624950B2 (en) * | 2002-11-26 | 2005-03-02 | セイコーエプソン株式会社 | ink cartridge |
US20040115794A1 (en) | 2002-12-12 | 2004-06-17 | Affymetrix, Inc. | Methods for detecting transcriptional factor binding sites |
US20050042639A1 (en) * | 2002-12-20 | 2005-02-24 | Caliper Life Sciences, Inc. | Single molecule amplification and detection of DNA length |
CA2772050C (en) * | 2002-12-26 | 2016-09-06 | Meso Scale Technologies, Llc. | Assay cartridges and methods of using the same |
US20040188648A1 (en) * | 2003-01-15 | 2004-09-30 | California Institute Of Technology | Integrated surface-machined micro flow controller method and apparatus |
US20060210984A1 (en) * | 2003-03-03 | 2006-09-21 | Jeremy Lambert | Use of nucleic acid mimics for internal reference and calibration in a flow cell microarray binding assay |
SE0300823D0 (en) * | 2003-03-23 | 2003-03-23 | Gyros Ab | Preloaded Microscale Devices |
US6986649B2 (en) * | 2003-04-09 | 2006-01-17 | Motorola, Inc. | Micropump with integrated pressure sensor |
US7435381B2 (en) * | 2003-05-29 | 2008-10-14 | Siemens Healthcare Diagnostics Inc. | Packaging of microfluidic devices |
WO2005003395A1 (en) * | 2003-07-02 | 2005-01-13 | Caliper Life Sciences, Inc. | Method for amplifying and detecting nucleic acids in microfluidic devices under continuous and non-continuous flow conditions |
US20050019951A1 (en) * | 2003-07-14 | 2005-01-27 | Gjerde Douglas T. | Method and device for extracting an analyte |
GB0321158D0 (en) * | 2003-09-10 | 2003-10-08 | Central Research Lab Ltd | Apparatus and method for handling cells,embryos or oocytes |
US8277760B2 (en) * | 2003-09-19 | 2012-10-02 | Applied Biosystems, Llc | High density plate filler |
WO2005028629A2 (en) * | 2003-09-19 | 2005-03-31 | Applera Corporation | Whole genome expression analysis system |
US7811443B2 (en) * | 2003-10-16 | 2010-10-12 | The Regents Of The University Of California | Microfluidic dynamic vapor control system |
NL1024578C2 (en) * | 2003-10-21 | 2005-04-22 | Univ Delft Tech | Device for carrying out a reaction. |
US7444005B2 (en) * | 2003-11-04 | 2008-10-28 | Becton, Dickinson And Company | Apparatus and method for using optical mouse engine to determine speed, direction, position of scanned device and to obtain quantitative or qualitative data from same |
WO2005047545A2 (en) * | 2003-11-04 | 2005-05-26 | Applera Corporation | Microarray controls |
US20050095602A1 (en) * | 2003-11-04 | 2005-05-05 | West Jason A. | Microfluidic integrated microarrays for biological detection |
US7695952B2 (en) * | 2003-11-07 | 2010-04-13 | Nanosphere, Inc. | Disposable sample processing module for detecting nucleic acids |
US20050208539A1 (en) * | 2003-12-31 | 2005-09-22 | Vann Charles S | Quantitative amplification and detection of small numbers of target polynucleotides |
US7526944B2 (en) * | 2004-01-07 | 2009-05-05 | Ashok Sabata | Remote monitoring of pipelines using wireless sensor network |
US7448734B2 (en) * | 2004-01-21 | 2008-11-11 | Silverbrook Research Pty Ltd | Inkjet printer cartridge with pagewidth printhead |
US20050176135A1 (en) * | 2004-02-06 | 2005-08-11 | Brian Jones | Cassette for isolation, amplification and identification of DNA or protein and method of use |
US20060094046A1 (en) * | 2004-02-11 | 2006-05-04 | Arie Abo | Compositions and methods relating to angiogenesis and tumorigenesis |
US7461560B2 (en) * | 2005-03-28 | 2008-12-09 | Microstrain, Inc. | Strain gauge with moisture barrier and self-testing circuit |
US7796266B2 (en) * | 2004-04-30 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Optical detection system using electromagnetic radiation to detect presence or quantity of analyte |
US9101302B2 (en) * | 2004-05-03 | 2015-08-11 | Abbott Diabetes Care Inc. | Analyte test device |
JP4683538B2 (en) * | 2004-05-06 | 2011-05-18 | セイコーインスツル株式会社 | Analysis system and analysis method including microchip for analysis |
US7694694B2 (en) * | 2004-05-10 | 2010-04-13 | The Aerospace Corporation | Phase-change valve apparatuses |
US8828320B2 (en) * | 2004-05-14 | 2014-09-09 | Honeywell International Inc. | Portable sample analyzer cartridge |
TWI291025B (en) * | 2004-06-29 | 2007-12-11 | Univ Nat Cheng Kung | An integral micro-dialysis electrophoresis chip having on-line labeling function and the analysis method thereof |
US7134319B2 (en) * | 2004-08-12 | 2006-11-14 | Honeywell International Inc. | Acoustic wave sensor with reduced condensation and recovery time |
EP1817573A4 (en) * | 2004-10-18 | 2010-02-10 | Univ Macquarie | Fluorescence detection |
US20080185043A1 (en) * | 2004-11-16 | 2008-08-07 | Koninklijke Philips Electronics, N.V. | Microfluidic Device |
US7785868B2 (en) * | 2004-12-02 | 2010-08-31 | Microfluidic Systems, Inc. | Apparatus to automatically lyse a sample |
JP4455306B2 (en) * | 2004-12-13 | 2010-04-21 | キヤノン株式会社 | Biochemical treatment method |
US20060153745A1 (en) * | 2005-01-11 | 2006-07-13 | Applera Corporation | Fluid processing device for oligonucleotide synthesis and analysis |
EP1849012A2 (en) * | 2005-01-28 | 2007-10-31 | Parker-Hannifin Corporation | Sampling probe, gripper and interface for laboratory sample management systems |
GB2438768A (en) * | 2005-02-15 | 2007-12-05 | Univ Singapore | Microfluidics package and method of fabricating the same |
EP1853911A1 (en) * | 2005-02-25 | 2007-11-14 | Inverness Medical Switzerland GmbH | Fluidic gating device |
EP2597472A3 (en) * | 2005-04-01 | 2014-03-05 | Konica Minolta Medical & Graphic, Inc. | Micro integrated analysis system, testing chip, and testing method |
KR101047836B1 (en) * | 2005-04-25 | 2011-07-08 | 가부시키가이샤 아루박 | Integral printhead assembly |
GB0508983D0 (en) * | 2005-05-03 | 2005-06-08 | Oxford Gene Tech Ip Ltd | Cell analyser |
US7738086B2 (en) * | 2005-05-09 | 2010-06-15 | The Trustees Of Columbia University In The City Of New York | Active CMOS biosensor chip for fluorescent-based detection |
WO2006122311A2 (en) * | 2005-05-11 | 2006-11-16 | The Trustees Of The University Of Pennsylvania | Microfluidic chip |
CN101223101A (en) * | 2005-05-12 | 2008-07-16 | 意法半导体股份有限公司 | Microfluidic device with integrated micropump, in particular biochemical microreactor, and manufacturing method thereof |
WO2006133102A2 (en) * | 2005-06-03 | 2006-12-14 | Trans-Dermal Patents Company, Llc | Agent delivery system and uses of the same |
US20070031283A1 (en) * | 2005-06-23 | 2007-02-08 | Davis Charles Q | Assay cartridges and methods for point of care instruments |
US8288151B2 (en) * | 2005-06-29 | 2012-10-16 | Canon Kabushiki Kaisha | Biochemical reaction cassette |
WO2007005974A2 (en) * | 2005-07-01 | 2007-01-11 | Honeywell International, Inc. | A flow metered analyzer |
KR100672690B1 (en) * | 2005-08-03 | 2007-01-22 | 동부일렉트로닉스 주식회사 | Method for manufacturing of cmos image sensor |
US7731910B2 (en) * | 2005-08-05 | 2010-06-08 | Hewlett-Packard Development Company, L.P. | Microfluidic mixing assembly |
WO2007033385A2 (en) * | 2005-09-13 | 2007-03-22 | Fluidigm Corporation | Microfluidic assay devices and methods |
US20070081920A1 (en) * | 2005-10-12 | 2007-04-12 | Murphy R S | Semi-disposable optoelectronic rapid diagnostic test system |
EP1934610B1 (en) * | 2005-10-12 | 2010-01-27 | Allergan, Inc. | Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret) |
US8372340B2 (en) * | 2005-10-19 | 2013-02-12 | Luminex Corporation | Apparatus and methods for integrated sample preparation, reaction and detection |
US20070116607A1 (en) * | 2005-11-23 | 2007-05-24 | Pharmacom Microlelectronics, Inc. | Microsystems that integrate three-dimensional microarray and multi-layer microfluidics for combinatorial detection of bioagent at single molecule level |
US20080210748A1 (en) * | 2005-11-30 | 2008-09-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware, | Systems and methods for receiving pathogen related information and responding |
US20080241910A1 (en) * | 2007-03-27 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Devices for pathogen detection |
CN101389956B (en) * | 2005-12-21 | 2013-01-02 | 三星电子株式会社 | Bio memory disc and bio memory disc drive apparatus, and assay method using the same |
CA2634735A1 (en) * | 2005-12-29 | 2007-07-12 | I-Stat Corporation | Molecular diagnostics amplification system and methods |
US8062595B2 (en) | 2006-02-06 | 2011-11-22 | Stmicroelectronics S.R.L. | Nucleic acid analysis chip integrating a waveguide and optical apparatus for the inspection of nucleic acid probes |
US7815868B1 (en) * | 2006-02-28 | 2010-10-19 | Fluidigm Corporation | Microfluidic reaction apparatus for high throughput screening |
JP4770530B2 (en) * | 2006-03-13 | 2011-09-14 | 株式会社デンソー | Capacitive humidity sensor |
EP2007905B1 (en) * | 2006-03-15 | 2012-08-22 | Micronics, Inc. | Integrated nucleic acid assays |
US20100120132A1 (en) * | 2006-03-31 | 2010-05-13 | Intel Corporation | Bioassays by direct optical detection of nanoparticles |
US8232091B2 (en) * | 2006-05-17 | 2012-07-31 | California Institute Of Technology | Thermal cycling system |
US20070280857A1 (en) * | 2006-06-02 | 2007-12-06 | Applera Corporation | Devices and Methods for Positioning Dried Reagent In Microfluidic Devices |
US8637436B2 (en) * | 2006-08-24 | 2014-01-28 | California Institute Of Technology | Integrated semiconductor bioarray |
BRPI0712655A2 (en) * | 2006-06-08 | 2012-11-20 | Koninkl Philips Electronics Nv | microelectronic sensor device, method for investigating at least one biologically target substance, and, use of microelectronic sensor device |
WO2007148358A1 (en) * | 2006-06-23 | 2007-12-27 | Stmicroelectronics S.R.L. | Assembly of a microfluidic device for analysis of biological material |
US7629124B2 (en) * | 2006-06-30 | 2009-12-08 | Canon U.S. Life Sciences, Inc. | Real-time PCR in micro-channels |
WO2008014485A2 (en) * | 2006-07-28 | 2008-01-31 | California Institute Of Technology | Multiplex q-pcr arrays |
US7633606B2 (en) * | 2006-08-24 | 2009-12-15 | Microfluidic Systems, Inc. | Integrated airborne substance collection and detection system |
US8173071B2 (en) * | 2006-08-29 | 2012-05-08 | International Business Machines Corporation | Micro-fluidic test apparatus and method |
WO2008036614A1 (en) * | 2006-09-18 | 2008-03-27 | California Institute Of Technology | Apparatus for detecting target molecules and related methods |
WO2008061165A2 (en) * | 2006-11-14 | 2008-05-22 | Handylab, Inc. | Microfluidic cartridge and method of making same |
US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
WO2008089449A2 (en) * | 2007-01-19 | 2008-07-24 | Biodot, Inc. | Systems and methods for high speed array printing and hybridization |
WO2008089493A2 (en) * | 2007-01-19 | 2008-07-24 | Fluidigm Corporation | High precision microfluidic devices and methods |
US7622783B2 (en) * | 2007-02-14 | 2009-11-24 | Innovative Micro Technology | MEMS thermal actuator and method of manufacture |
WO2008113112A1 (en) * | 2007-03-16 | 2008-09-25 | Cleveland Biosensors Pty Ltd | Stop structure for microfluidic device |
US20100086991A1 (en) * | 2007-03-23 | 2010-04-08 | Koninklijke Philips Electronics N.V. | Integrated microfluidic device with reduced peak power consumption |
GB2447698A (en) * | 2007-03-23 | 2008-09-24 | Univ Exeter | Fabrication of photonic biosensor arrays |
US20090227005A1 (en) * | 2007-03-27 | 2009-09-10 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods for pathogen detection |
EP1977830A1 (en) * | 2007-03-30 | 2008-10-08 | Roche Diagnostics GmbH | Micro-fluidic temperature driven valve |
AU2008236691B2 (en) * | 2007-04-04 | 2014-08-07 | Ande Corporation | Integrated nucleic acid analysis |
US9110010B2 (en) * | 2007-05-11 | 2015-08-18 | The United States Of America, As Represented By The Secretary Of The Navy | Electrical detection using confined fluids |
CN101855362A (en) * | 2007-05-18 | 2010-10-06 | 美国政府健康及人类服务部,疾病控制和预防中心 | Primers and probes for the detection of streptococcus pneumoniae |
WO2009017627A1 (en) * | 2007-07-30 | 2009-02-05 | Gn Biosystems Incorporated | Apparatus and method for conducting high-throughput micro-volume experiments |
WO2009015689A1 (en) * | 2007-07-31 | 2009-02-05 | Telefonaktiebolaget Lm Ericsson (Publ) | All optical batcher banyan switch, batcher switch, banyan switch and contention manager |
WO2009021215A1 (en) * | 2007-08-09 | 2009-02-12 | Celula, Inc. | Methods and devices for correlated, multi-parameter single cell measurements and recovery of remnant biological material |
WO2009035621A1 (en) * | 2007-09-13 | 2009-03-19 | Arryx, Inc. | Methods and apparatuses for sorting objects in forensic dna analysis and medical diagnostics |
US20090107907A1 (en) * | 2007-10-24 | 2009-04-30 | University Of Alaska Fairbanks | Droplet-based digital microdialysis |
EP2214801A4 (en) | 2007-11-22 | 2016-12-21 | Samsung Electronics Co Ltd | Thin film valve device and its controlling apparatus |
US8396701B2 (en) * | 2007-12-04 | 2013-03-12 | Lester F. Ludwig | Software systems for development, control, programming, simulation, and emulation of fixed and reconfigurable lab-on-a-chip devices |
EP2072133A1 (en) * | 2007-12-20 | 2009-06-24 | Koninklijke Philips Electronics N.V. | Multi-compartment device with magnetic particles |
KR101435522B1 (en) * | 2008-01-23 | 2014-09-02 | 삼성전자 주식회사 | Biochip |
DE102008009185A1 (en) * | 2008-02-15 | 2009-09-24 | Siemens Aktiengesellschaft | Apparatus and method for detecting liquids or substances from liquids and use of the apparatus |
WO2009118690A2 (en) * | 2008-03-28 | 2009-10-01 | Koninklijke Philips Electronics N.V. | Microfluidic device and method |
DK2138233T3 (en) | 2008-06-02 | 2011-01-31 | Boehringer Ingelheim Micropart | Microfluidic film structure for dosing liquids |
US7887756B2 (en) * | 2008-06-20 | 2011-02-15 | Silverbrook Research Pty Ltd | Microfluidic system comprising mechanically-actuated microfluidic pinch valve |
EP2138587A1 (en) * | 2008-06-23 | 2009-12-30 | Koninklijke Philips Electronics N.V. | Amplification of nucleic acids using temperature zones |
US9724695B2 (en) * | 2008-06-23 | 2017-08-08 | Canon U.S. Life Sciences, Inc. | Systems and methods for amplifying nucleic acids |
CN102076870A (en) * | 2008-06-25 | 2011-05-25 | 实时基因组有限公司 | Method and apparatus for melting curve analysis of nucleic acids in microarray format |
US8133451B2 (en) * | 2008-08-28 | 2012-03-13 | Microfluidic Systems, Inc. | Sample preparation apparatus |
WO2010025425A1 (en) * | 2008-08-29 | 2010-03-04 | Angros Lee H | Multiplexed microscope slide staining apparatus |
US20100056394A1 (en) * | 2008-09-04 | 2010-03-04 | Chung Yuan Christian University | Mini Bio-Reactor |
US8707781B2 (en) * | 2008-09-11 | 2014-04-29 | Nxp, B.V. | Sensor has combined in-plane and parallel-plane configuration |
US20100075340A1 (en) * | 2008-09-22 | 2010-03-25 | Mehdi Javanmard | Electrical Detection Of Biomarkers Using Bioactivated Microfluidic Channels |
US9156010B2 (en) * | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
JP2010076380A (en) | 2008-09-29 | 2010-04-08 | Seiko Epson Corp | Liquid container |
US20100089135A1 (en) * | 2008-10-10 | 2010-04-15 | Nxp B.V. | Device and method for measuring sensor chips |
WO2010040227A1 (en) * | 2008-10-10 | 2010-04-15 | The Governing Council Of The University Of Toronto | Hybrid digital and channel microfluidic devices and methods of use thereof |
EP2346604A1 (en) * | 2008-11-13 | 2011-07-27 | Koninklijke Philips Electronics N.V. | Interfacing an inlet to a capillary channel of a microfluidic system |
US8169006B2 (en) * | 2008-11-29 | 2012-05-01 | Electronics And Telecommunications Research Institute | Bio-sensor chip for detecting target material |
EP2194381B1 (en) * | 2008-12-03 | 2015-12-02 | Roche Diagnostics GmbH | Testing element with combined control and calibration zone |
US7964474B2 (en) * | 2008-12-31 | 2011-06-21 | Stmicroelectronics, Inc. | Use of field oxidation to simplify chamber fabrication in microfluidic devices |
US8450063B2 (en) * | 2009-01-28 | 2013-05-28 | Fluidigm Corporation | Determination of copy number differences by amplification |
US8637301B2 (en) * | 2009-03-02 | 2014-01-28 | The Johns Hopkins University | Microfluidic solution for high-throughput, droplet-based single molecule analysis with low reagent consumption |
KR20120031218A (en) * | 2009-06-05 | 2012-03-30 | 인터젠엑스 인크. | Universal sample preparation system and use in an integrated analysis system |
US9376713B2 (en) * | 2009-09-23 | 2016-06-28 | The Board Of Trustees Of The University Of Illinois | Label free detection of nucleic acid amplification |
ES2743959T3 (en) * | 2009-10-21 | 2020-02-21 | Univ Brandeis | Kits to analyze single stranded nucleic acid sequences |
WO2011071772A2 (en) * | 2009-12-07 | 2011-06-16 | Meso Scale Technologies, Llc. | Assay cartridges and methods of using the same |
US8500979B2 (en) * | 2009-12-31 | 2013-08-06 | Intel Corporation | Nanogap chemical and biochemical sensors |
CN102906573B (en) * | 2010-02-23 | 2015-02-18 | 瑞昂尼克公司 | Self-contained biological assay apparatus, methods, and applications |
US9188585B2 (en) * | 2010-05-13 | 2015-11-17 | Robert Bosch Gmbh | Device and method for indirect modulation of detection environment |
US20110312712A1 (en) * | 2010-06-17 | 2011-12-22 | Geneasys Pty Ltd | Genetic analysis loc for pcr amplification of nucleic acids from whole blood |
KR20120063162A (en) * | 2010-12-07 | 2012-06-15 | 삼성전자주식회사 | Gene analysis apparatus and method of analyzing gene using the same |
-
2011
- 2011-06-01 US US13/150,049 patent/US20110312712A1/en not_active Abandoned
- 2011-06-01 US US13/149,934 patent/US20110312644A1/en not_active Abandoned
- 2011-06-01 US US13/150,239 patent/US20110312811A1/en not_active Abandoned
- 2011-06-01 US US13/149,918 patent/US20110312638A1/en not_active Abandoned
- 2011-06-01 US US13/149,919 patent/US20110312073A1/en not_active Abandoned
- 2011-06-01 US US13/149,900 patent/US20110312628A1/en not_active Abandoned
- 2011-06-01 US US13/149,922 patent/US20110312074A1/en not_active Abandoned
- 2011-06-01 US US13/149,929 patent/US20110311411A1/en not_active Abandoned
- 2011-06-01 US US13/150,191 patent/US20110312606A1/en not_active Abandoned
- 2011-06-01 US US13/149,973 patent/US20110312676A1/en not_active Abandoned
- 2011-06-01 US US13/150,023 patent/US20110312566A1/en not_active Abandoned
- 2011-06-01 US US13/150,270 patent/US20110312839A1/en not_active Abandoned
- 2011-06-01 US US13/150,264 patent/US20110312833A1/en not_active Abandoned
- 2011-06-01 US US13/150,194 patent/US20110312850A1/en not_active Abandoned
- 2011-06-01 US US13/150,200 patent/US20110312793A1/en not_active Abandoned
- 2011-06-01 US US13/150,131 patent/US8354074B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,014 patent/US20110312561A1/en not_active Abandoned
- 2011-06-01 US US13/150,019 patent/US20110312698A1/en not_active Abandoned
- 2011-06-01 US US13/150,196 patent/US20110312791A1/en not_active Abandoned
- 2011-06-01 US US13/150,076 patent/US20110312581A1/en not_active Abandoned
- 2011-06-01 US US13/150,047 patent/US20110312710A1/en not_active Abandoned
- 2011-06-01 US US13/150,183 patent/US20110312848A1/en not_active Abandoned
- 2011-06-01 US US13/149,902 patent/US20110312629A1/en not_active Abandoned
- 2011-06-01 US US13/150,109 patent/US20110312753A1/en not_active Abandoned
- 2011-06-01 US US13/150,192 patent/US20110312607A1/en not_active Abandoned
- 2011-06-01 US US13/149,893 patent/US20110312545A1/en not_active Abandoned
- 2011-06-01 US US13/150,176 patent/US20110312847A1/en not_active Abandoned
- 2011-06-01 US US13/150,062 patent/US20110312723A1/en not_active Abandoned
- 2011-06-01 US US13/150,218 patent/US20110312609A1/en not_active Abandoned
- 2011-06-01 US US13/150,022 patent/US20110312699A1/en not_active Abandoned
- 2011-06-01 US US13/150,139 patent/US20110312590A1/en not_active Abandoned
- 2011-06-01 US US13/150,204 patent/US20110312795A1/en not_active Abandoned
- 2011-06-01 US US13/150,096 patent/US20110312616A1/en not_active Abandoned
- 2011-06-01 US US13/149,964 patent/US20110312668A1/en not_active Abandoned
- 2011-06-01 US US13/149,971 patent/US20110312674A1/en not_active Abandoned
- 2011-06-01 US US13/150,099 patent/US20110312746A1/en not_active Abandoned
- 2011-06-01 US US13/150,082 patent/US20110312735A1/en not_active Abandoned
- 2011-06-01 US US13/150,185 patent/US20110312787A1/en not_active Abandoned
- 2011-06-01 US US13/149,908 patent/US20110312548A1/en not_active Abandoned
- 2011-06-01 US US13/150,097 patent/US20110312744A1/en not_active Abandoned
- 2011-06-01 US US13/149,960 patent/US20110312553A1/en not_active Abandoned
- 2011-06-01 US US13/150,051 patent/US20110312714A1/en not_active Abandoned
- 2011-06-01 US US13/150,243 patent/US20110312814A1/en not_active Abandoned
- 2011-06-01 US US13/149,917 patent/US20110312637A1/en not_active Abandoned
- 2011-06-01 US US13/150,036 patent/US20110312571A1/en not_active Abandoned
- 2011-06-01 US US13/150,133 patent/US20110311409A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000673 patent/WO2011156850A1/en active Application Filing
- 2011-06-01 US US13/150,222 patent/US20110311415A1/en not_active Abandoned
- 2011-06-01 US US13/150,238 patent/US20110312810A1/en not_active Abandoned
- 2011-06-01 US US13/150,041 patent/US20110312706A1/en not_active Abandoned
- 2011-06-01 US US13/149,951 patent/US20110312656A1/en not_active Abandoned
- 2011-06-01 US US13/149,974 patent/US20110312067A1/en not_active Abandoned
- 2011-06-01 US US13/150,230 patent/US20110312804A1/en not_active Abandoned
- 2011-06-01 US US13/150,105 patent/US20110312750A1/en not_active Abandoned
- 2011-06-01 US US13/150,065 patent/US20110312726A1/en not_active Abandoned
- 2011-06-01 US US13/150,197 patent/US20110312792A1/en not_active Abandoned
- 2011-06-01 US US13/150,081 patent/US20110312527A1/en not_active Abandoned
- 2011-06-01 US US13/150,156 patent/US20110312617A1/en not_active Abandoned
- 2011-06-01 US US13/150,093 patent/US20110312741A1/en not_active Abandoned
- 2011-06-01 US US13/150,046 patent/US20110312709A1/en not_active Abandoned
- 2011-06-01 US US13/149,959 patent/US20110312664A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000679 patent/WO2011156856A1/en active Application Filing
- 2011-06-01 US US13/150,248 patent/US20110312819A1/en not_active Abandoned
- 2011-06-01 US US13/149,991 patent/US20110312556A1/en not_active Abandoned
- 2011-06-01 US US13/149,979 patent/US20110312555A1/en not_active Abandoned
- 2011-06-01 US US13/150,078 patent/US20110312526A1/en not_active Abandoned
- 2011-06-01 US US13/150,143 patent/US20110312842A1/en not_active Abandoned
- 2011-06-01 US US13/149,970 patent/US20110312673A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000675 patent/WO2011156852A1/en active Application Filing
- 2011-06-01 US US13/149,962 patent/US20110312666A1/en not_active Abandoned
- 2011-06-01 US US13/150,075 patent/US20110312731A1/en not_active Abandoned
- 2011-06-01 US US13/150,137 patent/US20110312081A1/en not_active Abandoned
- 2011-06-01 US US13/150,155 patent/US20110312774A1/en not_active Abandoned
- 2011-06-01 US US13/150,138 patent/US20110312772A1/en not_active Abandoned
- 2011-06-01 US US13/150,190 patent/US20110312788A1/en not_active Abandoned
- 2011-06-01 US US13/150,037 patent/US20110312704A1/en not_active Abandoned
- 2011-06-01 US US13/150,261 patent/US20110312612A1/en not_active Abandoned
- 2011-06-01 US US13/150,117 patent/US20110312761A1/en not_active Abandoned
- 2011-06-01 US US13/149,890 patent/US20110312622A1/en not_active Abandoned
- 2011-06-01 US US13/150,182 patent/US20110312604A1/en not_active Abandoned
- 2011-06-01 US US13/150,083 patent/US20110312736A1/en not_active Abandoned
- 2011-06-01 US US13/150,147 patent/US20110312593A1/en not_active Abandoned
- 2011-06-01 US US13/150,211 patent/US20110312799A1/en not_active Abandoned
- 2011-06-01 US US13/150,063 patent/US20110312724A1/en not_active Abandoned
- 2011-06-01 US US13/149,899 patent/US20110312546A1/en not_active Abandoned
- 2011-06-01 US US13/150,150 patent/US20110312773A1/en not_active Abandoned
- 2011-06-01 US US13/150,223 patent/US20110312611A1/en not_active Abandoned
- 2011-06-01 US US13/150,038 patent/US20110312540A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000667 patent/WO2011156844A1/en active Application Filing
- 2011-06-01 US US13/150,048 patent/US20110312711A1/en not_active Abandoned
- 2011-06-01 US US13/150,232 patent/US20110312621A1/en not_active Abandoned
- 2011-06-01 US US13/149,913 patent/US20110312071A1/en not_active Abandoned
- 2011-06-01 US US13/150,188 patent/US20110312542A1/en not_active Abandoned
- 2011-06-01 US US13/150,115 patent/US20110312759A1/en not_active Abandoned
- 2011-06-01 US US13/150,233 patent/US20110312806A1/en not_active Abandoned
- 2011-06-01 US US13/149,986 patent/US20110312537A1/en not_active Abandoned
- 2011-06-01 US US13/149,993 patent/US20110312686A1/en not_active Abandoned
- 2011-06-01 US US13/149,996 patent/US20110312688A1/en not_active Abandoned
- 2011-06-01 US US13/150,256 patent/US20110312826A1/en not_active Abandoned
- 2011-06-01 US US13/150,110 patent/US20110312754A1/en not_active Abandoned
- 2011-06-01 US US13/150,199 patent/US20110312851A1/en not_active Abandoned
- 2011-06-01 US US13/150,044 patent/US20110312573A1/en not_active Abandoned
- 2011-06-01 US US13/149,985 patent/US20110312683A1/en not_active Abandoned
- 2011-06-01 US US13/150,107 patent/US20110312586A1/en not_active Abandoned
- 2011-06-01 US US13/150,053 patent/US8394340B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,257 patent/US20110312827A1/en not_active Abandoned
- 2011-06-01 US US13/150,144 patent/US20110312592A1/en not_active Abandoned
- 2011-06-01 US US13/149,961 patent/US20110312665A1/en not_active Abandoned
- 2011-06-01 US US13/149,931 patent/US20110312641A1/en not_active Abandoned
- 2011-06-01 US US13/150,129 patent/US20110311408A1/en not_active Abandoned
- 2011-06-01 US US13/150,235 patent/US20110312807A1/en not_active Abandoned
- 2011-06-01 US US13/150,179 patent/US20110312603A1/en not_active Abandoned
- 2011-06-01 US US13/150,125 patent/US20110312069A1/en not_active Abandoned
- 2011-06-01 US US13/149,966 patent/US20110312670A1/en not_active Abandoned
- 2011-06-01 US US13/150,231 patent/US20110312805A1/en not_active Abandoned
- 2011-06-01 US US13/150,216 patent/US20110312608A1/en not_active Abandoned
- 2011-06-01 US US13/150,106 patent/US20110312751A1/en not_active Abandoned
- 2011-06-01 US US13/149,939 patent/US20110312648A1/en not_active Abandoned
- 2011-06-01 US US13/149,957 patent/US20110312662A1/en not_active Abandoned
- 2011-06-01 US US13/149,892 patent/US20110312623A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000663 patent/WO2011156840A1/en active Application Filing
- 2011-06-01 US US13/149,924 patent/US20110312551A1/en not_active Abandoned
- 2011-06-01 US US13/150,011 patent/US20110312695A1/en not_active Abandoned
- 2011-06-01 US US13/150,132 patent/US8394339B2/en not_active Expired - Fee Related
- 2011-06-01 WO PCT/AU2011/000672 patent/WO2011156849A1/en active Application Filing
- 2011-06-01 US US13/150,134 patent/US20110312770A1/en not_active Abandoned
- 2011-06-01 US US13/149,968 patent/US20110312671A1/en not_active Abandoned
- 2011-06-01 US US13/149,942 patent/US20110312650A1/en not_active Abandoned
- 2011-06-01 US US13/150,035 patent/US20110312703A1/en not_active Abandoned
- 2011-06-01 US US13/150,142 patent/US20110312591A1/en not_active Abandoned
- 2011-06-01 US US13/150,032 patent/US20110312702A1/en not_active Abandoned
- 2011-06-01 US US13/150,265 patent/US20110312834A1/en not_active Abandoned
- 2011-06-01 US US13/150,272 patent/US20110308945A1/en not_active Abandoned
- 2011-06-01 US US13/150,152 patent/US20110312844A1/en not_active Abandoned
- 2011-06-01 US US13/150,189 patent/US20110312618A1/en not_active Abandoned
- 2011-06-01 US US13/149,980 patent/US20110312679A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000665 patent/WO2011156842A1/en active Application Filing
- 2011-06-01 US US13/149,943 patent/US20110312076A1/en not_active Abandoned
- 2011-06-01 US US13/150,180 patent/US20110312785A1/en not_active Abandoned
- 2011-06-01 US US13/150,205 patent/US20110311407A1/en not_active Abandoned
- 2011-06-01 US US13/150,066 patent/US20110312576A1/en not_active Abandoned
- 2011-06-01 US US13/149,992 patent/US20110312557A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000664 patent/WO2011156841A1/en active Application Filing
- 2011-06-01 US US13/150,056 patent/US20110312718A1/en not_active Abandoned
- 2011-06-01 US US13/150,167 patent/US20110312599A1/en not_active Abandoned
- 2011-06-01 US US13/150,225 patent/US20110312801A1/en not_active Abandoned
- 2011-06-01 US US13/150,040 patent/US20110312705A1/en not_active Abandoned
- 2011-06-01 US US13/150,087 patent/US20110312615A1/en not_active Abandoned
- 2011-06-01 US US13/150,059 patent/US20110312575A1/en not_active Abandoned
- 2011-06-01 US US13/150,165 patent/US20110312778A1/en not_active Abandoned
- 2011-06-01 US US13/150,088 patent/US20110312739A1/en not_active Abandoned
- 2011-06-01 US US13/150,068 patent/US20110312577A1/en not_active Abandoned
- 2011-06-01 US US13/149,895 patent/US20110312625A1/en not_active Abandoned
- 2011-06-01 US US13/149,897 patent/US20110312626A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000666 patent/WO2011156843A1/en active Application Filing
- 2011-06-01 US US13/150,201 patent/US8398938B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,170 patent/US20110312781A1/en not_active Abandoned
- 2011-06-01 US US13/150,090 patent/US20110312583A1/en not_active Abandoned
- 2011-06-01 US US13/150,020 patent/US20110312564A1/en not_active Abandoned
- 2011-06-01 US US13/150,007 patent/US20110312559A1/en not_active Abandoned
- 2011-06-01 US US13/150,163 patent/US20110312777A1/en not_active Abandoned
- 2011-06-01 US US13/150,071 patent/US20110312728A1/en not_active Abandoned
- 2011-06-01 US US13/149,930 patent/US20110312552A1/en not_active Abandoned
- 2011-06-01 US US13/150,064 patent/US8398940B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,241 patent/US20110312813A1/en not_active Abandoned
- 2011-06-01 US US13/149,903 patent/US20110312547A1/en not_active Abandoned
- 2011-06-01 US US13/150,104 patent/US20110312749A1/en not_active Abandoned
- 2011-06-01 US US13/150,069 patent/US20110312578A1/en not_active Abandoned
- 2011-06-01 US US13/150,092 patent/US20110312585A1/en not_active Abandoned
- 2011-06-01 US US13/150,247 patent/US20110312818A1/en not_active Abandoned
- 2011-06-01 US US13/150,166 patent/US20110312079A1/en not_active Abandoned
- 2011-06-01 US US13/149,935 patent/US20110312645A1/en not_active Abandoned
- 2011-06-01 US US13/150,119 patent/US20110312763A1/en not_active Abandoned
- 2011-06-01 US US13/149,954 patent/US20110312659A1/en not_active Abandoned
- 2011-06-01 US US13/149,944 patent/US20110312651A1/en not_active Abandoned
- 2011-06-01 US US13/150,210 patent/US20110312798A1/en not_active Abandoned
- 2011-06-01 US US13/149,928 patent/US20110312640A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000668 patent/WO2011156845A1/en active Application Filing
- 2011-06-01 US US13/150,089 patent/US20110312740A1/en not_active Abandoned
- 2011-06-01 US US13/150,146 patent/US20110311394A1/en not_active Abandoned
- 2011-06-01 US US13/150,018 patent/US20110312697A1/en not_active Abandoned
- 2011-06-01 US US13/150,162 patent/US20110312598A1/en not_active Abandoned
- 2011-06-01 US US13/149,952 patent/US20110312657A1/en not_active Abandoned
- 2011-06-01 US US13/149,910 patent/US20110312549A1/en not_active Abandoned
- 2011-06-01 US US13/149,995 patent/US20110312687A1/en not_active Abandoned
- 2011-06-01 US US13/150,108 patent/US20110312752A1/en not_active Abandoned
- 2011-06-01 US US13/149,956 patent/US20110312661A1/en not_active Abandoned
- 2011-06-01 US US13/150,202 patent/US20110312794A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000671 patent/WO2011156848A1/en active Application Filing
- 2011-06-01 US US13/150,161 patent/US20110312776A1/en not_active Abandoned
- 2011-06-01 US US13/150,229 patent/US20110312803A1/en not_active Abandoned
- 2011-06-01 US US13/150,102 patent/US20110312748A1/en not_active Abandoned
- 2011-06-01 US US13/150,070 patent/US20110312579A1/en not_active Abandoned
- 2011-06-01 US US13/150,253 patent/US20110312824A1/en not_active Abandoned
- 2011-06-01 US US13/150,094 patent/US20110312742A1/en not_active Abandoned
- 2011-06-01 US US13/150,212 patent/US20110312853A1/en not_active Abandoned
- 2011-06-01 US US13/150,021 patent/US20110312565A1/en not_active Abandoned
- 2011-06-01 US US13/150,027 patent/US20110312568A1/en not_active Abandoned
- 2011-06-01 US US13/150,164 patent/US20110312846A1/en not_active Abandoned
- 2011-06-01 US US13/150,260 patent/US20110312830A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000659 patent/WO2011156836A1/en active Application Filing
- 2011-06-01 US US13/150,054 patent/US20110312716A1/en not_active Abandoned
- 2011-06-01 US US13/149,912 patent/US20110312635A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000658 patent/WO2011156835A1/en active Application Filing
- 2011-06-01 US US13/150,206 patent/US20110312796A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000670 patent/WO2011156847A1/en active Application Filing
- 2011-06-01 US US13/150,160 patent/US20110312845A1/en not_active Abandoned
- 2011-06-01 US US13/149,950 patent/US20110312655A1/en not_active Abandoned
- 2011-06-01 US US13/150,058 patent/US20110312720A1/en not_active Abandoned
- 2011-06-01 US US13/150,127 patent/US20120053088A1/en not_active Abandoned
- 2011-06-01 US US13/150,168 patent/US20110312779A1/en not_active Abandoned
- 2011-06-01 US US13/149,946 patent/US20110312652A1/en not_active Abandoned
- 2011-06-01 US US13/150,250 patent/US20110312821A1/en not_active Abandoned
- 2011-06-01 US US13/150,112 patent/US20110312756A1/en not_active Abandoned
- 2011-06-01 US US13/149,972 patent/US20110312675A1/en not_active Abandoned
- 2011-06-01 US US13/149,999 patent/US20110312689A1/en not_active Abandoned
- 2011-06-01 US US13/150,012 patent/US20110312696A1/en not_active Abandoned
- 2011-06-01 US US13/149,907 patent/US20110312632A1/en not_active Abandoned
- 2011-06-01 US US13/150,031 patent/US20110312070A1/en not_active Abandoned
- 2011-06-01 US US13/150,221 patent/US20120004145A1/en not_active Abandoned
- 2011-06-01 US US13/150,091 patent/US20110312584A1/en not_active Abandoned
- 2011-06-01 US US13/149,914 patent/US20110312636A1/en not_active Abandoned
- 2011-06-01 US US13/150,118 patent/US20110312762A1/en not_active Abandoned
- 2011-06-01 US US13/150,240 patent/US20110312812A1/en not_active Abandoned
- 2011-06-01 US US13/150,220 patent/US20110312610A1/en not_active Abandoned
- 2011-06-01 US US13/150,124 patent/US20110312766A1/en not_active Abandoned
- 2011-06-01 US US13/149,990 patent/US20110312685A1/en not_active Abandoned
- 2011-06-01 US US13/150,255 patent/US20110312825A1/en not_active Abandoned
- 2011-06-01 US US13/149,911 patent/US20110312634A1/en not_active Abandoned
- 2011-06-01 US US13/150,052 patent/US20110312574A1/en not_active Abandoned
- 2011-06-01 US US13/150,187 patent/US20110312605A1/en not_active Abandoned
- 2011-06-01 US US13/150,030 patent/US20110312701A1/en not_active Abandoned
- 2011-06-01 US US13/150,003 patent/US20110312693A1/en not_active Abandoned
- 2011-06-01 US US13/150,039 patent/US20110312572A1/en not_active Abandoned
- 2011-06-01 US US13/150,157 patent/US20110312597A1/en not_active Abandoned
- 2011-06-01 US US13/149,981 patent/US20110312680A1/en not_active Abandoned
- 2011-06-01 US US13/149,975 patent/US20110312677A1/en not_active Abandoned
- 2011-06-01 US US13/150,193 patent/US20110312789A1/en not_active Abandoned
- 2011-06-01 US US13/150,195 patent/US20110312790A1/en not_active Abandoned
- 2011-06-01 US US13/149,921 patent/US20110312550A1/en not_active Abandoned
- 2011-06-01 US US13/150,033 patent/US20110312077A1/en not_active Abandoned
- 2011-06-01 US US13/150,057 patent/US8383065B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,209 patent/US20110309275A1/en not_active Abandoned
- 2011-06-01 US US13/150,245 patent/US20110312816A1/en not_active Abandoned
- 2011-06-01 US US13/150,072 patent/US20110312580A1/en not_active Abandoned
- 2011-06-01 US US13/150,228 patent/US20110312802A1/en not_active Abandoned
- 2011-06-01 US US13/150,175 patent/US20110312601A1/en not_active Abandoned
- 2011-06-01 US US13/150,174 patent/US20110312783A1/en not_active Abandoned
- 2011-06-01 US US13/150,113 patent/US20110312757A1/en not_active Abandoned
- 2011-06-01 US US13/150,080 patent/US20110312734A1/en not_active Abandoned
- 2011-06-01 US US13/150,084 patent/US20110312737A1/en not_active Abandoned
- 2011-06-01 US US13/149,920 patent/US20110312639A1/en not_active Abandoned
- 2011-06-01 US US13/150,226 patent/US20110312620A1/en not_active Abandoned
- 2011-06-01 US US13/149,989 patent/US20110312684A1/en not_active Abandoned
- 2011-06-01 US US13/149,997 patent/US20110312558A1/en not_active Abandoned
- 2011-06-01 US US13/150,067 patent/US20110312727A1/en not_active Abandoned
- 2011-06-01 US US13/150,224 patent/US20110312855A1/en not_active Abandoned
- 2011-06-01 US US13/149,948 patent/US20110312654A1/en not_active Abandoned
- 2011-06-01 TW TW100119255A patent/TW201213798A/en unknown
- 2011-06-01 US US13/150,008 patent/US20110312539A1/en not_active Abandoned
- 2011-06-01 US US13/150,128 patent/US20110312767A1/en not_active Abandoned
- 2011-06-01 US US13/150,009 patent/US20110312560A1/en not_active Abandoned
- 2011-06-01 US US13/150,141 patent/US20110312082A1/en not_active Abandoned
- 2011-06-01 US US13/150,159 patent/US20110312775A1/en not_active Abandoned
- 2011-06-01 US US13/150,186 patent/US20110312849A1/en not_active Abandoned
- 2011-06-01 US US13/150,079 patent/US20110312733A1/en not_active Abandoned
- 2011-06-01 US US13/150,263 patent/US20110312832A1/en not_active Abandoned
- 2011-06-01 US US13/149,978 patent/US20110312678A1/en not_active Abandoned
- 2011-06-01 US US13/150,002 patent/US20110312692A1/en not_active Abandoned
- 2011-06-01 US US13/150,120 patent/US20110311418A1/en not_active Abandoned
- 2011-06-01 US US13/149,976 patent/US20110312068A1/en not_active Abandoned
- 2011-06-01 US US13/150,234 patent/US20110312856A1/en not_active Abandoned
- 2011-06-01 US US13/150,060 patent/US20110312721A1/en not_active Abandoned
- 2011-06-01 US US13/150,045 patent/US20110312708A1/en not_active Abandoned
- 2011-06-01 US US13/150,158 patent/US20110311395A1/en not_active Abandoned
- 2011-06-01 US US13/150,236 patent/US20110312808A1/en not_active Abandoned
- 2011-06-01 US US13/150,050 patent/US8398939B2/en not_active Expired - Fee Related
- 2011-06-01 WO PCT/AU2011/000661 patent/WO2011156838A1/en active Application Filing
- 2011-06-01 US US13/149,891 patent/US20110312841A1/en not_active Abandoned
- 2011-06-01 US US13/150,172 patent/US20110312782A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000676 patent/WO2011156853A1/en active Application Filing
- 2011-06-01 US US13/150,207 patent/US20110312797A1/en not_active Abandoned
- 2011-06-01 US US13/150,208 patent/US20110312852A1/en not_active Abandoned
- 2011-06-01 US US13/150,213 patent/US20110312800A1/en not_active Abandoned
- 2011-06-01 US US13/150,111 patent/US20110312755A1/en not_active Abandoned
- 2011-06-01 US US13/149,958 patent/US20110312663A1/en not_active Abandoned
- 2011-06-01 US US13/150,184 patent/US8425845B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,121 patent/US20110312764A1/en not_active Abandoned
- 2011-06-01 US US13/149,916 patent/US20110312072A1/en not_active Abandoned
- 2011-06-01 US US13/150,086 patent/US20110312738A1/en not_active Abandoned
- 2011-06-01 US US13/150,262 patent/US20110312831A1/en not_active Abandoned
- 2011-06-01 US US13/150,214 patent/US20110311413A1/en not_active Abandoned
- 2011-06-01 US US13/150,219 patent/US20110311414A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000662 patent/WO2011156839A1/en active Application Filing
- 2011-06-01 US US13/150,151 patent/US20110312595A1/en not_active Abandoned
- 2011-06-01 US US13/150,266 patent/US20110312835A1/en not_active Abandoned
- 2011-06-01 US US13/150,268 patent/US20110312837A1/en not_active Abandoned
- 2011-06-01 US US13/150,000 patent/US20110312690A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000669 patent/WO2011156846A1/en active Application Filing
- 2011-06-01 US US13/149,894 patent/US20110312624A1/en active Pending
- 2011-06-01 US US13/149,965 patent/US20110312669A1/en not_active Abandoned
- 2011-06-01 US US13/149,984 patent/US20110312682A1/en not_active Abandoned
- 2011-06-01 US US13/150,267 patent/US20110312836A1/en not_active Abandoned
- 2011-06-01 US US13/150,016 patent/US20110312562A1/en not_active Abandoned
- 2011-06-01 US US13/150,116 patent/US20110312760A1/en not_active Abandoned
- 2011-06-01 US US13/150,061 patent/US8388910B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,269 patent/US20110312838A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000680 patent/WO2011156857A1/en active Application Filing
- 2011-06-01 US US13/150,153 patent/US20120028842A1/en not_active Abandoned
- 2011-06-01 US US13/149,953 patent/US20110312658A1/en not_active Abandoned
- 2011-06-01 US US13/150,169 patent/US20110312780A1/en not_active Abandoned
- 2011-06-01 US US13/150,095 patent/US20110312743A1/en not_active Abandoned
- 2011-06-01 US US13/150,246 patent/US20110312817A1/en not_active Abandoned
- 2011-06-01 US US13/149,898 patent/US8349277B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,123 patent/US20110312765A1/en not_active Abandoned
- 2011-06-01 US US13/150,148 patent/US20110312843A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000678 patent/WO2011156855A1/en active Application Filing
- 2011-06-01 US US13/150,178 patent/US20110312784A1/en not_active Abandoned
- 2011-06-01 US US13/149,967 patent/US20110312554A1/en not_active Abandoned
- 2011-06-01 US US13/150,004 patent/US20110312694A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000677 patent/WO2011156854A1/en active Application Filing
- 2011-06-01 US US13/149,925 patent/US20120052562A1/en not_active Abandoned
- 2011-06-01 US US13/150,042 patent/US20110312707A1/en not_active Abandoned
- 2011-06-01 US US13/150,244 patent/US20110312815A1/en not_active Abandoned
- 2011-06-01 US US13/150,001 patent/US20110312691A1/en not_active Abandoned
- 2011-06-01 US US13/150,271 patent/US20110312840A1/en not_active Abandoned
- 2011-06-01 US US13/150,130 patent/US20110312768A1/en not_active Abandoned
- 2011-06-01 US US13/150,135 patent/US8383064B2/en not_active Expired - Fee Related
- 2011-06-01 US US13/150,177 patent/US20110312602A1/en not_active Abandoned
- 2011-06-01 US US13/150,126 patent/US20110312541A1/en not_active Abandoned
- 2011-06-01 US US13/150,025 patent/US20110312700A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000674 patent/WO2011156851A1/en active Application Filing
- 2011-06-01 US US13/150,101 patent/US20110312747A1/en not_active Abandoned
- 2011-06-01 US US13/150,024 patent/US20110312567A1/en not_active Abandoned
- 2011-06-01 US US13/150,100 patent/US20110312078A1/en not_active Abandoned
- 2011-06-01 US US13/149,947 patent/US20110312653A1/en not_active Abandoned
- 2011-06-01 US US13/150,252 patent/US20110312823A1/en not_active Abandoned
- 2011-06-01 US US13/150,085 patent/US20110312582A1/en not_active Abandoned
- 2011-06-01 US US13/150,077 patent/US20110312732A1/en not_active Abandoned
- 2011-06-01 US US13/150,237 patent/US20110312809A1/en not_active Abandoned
- 2011-06-01 US US13/150,227 patent/US20110309276A1/en not_active Abandoned
- 2011-06-01 US US13/149,927 patent/US20110312075A1/en not_active Abandoned
- 2011-06-01 US US13/149,969 patent/US20110312672A1/en not_active Abandoned
- 2011-06-01 US US13/150,074 patent/US20110312730A1/en not_active Abandoned
- 2011-06-01 US US13/149,941 patent/US20110312649A1/en not_active Abandoned
- 2011-06-01 US US13/150,122 patent/US20110312587A1/en not_active Abandoned
- 2011-06-01 US US13/150,017 patent/US20110312563A1/en not_active Abandoned
- 2011-06-01 US US13/150,055 patent/US20110312717A1/en not_active Abandoned
- 2011-06-01 US US13/150,251 patent/US20110312822A1/en not_active Abandoned
- 2011-06-01 US US13/150,028 patent/US20110312569A1/en not_active Abandoned
- 2011-06-01 US US13/150,203 patent/US20110312619A1/en not_active Abandoned
- 2011-06-01 US US13/149,963 patent/US20110312667A1/en not_active Abandoned
- 2011-06-01 US US13/150,029 patent/US20110312570A1/en not_active Abandoned
- 2011-06-01 US US13/150,217 patent/US20110312854A1/en not_active Abandoned
- 2011-06-01 US US13/149,955 patent/US20110312660A1/en not_active Abandoned
- 2011-06-01 US US13/150,140 patent/US20110311393A1/en not_active Abandoned
- 2011-06-01 US US13/150,114 patent/US20110312758A1/en not_active Abandoned
- 2011-06-01 US US13/150,136 patent/US20110312771A1/en not_active Abandoned
- 2011-06-01 US US13/149,936 patent/US20110312646A1/en not_active Abandoned
- 2011-06-01 US US13/150,149 patent/US20110312594A1/en not_active Abandoned
- 2011-06-01 US US13/150,242 patent/US20110308313A1/en not_active Abandoned
- 2011-06-01 WO PCT/AU2011/000660 patent/WO2011156837A1/en active Application Filing
- 2011-06-01 US US13/150,173 patent/US20110312600A1/en not_active Abandoned
- 2011-06-01 US US13/149,909 patent/US20110312633A1/en not_active Abandoned
- 2011-06-01 US US13/150,098 patent/US20110312745A1/en not_active Abandoned
- 2011-06-01 US US13/150,181 patent/US20110312786A1/en not_active Abandoned
- 2011-06-01 US US13/149,983 patent/US20110312681A1/en not_active Abandoned
- 2011-06-01 US US13/150,006 patent/US20110312538A1/en not_active Abandoned
- 2011-06-01 US US13/150,258 patent/US20110312828A1/en not_active Abandoned
- 2011-06-01 US US13/150,154 patent/US20110312596A1/en not_active Abandoned
- 2011-06-01 US US13/150,249 patent/US20110312820A1/en not_active Abandoned
- 2011-06-01 US US13/149,937 patent/US20110312647A1/en not_active Abandoned
- 2011-06-01 US US13/149,904 patent/US20110312630A1/en not_active Abandoned
- 2011-06-01 US US13/149,933 patent/US20110312643A1/en not_active Abandoned
- 2011-06-01 US US13/149,932 patent/US20110312642A1/en not_active Abandoned
- 2011-06-01 US US13/149,906 patent/US20110312631A1/en not_active Abandoned
- 2011-06-01 US US13/150,259 patent/US20110312829A1/en not_active Abandoned
- 2011-06-01 US US13/150,073 patent/US20110312729A1/en not_active Abandoned
-
2012
- 2012-11-26 US US13/685,105 patent/US20130079254A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055198A2 (en) * | 2002-12-12 | 2004-07-01 | Chiron Corporation | Device and method for in-line blood testing using biochips |
WO2004065010A2 (en) * | 2003-01-21 | 2004-08-05 | Micronics Inc. | Method and system for microfluidic manipulation, amplification and analysis of fluids, for example, bacteria assays and antiglobulin testing |
US20040265182A1 (en) * | 2003-06-24 | 2004-12-30 | Chien-Hua Chen | Fluidic MEMS device |
US20090325276A1 (en) * | 2006-09-27 | 2009-12-31 | Micronics, Inc. | Integrated microfluidic assay devices and methods |
Non-Patent Citations (7)
Title |
---|
ANDERSON, R. ET AL.: "A miniature integrated device for automated multistep genetic assays, art e60", NUCLEIC ACIDS RESEARCH, vol. 28, no. 12, June 2000 (2000-06-01), pages I - VI, XP002255747 * |
CHEN, Z. ET AL.: "A microfluidic system for saliva-based detection of infectious diseases", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES., vol. 1098, March 2007 (2007-03-01), pages 429 - 436 * |
ERILL, I. ET AL.: "Development of a CMOS-compatible PCR chip: comparison of design and system strategies", JOURNAL OF MICROMECHANICS AND MICROENGINEERING., vol. 14, no. 11, November 2004 (2004-11-01), pages 1558 - 1568 * |
LEE, B. ET AL.: "Biosensor system-on-a-chip including CMOS-based signal processing circuits and 64 carbon nanotube-based sensors for the detection of a neurotransmitter", LAB ON A CHIP., vol. 10, no. 7, April 2010 (2010-04-01), pages 894 - 898 * |
LIU, R. ET AL.: "Self-contained, fully integrated biochip for sample preparation, polymerase chain reaction amplification, and DNA microarray detection", ANALYTICAL CHEMISTRY, vol. 76, no. 7, April 2004 (2004-04-01), pages 1824 - 1831 * |
SAUER-BUDGE, A. ET AL.: "Low cost and manufacturable complete microTAS for detecting bacteria", LAB ON A CHIP., vol. 9, no. 19, October 2009 (2009-10-01), pages 2803 - 2810 * |
YEUNG, S. ET AL.: "A DNA biochip for on-the-spot multiplexed pathogen identification, art. e118", NUCLEIC ACIDS RESEARCH, vol. 34, no. 18, September 2006 (2006-09-01), pages 7PP, XP002488746 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8394339B2 (en) | LOC device with on-chip semiconductor controlled incubation section | |
TW201219770A (en) | Test module incorporating spectrometer | |
Chen et al. | An integrated, self-contained microfluidic cassette for isolation, amplification, and detection of nucleic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11794930 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11794930 Country of ref document: EP Kind code of ref document: A1 |